lopinavir has been researched along with HIV Coinfection in 1205 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (1.00) | 18.2507 |
| 2000's | 534 (44.32) | 29.6817 |
| 2010's | 572 (47.47) | 24.3611 |
| 2020's | 87 (7.22) | 2.80 |
| Authors | Studies |
|---|---|
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Babacan, E; Kaykhin, P; Lötsch, J; Staszewski, S; Stephan, C; Stürmer, M; von Hentig, N | 1 |
| Aldrovandi, G; Alvero, C; Borkowsky, W; Capparelli, EV; Chadwick, EG; Fenton, T; Havens, PL; Heckman, B; Pelton, SI; Robbins, BL; Rodman, J; Serchuck, L; Smith, ME; Worrell, C; Yogev, R | 1 |
| Achalapong, J; Chotivanich, N; Cressey, TR; Jourdain, G; Maupin, R; Mirochnick, M; Prommas, S; Puthanakit, T; Roongpisuthipong, A; Shapiro, DE; Smith, E; Van Dyke, R; Yuthavisuthi, P | 1 |
| Ewart, G; Khoury, G; Luscombe, C; Miller, M; Wilkinson, J | 1 |
| Gibbs, CS; Margot, NA; Miller, MD | 1 |
| Lisovsky, I; Martinez-Cajas, JL; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA | 1 |
| Brunzelle, JS; Dewdney, TG; Kovari, IA; Kovari, LC; Liu, Z; Reiter, SJ; Sharma, SK; Wang, Y; Woster, PM | 1 |
| Agniswamy, J; Aoki, M; Bulut, H; Das, D; Ghosh, AK; Hayashi, H; Martyr, CD; Mitsuya, H; Nyalapatla, PR; Osswald, HL; Rao, KV; Wang, YF; Weber, IT | 1 |
| Ali, A; Henes, M; Kosovrasti, K; Kurt Yilmaz, N; Lee, SK; Lockbaum, GJ; Nalivaika, EA; Rao, DN; Rusere, LN; Schiffer, CA; Spielvogel, E; Swanstrom, R | 1 |
| Campos L, A; Castro-Moraga, ME; Figueroa V, C; Piñera M, C; Yizmeyián M, A | 1 |
| Beerenwinkel, N; Günthard, HF; Kouyos, R; Kuipers, J; Montazeri, H; Posada-Céspedes, S; Rhee, SY; Van Zyl, G | 1 |
| Jarvis, MF; Morris, JB; Mostafa, NM; Munasinghe, WP; Saeed, AM; Schmidt, JM; Vallabh, BK | 1 |
| Eggers, Y; Feldt, T; Fuchs, A; Häussinger, D; Heger, E; Hurissa, Z; Jarso, G; Jensen, BO; Kaiser, R; Knops, E; Lübke, N; Luedde, T; Orth, HM; Tufa, TB | 1 |
| Ho, RJY; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Ho, RJY; Perazzolo, S; Shen, DD | 1 |
| Akelo, V; Angira, F; Chen, H; Coombs, R; Hogg, E; Kosgei, J; Kumwenda, J; McKhann, A; Murphy, SC; Schooley, R; Shaffer, D; Ssali, F; Stewart, VA; Tonui, R | 1 |
| Andrieux-Meyer, I; Bekker, A; Capparelli, E; Cotton, MF; Cressey, R; Cressey, TR; du Toit, S; Groenewald, M; Kumar, M; Lallemant, M; Nielsen, J; Rabie, H; Salvadori, N; Than-In-At, K | 1 |
| Dunk, CE; Serghides, L | 1 |
| Alfaro Martínez, JJ; Sirvent Segovia, AE | 1 |
| Aidara, M; Alleyo, A; Diallo, K; Manga, NM; Wembulua, BS | 1 |
| Abdullahi, A; Abdullahi, M; Atiku, A; Dauda, H; Gwamna, J; Ige, O; Kambai, H; Kera, HN; Musa, S; Olasinde, T; Oyefabi, A; Sheyin, J; Sunday, J; Umeh, GC; Usman, I | 1 |
| Mason, AL; Saxinger, L; Turvey, SL | 1 |
| Abdelnabi, R; Annaert, PP; Augustijns, PF; Cambier, S; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Delang, L; Foo, CS; Gouwy, M; Heylen, E; Jochmans, D; Kaptein, SJF; Leyssen, P; Mols, R; Neyts, J; Proost, P; Rocha-Pereira, J; Ter Horst, S; van Laer, C; Vandooren, J; Vangeel, L; Vergote, V; Weynand, B; Zhang, X | 1 |
| Au, ICH; Chung, MSH; Cowling, BJ; Kwan, MYW; Kwok, ACY; Lau, EHY; Lau, KTK; Low, MCH; Lui, AYC; Wong, CKH; Xiong, X | 1 |
| Abdelwahab, MT; Andrieux-Meyer, I; Bekker, A; Chabala, C; Cotton, MF; Davies, G; Denti, P; Hesseling, A; Lee, J; McIlleron, H; Rabie, H; Tikiso, T; Wiesner, L; Zar, HJ | 1 |
| Abu Khattab, M; Al Maslamani, M; Al Soub, H; Al-Khal, A; Alibrahim, R; Elmekaty, EZI; Elsayed, A; Eltaib, S; Hassanin, R; Mohamed Ibrahim, MI; Rustom, F | 1 |
| Akpomiemie, G; Christofides, N; Lalla-Edward, S; Machisa, M; Mokgethi, NO | 1 |
| Cai, WP; Chen, JF; Chen, YY; Dai, LL; He, Y; Hu, JH; Hu, M; Jiang, TY; Li, LH; Liu, L; Liu, X; Lu, HZ; Lu, RJ; Lun, WH; Mu, TT; Peng, HY; Shao, YM; Su, B; Sun, CC; Sun, LJ; Sun, YT; Wang, H; Wang, M; Wang, MX; Wang, Y; Wu, H; Xia, W; Xie, D; Xing, H; Yao, C; Yu, JH; Zhang, FJ; Zhang, T; Zhang, YH; Zhao, M; Zhao, QX; Zheng, QS; Zheng, YH; Zhu, B | 1 |
| Jacobs, BA; Mtshali, S | 1 |
| El Maghraby, GM; Essa, EA; Fayed, ND | 1 |
| Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K | 1 |
| Avihingsanon, A; Chaivichacharn, P; Gatechompol, S; Punyawudho, B; Ubolyam, S | 1 |
| Cere, MC; Chatelut, E; Fraissinet, F; Gandia, P; Lavit, M; Oumar, AA; Seraissol, P | 1 |
| Chen, M; Huobu-Mo, M; Li, C; Li, J; Wu, M; Xiao, H; Zeng, L; Zhang, Y | 1 |
| Ballesteros, A; Buck, WC; Burger, DM; Chabala, C; Chitsamatanga, M; Colbers, A; Domínguez-Rodríguez, S; Jacobs, TG; Madrid, L; Moraleda, C; Mujuru, HA; Mumbiro, V; Namuziya, N; Nathoo, KJ; Nduna, B; Passanduca, A; Rojo, P; Tagarro, A | 1 |
| Ajibola, G; Batlang, O; Bennett, K; Capparelli, EV; Hughes, MD; Jean-Philippe, P; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Mohammed, T; Moyo, S; Pretorius-Holme, M; Ricci, L; Sakoi, M; Shapiro, RL | 1 |
| Boyd, BJ; Clulow, AJ; Hawley, A; Ramirez, G; Salim, M | 1 |
| Bonfanti, P; Cascio, A; Celesia, BM; Cenderello, G; Costa, C; De Socio, GV; De Vito, A; Di Biagio, A; Falasca, K; Madeddu, G; Martinelli, CV; Menzaghi, B; Molteni, C; Orofino, G; Parruti, G; Pellicanò, GF; Ricci, E; Sarchi, E; Squillace, N; Taramasso, L; Valsecchi, L | 1 |
| Chen, H; Deng, Y; Gao, Y; Ge, X; Ge, Y; Lan, G; Li, B; Li, S; Liu, S; Luo, H; Luo, L; Meng, Q; Qin, G; Qin, H; Wang, Y; Wen, P; Wu, X; Yang, H; Zhu, J; Zhu, Q | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Bukachi, FO; Makamu, BL; Mwangi, PW | 1 |
| Gill, MM; Herrera, N; Maile, L; Masenyetse, L; Masitha, M; Mokone, M; Tukei, VJ | 1 |
| Chabala, C; Choo, L; Chungu, C; Crook, A; Gibb, D; Kapasa, M; LeBeau, K; Lungu, J; McIlleron, H; Mulenga, V; Tembo, CH; Turkova, A; Weisner, L; Zimba, K; Zyambo, K | 1 |
| Andre, P; Buclin, T; Calmy, A; Decosterd, LA; Delfraysse, M; Fedeli, C; Guidi, M; Thoueille, P; Ustero, P | 1 |
| Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H | 1 |
| Alabdalaali, MM; Hadi, AM | 1 |
| Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V | 1 |
| Lallemant, M; Lee, J; Marchal, B; Nebot Giralt, A; Nöstlinger, C; Nyamongo, I; Onyango-Ouma, W; Salami, O | 1 |
| Cecka, F; Cerveny, L; Huliciak, M; Martinec, O; Staud, F; Vokral, I | 1 |
| Cahn, P; Figueroa, MI; Gun, A; Hull, MW; Kaul, R; Raboud, JM; Rolon, MJ; Sued, O; Szadkowski, L; Tan, DHS; Walmsley, SL | 1 |
| Blanche, S; Engebretsen, I; Eymard-Duvernay, S; Flück, CE; Foissac, F; Hartmann, MF; Hirt, D; Kankasa, C; Kariyawasam, D; Meda, N; Molès, JP; Mwiya, M; Nagot, N; Peries, M; Polak, M; Singata-Madliki, M; Treluyer, JM; Tumwine, J; Tylleskär, T; Van De Perre, P; Wudy, SA | 1 |
| Dai, L; Li, J; Liu, A; Mahajan, SD; Schwartz, SA; Scott, SR; Shao, Y; Su, B; Sun, L; Wu, H; Ye, J; Yu, H; Zhang, H; Zhang, T | 1 |
| Karbwang, J; Na-Bangchang, K; Rajoli, RKR; Saeheng, T; Siccardi, M | 1 |
| Collier, AC; de Jesus, CS; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hovind, L; Hughes, MD; Mellors, JW; Mngqibisa, R; Mugyenyi, P; Ritz, J; Salata, R; Saravanan, S; van Schalkwyk, M; Viana, R; Wallis, CL; Wieclaw, L | 1 |
| Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L | 1 |
| Barreto, J; Borrego, P; Gomes, P; Gonçalves, F; Moranguinho, I; Rocha, J; Taveira, N | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Fischer, A; Gumede, SB; Lalla-Edward, ST; Venter, WDF | 1 |
| Aizire, J; Brooks, KM; Butler, K; Cababasay, M; Fenton, T; Flynn, PM; Fowler, MG; Kiser, JJ; Mirochnick, M; Siberry, GK | 1 |
| Ebrahim, I; Maartens, G; McIlleron, H; Orrell, C; Smythe, W; Wiesner, L | 1 |
| Collier, AC; Ho, RJY; Kinman, L; Koehn, J; Lane, S; Lee, W; McConnachie, LA; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Coelho, L; Collier, AC; Fletcher, CV; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Matoga, M; Mngqibisa, R; Mumbi, ME; Poongulali, S; Ritz, J; Salata, R; Van Schalkwyk, M; Wallis, CL | 1 |
| Aweeka, FT; Barnes, KI; Byakika-Kibwika, P; Bygbjerg, IC; Chijioke-Nwauche, I; Denti, P; Francis, J; Hoglund, RM; Khoo, SH; Kredo, T; Lamorde, M; Lemnge, MM; Merry, C; Nyagonde, N; Parikh, S; Scarsi, KK; Sutherland, CJ; Tarning, J; Vestergaard, LS; Walimbwa, SI; Workman, L | 1 |
| Andrieux-Meyer, I; Bobat, R; Cotton, M; Denti, P; Fairlie, L; Lallemant, M; Lee, J; Liberty, A; McIlleron, H; Rabie, H; Strehlau, R; Tikiso, T | 1 |
| Cao, Y; Xu, S; Zhou, M; Zhu, F | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Bernacchia, D; Cattaneo, D; Conti, F; Gervasoni, C; Lupo, A; Merli, S; Pezzati, L; Riva, A; Rusconi, S; Siano, M; Sollima, S | 1 |
| Adeoye, O; Bártolo, I; Cabral-Marques, H; Conceição, J; da Silva, AB; Duarte, N; Francisco, AP; Taveira, N | 1 |
| Burger, DM; Carmona, S; Hermans, LE; Legg-E'Silva, D; Moraba, R; Nijhuis, M; Pillay, T; Schapiro, JM; Schuurman, R; Snyman, T; Steegen, K; Tempelman, HA; Ter Heine, R; van Maarseveen, E; Wensing, AM | 1 |
| Abrams, EJ; Arpadi, SM; Coovadia, A; Kuhn, L; Shen, J; Shiau, S; Strehlau, R; Yin, MT | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Alonso-Castro, AJ; Alvarez-Alvarez, RM; Del Carmen Preciado-Puga, M; Del Rocio Ibarra-Reynoso, L; Lazo-de-la-Vega-Monroy, ML; Ruiz-Noa, Y; Ruiz-Padilla, AJ; Sánchez-Barajas, M | 1 |
| Acosta, S; Dunk, C; Kala, S; Serghides, L | 1 |
| Charpentier, C; Coffie, PA; Dabis, F; Descamps, D; Eholie, SP; Ekouevi, DK; Tchounga, BK | 1 |
| Balerdi-Sarasola, L; Gainzarain-Arana, JC; Ganchegui-Aguirre, M; Molina-Iturritza, E; Ortiz-de-Zárate-Ibarra, Z; Portu-Zapirain, J; San-José-Muñiz, I | 1 |
| Aarnoutse, RE; Burger, DM; Colbers, A; Dooley, KE; Jacobs, TG; McIlleron, H; Musiime, V; Rojo, P; Svensson, EM; Turkova, A | 1 |
| Bulayeva, N; Crutchley, RD; Garey, KW; Gathe, J; Jacobs, DM; Mayberry, C; Rosenblatt, KP | 1 |
| Asafu-Agyei, NAA; Frigati, L; Machemedze, T; Mahtab, S; Myer, L; Scott, C; Zar, HJ | 1 |
| Batra, H; Chawla, H; Das, BK; Hussain, AW; Kabra, SK; Katpara, S; Kumar, S; Lodha, R; Luthra, K; Singh, R; Singh, S | 1 |
| Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO | 1 |
| Agolory, S; Bikinesi, L; Carmona, S; Dean, N; Fisher-Walker, CL; Hamunime, N; Hong, SY; Hunter, CJ; Jordan, MR; Kana, V; Mutenda, N; Negussie, T; Parkin, N; Raizes, EG; Sawadogo, S; Shiningavamwe, AN; Steegen, K; Tang, AM; Yang, C | 1 |
| Åstrøm, AN; Birungi, N; Engebretsen, IMS; Fadnes, LT; Tumwine, JK | 1 |
| Cory, TJ; Mu, Y | 1 |
| Agbaji, O; Darin, KM; Ejeliogu, E; Imade, G; Kanki, PJ; McIlleron, HM; Odaibo, G; Oguche, S; Ogunbosi, BO; Okonkwo, P; Oladokun, R; Olaleye, D; Rawizza, HE; Scarsi, KK; Wiesner, L | 1 |
| Agide, FD; Mohraz, M; Nikfar, S; Tigabu, BM | 1 |
| Aweeka, F; Bradford, S; Browning, R; Coletti, A; Costello, D; Graham, B; Hughes, E; Kamthunzi, P; Kawalazira, R; Mmbaga, BT; Moye, J; Musoke, P; Nathoo, K; Norman, J; Owor, M; Purdue, L; Reding, C; Tierney, C; Whalen, ME; Wiesner, L; Ziemba, L | 1 |
| Bangirana, P; Batting, J; Cournil, A; Engebretsen, IMS; Kankasa, C; Meda, N; Molès, JP; Mwiya, M; Nagot, N; Nalugya, J; Ndeezi, G; Peries, M; Perre, PV; Quillet, C; Singata-Madliki, M; Tassembedo, S; Tonga, MW; Tumwine, J; Tylleskär, T | 1 |
| Aizire, J; Browning, R; Dadabhai, S; Fan, B; Fowler, MG; George, K; Mofenson, LM; Moodley, D; Mukwasi-Kahari, C; Nelson, B; Sebikari, D; Shepherd, J; Siberry, GK; Sommer, MJ; Stranix-Chibanda, L; Theron, G; Tierney, C; Vhembo, T; Violari, A; Zanga, A | 1 |
| Castelli, F; Magro, P; Pescarolo, M; Quiros-Roldan, E; Zanella, I | 1 |
| Casado Lima, BC; Copertino, DC; de Mulder Rougvie, M; Duarte, RRR; Gulick, RM; Nixon, DF; Ormsby, CE; Powell, TR; Wilkin, T | 1 |
| Eche, S; Gordon, ML; Kumar, A; Sonela, N | 1 |
| Kandel, SE; Lampe, JN | 1 |
| Apornpong, T; Badal-Faesen, S; Chotirosniramit, N; Collier, AC; Fletcher, CV; Gandhi, M; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hosseinipour, MC; Hovind, LJ; Hughes, M; Kanyama, C; Kerr, SJ; Kumarasamy, N; Mawlana, S; Mngqbisa, R; Ritz, J; Ruxrungtham, K; Salata, R; Santos, BR; Shah, S; Van Schalkwyk, M; Wallis, CL | 1 |
| Cabral, LM; de Sousa, VP; Pinto, EC; Velozo, CT | 1 |
| Arpadi, SM; Burke, M; Coovadia, A; Dympna, G; Johnson, CT; Kuhn, L; Patel, F; Rizkalla, B; Shen, Y; Shiau, S; Strehlau, R; Yin, MT | 1 |
| Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X | 1 |
| Burger, DM; Heine, RT; Hermans, LE; Houts, T; Nijhuis, M; Schuurman, R; Tempelman, HA; Wensing, AMJ | 1 |
| Bakeera-Kitaka, S; Cusick, SE; Idro, R; Kisitu, GP; Piloya, TW | 1 |
| Archary, M; Burger, D; Cotton, MF; Denti, P; Gibb, D; Hennig, S; Lallemant, M; Lee, J; McIlleron, H; Rabie, H; Tikiso, T | 1 |
| Barnes, EL; Kinlaw, AC; Li, X; Moon, AM; Tang, H; Wang, T; Yang, JY; Zhou, L | 1 |
| Benson, CA; Cardoso, SW; Fletcher, CV; Ive, P; Kendall, MA; Lalloo, U; Podany, AT; Wu, X | 1 |
| Castelnuovo, B; Haguma, P; Kalibbala, D; Kirenga, B; Muddu, M; Mulindwa, F; Semitala, FC | 1 |
| Arduino, G; Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; Di Perri, G; Marinaro, L; Pagani, N; Tettoni, MC; Trentini, L | 1 |
| Fernández Cooke, E; Holguín, Á; Jiménez De Ory, S; Navarro, ML; Prieto, L; Ramos, JT; Rojas Sánchez, P | 1 |
| Lallemant, M; Lee, J; Marchal, B; Nebot Giralt, A; Nöstlinger, C; Nyamongo, I; Ouma, O; Salami, O | 1 |
| Abdel-Maboud, M; Abushouk, AI; Ahmed, H; Attia, A; Elmaraezy, A; Gadelkarim, M; Ismail, A; Menshawy, A; Menshawy, E; Negida, A | 1 |
| Arenas-Pinto, A; Benn, P; Brima, N; Clarke, A; Copas, A; Fisher, M; Gilson, R; Hawkins, D; Milinkovic, A; Schembri, G; Williams, A | 1 |
| Callard, RE; Klein, NJ; Lewis, J; Majekodunmi, AO; Malyuta, R; Thorne, C; Volokha, A | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Mbete, N; Murnane, PM; Patel, F; Shiau, S; Strehlau, R | 1 |
| Amani-Bosse, C; Amorissani-Folquet, M; Avit, D; Blanche, S; Coulibaly, M; Dahourou, DL; Eboua, F; Kalmogho, A; Lepage, P; Leroy, V; Malateste, K; Meda, N; N'Gbeche, S; Ouédraogo, R; Ouédraogo, S; Salamon, R; Seguin-Devaux, C; Timité-Konan, M; Toni, T; Van de Perre, P; Yonaba, C | 1 |
| Amani-Bosse, C; Amorissani-Folquet, M; Barry, M; Blanche, S; Coulibaly, M; Dahourou, DL; Dattez, S; Emieme, A; Leroy, V; Malateste, K; Mea, V; Meda, N; N'gbeche, S; Ouédraogo, S; Rouzioux, C; Seguin-Devaux, C; Timité-Konan, M; Yonaba, C | 1 |
| Bastiaans, DET; Burger, DM; de Groot, R; Driessen, GJA; Fraaij, PLA; Gondrie, IPE; Hartwig, NG; van der Knaap, LC; van Jaarsveld, P; van Rossum, AMC; Visser, EG | 1 |
| Bagenda, L; Bertagnolio, S; Easterbrook, PJ; Hakim, J; Hoppe, A; Kambugu, A; Kiconco, M; Kityo, C; Mugyenyi, P; Nankya, I; Paton, NI; Thompson, J; van Oosterhout, JJ; Walker, AS | 1 |
| Abbasian, L; Ahsani-Nasab, S; Bayat Jozani, Z; Esmaeeli Djavid, G; Khazaee-Pool, M; Moradmand Badie, B; Pargar, A; Rasooli-Nejad, M | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Bader, P; Königs, C; Radeloff, D; Reimers, B; Salzmann-Manrique, E; Schwabe, D; Weber, V | 1 |
| Cassim, H; Gray, GE; Greeff, OBW; Lazarus, E; Liberty, A; Otwombe, K; Violari, A | 1 |
| Cheng, Y; Liu, X; Ma, Q; Ma, Y; Mu, W; Sun, X; Zhang, F; Zhang, H; Zhao, Y | 1 |
| Ayers, D; Calmy, A; Chan, K; Cooper, DA; Doherty, M; Ford, N; Kanters, S; Mills, EJ; Nsanzimana, S; Paton, NI; Popoff, E; Socias, ME; Vitoria, M; Wiens, MO | 1 |
| Bacchetti, P; Gandhi, M; Horng, H; Jin, C; Kerr, S; Koss, CA; Kuncze, K; Louie, A; Phung, N; Pintye, J; Prasitsuebsai, W; Singtoroj, T; Sohn, AH; Teeraananchai, S | 1 |
| Agarwal, A; Alexander, PE; Chang, Y; Foroutan, F; Guyatt, GH; Hepworth, E; Lee, Y; Lesi, O; Mah Ming, J; Merglen, A; Mir, H; Mirza, R; Siemieniuk, RA; Zeraatkar, D; Zhang, Y | 1 |
| Compagnucci, A; Harrison, L; Melvin, AJ; Saidi, Y; Tudor-Williams, G; Turkova, A; Warshaw, M | 1 |
| Lowenthal, ED; Mathew, PS; Mennella, JA | 1 |
| Cohan, D; Conroy, AL; Dorsey, G; Gamble, JL; Havlir, DV; Kain, KC; Kamya, MR; McDonald, CR; Natureeba, P; Olwoch, P | 1 |
| Achan, J; Bangirana, P; Banik, A; Boivin, MJ; Giron, LB; Pillai, SK; Ruel, TD; Sikorskii, A | 1 |
| Avihingsanon, A; Burger, DM; Mitruk, S; Punyawudho, B; Rungtivasuwan, K; Ruxrungtham, K; Sukasem, C; Thammajaruk, N | 1 |
| Capparelli, EV; Cressey, TR; Mirochnick, M; Pinto, JA; Qin, M; Siberry, GK; Smith, B; Spector, SA; Warshaw, M; Zimmer, B | 1 |
| Arnaiz, JA; Cruceta, A; García, F; Gatell, JM; González, E; González-Cordón, A; Inciarte, A; Laguno, M; Leal, L; León, A; Lucero, C; Mallolas, J; Martínez-Rebollar, M; Rojas, J; Torres, B | 1 |
| Coetzer, M; Diero, L; Kantor, R; Kemboi, E; Ledingham, L; Orido, M | 1 |
| Abongomera, G; Easterbrook, P; Hakim, JG; Hoppe, A; Kambugu, A; Kityo, C; Lugemwa, A; Mugyenyi, P; Mwebaze, R; Mweemba, A; Paton, NI; Siika, A; Thomason, MJ; Thompson, J; van Oosterhout, JJ; Walker, AS | 1 |
| de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J | 1 |
| Bailey, H; Favarato, G; Peters, H; Taylor, GP; Thorne, C; Tookey, PA; Townsend, CL | 1 |
| Cohan, D; Conroy, AL; Dorsey, G; Gamble, JL; Hawkes, M; Kain, KC; Kamya, M; Koss, CA; McDonald, CR; Natureeba, P; Olwoch, P; Papp, E; Serghides, L; Silverman, M | 1 |
| Bruno, S; Corrigan, B; Letsie, M; Mthethwa, N; Mukui, I; Mulenga, L; Rakhmanina, N | 1 |
| Beymer, MR; Bolan, RK; Flynn, RP; Jordan, WC; Kofron, RM; Landovitz, RJ; Perez, MJ; Sayles, JM; Tseng, CH | 1 |
| Archary, M; Bobat, R; Hennig, S; La Russa, P; Mcllleron, H; Sibaya, T; Wiesner, L | 1 |
| Amin, J; Boyd, M; Carey, D; Cooper, DA; Gazzard, B; Lim, PL; Losso, M; Mohapi, L; Molina, JM; Moore, C; Mwasakifwa, GE; Penteado, P | 1 |
| Domínguez-Castro, M; Figueroa-Damián, R; Flores-García, Z; Hernández-Pineda, J; Loaiza-Flores, G; López-Martínez, M; Plazola-Camacho, N; Ramírez-Ramírez, A; Rodríguez-Delgado, RG; Sánchez-Serrano, E | 1 |
| Collier, AC; Ho, RJY; Kinman, LM; Koehn, J; Kraft, JC; Lane, S; Lee, W; McConnachie, LA | 1 |
| Besseghir, A; Bouchaud, O; Chene, G; Fagard, C; Girard, PM; Kolta, S; Landman, R; Meynard, JL; Moinot, L; Morand-Joubert, L; Spire, B; Todesco, E | 1 |
| Gatanaga, H; Matsumoto, S; Mizushima, D; Nguyen, DT; Nguyen, DTH; Oka, S; Tanuma, J; Trung, NV; van Kinh, N | 1 |
| Arpadi, SM; Coovadia, A; Kuhn, L; Mbete, N; Patel, F; Shiau, S; Strehlau, R; Yin, MT | 1 |
| Brites, C; Lorenzo, C; Luz, E; Netto, EM; Nóbrega, I; Travassos, AG | 1 |
| Blanco, J; Clotet, B; Gómez-Mora, E; Hernández-Rodríguez, A; Marfil, S; Martínez-Bonet, M; Martinez-Picado, J; Matas, L; Moltó, J; Morón-López, S; Muñoz-Fernández, MA; Puertas, MC; Santos, JR; Urrea, V | 1 |
| Aguirrebengoa, K; de Jesus, SE; de Los Santos, I; Fariñas, MC; Flores, J; Galindo, MJ; García-Mercé, I; García-Vallecillos, C; Hernández-Quero, J; Hidalgo-Tenorio, C; Imaz, A; Lozano, F; Montes, ML; Orihuela, F; Pasquau, J; Ríos-Villegas, MJ; Romero-Palacios, A; Sanjoaquín, I; Vázquez, P; Vergas, J | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Gasa, L; Giralt, M; Maroto, AF; Mateo, GM; Morón-Ros, S; Moure, R; Quesada-López, T; Villarroya, F; Villarroya, J | 1 |
| Barr, E; Chadwick, EG; Currier, JS; Hernandez-Diaz, S; Hoffman, RM; Huo, Y; Patel, K; Rough, K; Seage, GR; Shapiro, DE; Williams, PL | 1 |
| Davidovich, U; Dijkstra, M; Kooij, KW; Prins, M; Reiss, P; Schim van der Loeff, MF; van Lunsen, RHW; van Zoest, RA; Wit, FWMN | 1 |
| Bouteloup, V; Calvez, V; Flandre, P; Girard, PM; Grude, M; Izopet, J; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Meynard, JL; Moinot, L; Morand-Joubert, L; Valantin, MA | 1 |
| Abrams, EJ; Arpadi, SM; Coovadia, A; Foca, M; Kuhn, L; Liberty, A; Patel, F; Shen, J; Shiau, S; Strehlau, R; Terry, MB; Violari, A; Wang, S; Yin, MT | 1 |
| Ding, H; Geng, W; Han, X; Jiang, Y; Kang, J; Li, X; Shang, H; Wang, Q; Wu, T; Zhang, Z | 1 |
| Bandera, A; Clerici, M; Fenizia, C; Giannattasio, C; Gori, A; Maloberti, A; Masetti, M; Muscatello, A; Sabbatini, F; Soria, A; Squillace, N; Trabattoni, D | 1 |
| Cavalli, RC; Duarte, G; Lanchote, VL; Moisés, ECD; Moreira, FL; Quintana, SM; Ribeiro, RMP | 1 |
| Bagayoko-Maiga, K; Bahachimi, A; Cere, MC; Chatelut, E; Dao, S; Diarra, Z; Gandia, P; Maiga, M; Murphy, RL; Oumar, AA; Sylla, M | 1 |
| Battegay, M; Berger, B; Donzelli, M; Duthaler, U; Erb, S; Gaugler, S; Haschke, M; Krähenbühl, S; Letang, E; Mnzava, D; Natamatungiro, A | 1 |
| Arribas, J; Dunn, D; Hakim, J; Hoppe, A; Kambugu, A; Kityo, C; Mugyenyi, P; Ndashimye, E; Paton, NI; Thompson, JA; van Oosterhout, JJ; Walker, AS | 1 |
| Abrams, EJ; Arpadi, S; Mogashoa, M; Mutiti, A; Nxele, M; Pepeta, L; Rivadeneira, ED; Sogaula, N; Teasdale, CA; Wang, C; Yuengling, KA | 1 |
| Aldrovandi, G; Angelidou, K; Lindsey, J; Palumbo, P; Patel, K | 1 |
| Boinett, R; Brooks, K; Buziba, N; Coetzer, M; DeLong, A; Diero, L; Emonyi, W; Hogan, J; Kantor, R; Kemboi, E; Obonge, S; Orido, M; Reitsma, M; Rono, M; Schreier, L | 1 |
| Bahr, GM; Echtay, KS; Fadel, JJ | 1 |
| Cattaneo, D; Perno, CF; Rizzardini, G | 1 |
| Tartaglia, A | 1 |
| Coetsee, M; Cohen, K; Dunn, L; Hislop, M; Kengne, AP; Leisegang, R; Maartens, G; Maharaj, S; Meintjes, G; Stewart, A; van Zyl, G | 1 |
| Apollo, T; Brophy, J; Chakanyuka, C; Kuwengwa, R; Murimwa, T; Mushavi, A; Pasipanodya, B; Prust, ML; Salami, O; Stewart, B | 1 |
| de Oliveira, MA; Franco, JB; Martins E Martins, F; Maureira Pena, LJ; Ortega, KL | 1 |
| Chasela, CS; Corbett, A; Davis, NL; Hudgens, MG; Jamieson, DJ; Kaullen, J; Kourtis, AP; Miller, WC; Nelson, JAE; Sichali, D | 1 |
| Hamers, RL | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| Gordon, M; Marie, V | 1 |
| Powis, KM; Siberry, GK | 1 |
| Blanche, S; Engebretsen, I; Kankasa, C; Meda, N; Mwiya, M; Nagot, N; Peries, M; Singata-Madliki, M; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Castelnuovo, B; Kaimal, A; Kiragga, A; Laker, EAO; Lamorde, M; Musubire, A; Nabaggala, MS; Nalwanga, D; Ratanshi, RP | 1 |
| Abraham, OC; Barnabas, R; Chacko, G; Kannangai, R; Karthik, R; Manesh, A; Mani, S; Varghese, GM | 1 |
| Golin, R; Larson, C; Malati, CY; O'Brien, L; Phelps, BR; Srivastava, M; Sugandhi, N | 1 |
| Adenuga, BA; Rennie, TW | 1 |
| McIlleron, H; Rabie, H; Rawizza, H; Van Rie, A; Wiesner, L; Winckler, J; Zar, H; Zuidewind, P | 1 |
| Aizire, J; Boivin, MJ; Familiar-Lopez, I; Fowler, MG; Kawalazira, R; Kuteesa, A; Maliwichi-Senganimalunje, L; Mallewa, M; Mutebe, A; Namukooli, JL; Nyakato, M; Ogwang, LW; Ruiseñor-Escudero, H; Sikorskii, A; Taha, TE | 1 |
| Akanmu, S; Brown, B; Chang, C; Darin, KM; David, N; Kanki, PJ; Ogunbosi, B; Okonkwo, P; Oladokun, R; Olaitan, O; Rawizza, HE; Scarsi, KK | 1 |
| Orkin, C | 1 |
| Akpomiemie, G; Arulappan, N; Boyles, T; Chitauri, G; Hill, A; Maharaj, E; Mashabane, N; Moorhouse, M; Qavi, A; Ripin, D; Serenata, C; Sim, JW; Sinxadi, PZ; Sokhela, S; Stacey, S; Venter, WDF; Wallis, C; Wiesner, L | 1 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| Prendergast, AJ | 1 |
| Decloedt, EH; Denti, P; Karlsson, MO; McIlleron, H; Ren, Y; Zhang, C | 1 |
| Akuma, SH; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Schöller-Gyüre, M; Spittaels, K; Vyncke, V; Witek, J | 1 |
| Arathoon, E; Baraldi, E; Lavreys, L; Lim, PL; Opravil, M; Schneider, S; Van De Casteele, T | 1 |
| Graham, E; Kulasegaram, R; McConkey, HZ; Williams, H | 1 |
| Anderson, J; Boyd, MA; Cooper, DA; Emery, S; Kaplan, R; Nwizu, C; Schneider, K; Wilson, DP | 1 |
| Bonfanti, P; Bonizzoni, E; Croce, D; Foglia, E; Porazzi, E; Restelli, U; Ricci, E; Rizzardini, G; Scolari, F | 1 |
| Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Galli, A; Gonzalez de Requena, D; Lazzarin, A; Nozza, S; Simiele, M | 1 |
| Anderson, PL; Erlandson, KM; Schoen, JC | 1 |
| Aulicino, P; Bellusci, CP; Bologna, R; Bramuglia, GF; Curras, V; Hegoburu, S; Mangano, A; Mecikovsky, D; Rocco, C; Sen, L | 1 |
| Aweeka, F; Greenblatt, R; Guglielmo, BJ; Gwaza, L; Huang, L; Lizak, P | 1 |
| Baran, RW; Caro, JJ; Dietz, B; Migliaccio-Walle, K; Möller, J; Pei, PP; Simpson, KN; Woodward, W | 1 |
| Aragonès-Eroles, AM; Cano-Marron, SM; Puig-Ganau, T; Schoenenberger-Arnaiz, JA | 1 |
| Holmes, D | 1 |
| Perelson, AS; Zhang, J | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Alcaro, S; Alteri, C; Antinori, A; Artese, A; Beheydt, G; Bertoli, A; Ceccherini-Silberstein, F; Costa, G; d'Arminio Monforte, A; Girardi, E; Gori, C; Orchi, N; Parrotta, L; Perno, CF; Santoro, MM; Svicher, V; Theys, K; Vandamme, AM | 1 |
| Benmarzouk-Hidalgo, OJ; Gutierrez-Valencia, A; Lluch, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Sánchez-Rivas, E; Torres-Cornejo, A; Viciana, P | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Blanche, S; Bui, E; Chaix, ML; Delmas, S; Ekoukou, D; Hirt, D; Le Chenadec, J; Mandelbrot, L; Rouzioux, C; Treluyer, JM; Tubiana, R; Warszawski, J | 1 |
| Gori, A; Soria, A | 1 |
| Boyd, MA; Cooper, DA; Emery, S; Kerr, S; Kumarasamy, N; Losso, MH; Martin, A; Mohapi, L; Molina, JM; Moore, CL; Nwizu, C; Sohn, AH; Teppler, H; Van de Steen, O | 1 |
| Acosta, W; Bollinger, RC; Castaño, E; Doherty, M; Estripeaut, D; Luciani, K; Mosser, J; Page, KR; Pascale, JM; Shah, H | 1 |
| Acosta, EP; Andrade, A; Campbell, T; Cillo, AR; Daar, ES; Feinberg, J; Flexner, C; Jacobson, JM; Kuritzkes, DR; Lederman, M; Lu, D; Mellors, JW; Rosenkranz, SL | 1 |
| Borkowsky, W; De La Vega, P; Duffy, PE; Hobbs, CV; Krzych, U; Penzak, SR; Sinnis, P; Van Vliet, J | 1 |
| Antinori, A; Castagna, A; d'Arminio Monforte, A; Galli, L; Gianotti, N; Lazzarin, A; Maserati, R; Quiros-Roldan, E; Salpietro, S; Torti, C | 1 |
| Belloso, W; Boyd, MA; Cooper, DA; Emery, S; Ferret, S; Hoy, J; Mallon, PW; Martin, A; Moore, C; Phanuphak, P | 1 |
| Back, D; Bravo, I; Canet, J; Clotet, B; Curran, A; Domingo, P; Llibre, JM; McClernon, DR; Moltó, J; Muñoz-Moreno, JA; Prats, A; Santos, JR; Watson, V | 1 |
| Achan, J; Ades, V; Aliba Luwedde, F; Clark, T; Cohan, D; Havlir, D; Kakuru, A; Kamya, M; Mwesigwa, J; Natureeba, P; Osterbauer, B; Plenty, A | 1 |
| Aoki, T; Gatanaga, H; Honda, H; Kikuchi, Y; Oka, S; Sano, K; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M | 1 |
| Cabrera Figueroa, SE; Carracedo, A; Cruz Guerrero, R; Domínguez-Gil Hurlé, A; López Aspiroz, E; Porras Hurtado, GL | 1 |
| De Hoffer, L; Di Biagio, A; Furfaro, E; Giacomet, V; Ginocchio, F; Miletich, F; Nulvesu, L; Prinapori, R; Rosso, R; Schiavetti, I; Signori, A; Sormani, MP; Taramasso, L; Viscoli, C | 1 |
| Andreoni, M; Antinori, A; Bonfanti, P; Celesia, BM; Costantini, A; Cozzi-Lepri, A; d'Arminio Monforte, A; di Perri, G; Galli, M; Gianotti, N; Lazzarin, A; Luciani, F; Maggiolo, F; Mazzarello, G; Orofino, G; Perno, CF; Pinnetti, C; Poli, A; Rizzardini, G; Sighinolfi, L | 1 |
| Achan, J; Aweeka, F; Bartelink, IH; Charlebois, E; Clark, T; Cohan, D; Gandhi, M; Havlir, D; Kamya, M; Mwesigwa, J; Plenty, A; Savic, RM; Young, SL | 1 |
| Bourdon, E; Boyer, F; Essop, MF; Fisher, TL; O'Connor, WG; Planesse, C; Reyskens, KM; Rogers, AB; Rondeau, P; Schisler, JC; Willis, MS | 1 |
| Achan, J; Ades, V; Aweeka, F; Charlebois, E; Clark, T; Cohan, D; Gandhi, M; Havlir, DV; Huang, Y; Kamya, MR; Luwedde, FA; Mwesigwa, J; Natureeba, P; Plenty, A; Ruel, TD | 1 |
| Bonafe, SM; Castelo, A; Costa, DA; Machado, RH; Pott-Junior, H; Senise, JF; Vaz, MJ | 1 |
| Ajisawa, A; Imamura, A; Sasaki, S; Suganuma, A; Yanagisawa, N | 1 |
| Belloso, WH; Boyd, MA; Cooper, DA; Emery, S; Ferret, S; Hoy, JF; Mallon, PW; Martin, A; Moore, CL; Phanuphak, P | 1 |
| Gisolf, EH; Langebeek, N; Legrand, J; Nieuwkerk, PT; Reiss, P; Richter, C; Sprangers, MA; Sprenger, HG | 1 |
| Cotton, M; Edson, C; Klinker, H; Lenker, U; Pretorius, E; Rabie, H; Rosenkranz, B; von Bibra, M | 1 |
| Aurpibul, L; Dejkhamron, P; Sirisanthana, V; Unachak, K | 1 |
| Ananworanich, J; Bunupuradah, T; Chuanjaroen, T; Kosalaraksa, P; Lumbiganon, P; Pancharoen, C; Panthong, A; Prasitsuebsai, W; Puthanakit, T; Sopharak, C; Udompanit, T; Wongsabut, J | 1 |
| de Carvalho, LP; Kulay, L; Nakamura, MU; Oliveira-Filho, RM; Simões, RS; Tavella, JS; Wagner, A | 1 |
| Marzi, I; Stephan, C; Walcher, F; Wicker, S; Wutzler, S | 1 |
| Ahmed, BS; Ferris, RE; Phelps, BR; Reuben, EB | 1 |
| Acosta, EP; D'Argenio, DZ; Delille, C; Kerstner-Wood, C; Lennox, JL; Ofotokun, I; Sheth, AN; Wang, K | 1 |
| Achan, J; Charlebois, E; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, M; Mwangwa, F; Rosenthal, PJ; Ruel, TD | 1 |
| Baran, RW; Desai, K; Dietz, B; Gooch, K; Möller, J; Simpson, K; Van de Steen, O | 1 |
| Bastiaans, DE; Burger, DM; Chalermpantmetagul, S; Colbers, AP; Compagnucci, A; Cressey, TR; Forcat, S; Giaquinto, C; Hansudewechakul, R; Harper, LM; Inshaw, JR; Kanjanavanit, S; Königs, C; Lyall, H; Noguera-Julian, A; Saïdi, Y | 1 |
| Degli Antoni, A; Fiscon, M; Floridia, M; Francisci, D; Giacomet, V; Liuzzi, G; Marconi, AM; Martinelli, P; Masuelli, G; Pinnetti, C; Ravizza, M; Spinillo, A; Tamburrini, E | 1 |
| Camara, S; Choquet, M; Dimi, S; Goudjo, A; Gravisse, J; Peytavin, G; Vasse, M; Zucman, D | 1 |
| Alós, L; Arnaiz, JA; Benito, JM; Clotet, B; Cruceta, A; Díaz, A; Garcia, F; Gatell, JM; Leal, L; León, A; Loncá, M; Lucero, C; Martínez, E; Negredo, E; Rallón, NI; Sánchez, M; Torres, B | 1 |
| Motsa, N; Mwanyumba, A; Perry, SH; Preidis, GA; Sarero, HN; Swamy, P | 1 |
| Crespo, M; Curran, A; Domingo, P; Fernández, I; Imaz, A; Iribarren, JA; Knobel, H; Martínez, E; Monteiro, P; Peñaranda, M; Podzamczer, D; Villar, J | 1 |
| Currier, J; Hogg, E; Hosseinipour, M; Hughes, MD; Lockman, S; Mulenga, L; Mwafongo, A; Nkanaunena, K; Samaneka, W; Siika, A; Zheng, Y | 1 |
| Ananworanich, J; Bowonwattanuwong, C; Bunupuradah, T; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Ruxrungtham, K; Sophonphan, J | 1 |
| Barrail-Tran, A; Borand, L; Connolly, C; Duc, NH; Dung, NH; Harries, AD; Lagarde, D; Lan, NN; Lan, NT; Laureillard, D; Lien, TT; Lienhardt, C; Pym, A; Quillet, C; Taburet, AM; Thu, NT | 1 |
| Agmon-Levin, N; Asher, I; Averbuch, D; Chowers, M; Elbirt, D; Elinav, H; Gottessman, BS; Grossman, Z; Hassoun, G; Istomin, V; Kra-Oz, Z; Levy, I; Maayan, S; Machleb-Guri, K; Olstein-Pops, K; Radian-Sade, S; Ram, D; Riesenberg, K; Rosenberg, S; Rudich, H; Schapiro, JM; Shahar, E; Shemer, Y; Sthoeger, Z | 1 |
| Benaboud, S; Blanche, S; Bouazza, N; Foissac, F; Frange, P; Hirt, D; Tréluyer, JM; Urien, S | 1 |
| Churchill, DR; Cresswell, FV; Richardson, D; Tomlins, J; Walker-Bone, K | 1 |
| Abrams, EJ; Arpadi, SM; Coovadia, A; Kuhn, L; Martens, L; McIlleron, H; Meredith, S; Shiau, S; Strehlau, R; Wiesner, L | 1 |
| Benki-Nugent, S; Bunts, L; Casper, C; Huang, ML; John-Stewart, G; Richardson, B; Slyker, JA; Tapia, K; Wamalwa, D | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Bao, Y; Currier, J; Hogg, E; Hughes, MD; Lockman, S; Moses, A; Sawe, F; Shaffer, D | 1 |
| Autran, B; Caby, F; Carcelain, G; Costagliola, D; Fourati, S; Guiguet, M; Guihot, A; Hattab, S; Katlama, C; Marcelin, AG | 1 |
| Cattani, VB; Estrela, Rde C; Gonçalves, JC; Grinsztejn, B; João, EC; Marins, LM; Pilotto, JH; Santini-Oliveira, M; Torres, TS; Velasque, L; Veloso, VG; Yanavich, C | 1 |
| Abiodun, OO; Akinbo, J; Ojurongbe, O | 1 |
| Bickel, M; Brodt, R; Haberl, A; Khaykin, P; Kotzerke, P; Kurowski, M; Nisius, G; Stephan, C; Stürmer, M; von Hentig, N | 1 |
| Cattaneo, D; Ripamonti, D | 1 |
| Bosch, RJ; Eron, JJ; Kuritzkes, DR; Taiwo, B; Vardhanabhuti, S | 1 |
| Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW | 1 |
| Sax, PE | 3 |
| Andrade-Villanueva, J; Arribas, JR; Cahn, P; Figueroa, MI; Gatell, JM; Lama, JR; Norton, M; Patterson, P; Rolon, MJ; Sierra Madero, J; Sued, O | 1 |
| Aga, E; Bartlett, J; Katzenstein, D; Kumarasamy, N; Norton, M; Ribaudo, H; Saravanan, S; Stevens, W; Wallis, CL | 1 |
| Abdi, AM; Bonora, S; Calcagno, A; D'Avolio, A; De Nicolò, A; Di Perri, G; Simiele, M | 1 |
| Lee, D; Nguyen, NH; Yee, BE | 1 |
| Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS | 1 |
| Hull, MW; Lima, VD; Montaner, JS; Richard Harrigan, P; Sierra-Madero, J; Singer, J; Wood, E; Wu, Z | 1 |
| Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Ghisetti, V; Lazzarin, A; Milia, MG; Nozza, S; Simiele, M | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Burger, D; Fillekes, Q; Gibb, DM; Keishanyu, R; Kekitiinwa, A; Kendall, L; Lallemant, M; Musiime, V; Namuddu, R; Opilo, W; Walker, AS; Young, N | 1 |
| Abrams, E; Muhe, LM; Penazzato, M; Prendergast, AJ; Tindyebwa, D | 1 |
| Chelin, N; Cohen, S; Gandhi, RT; Murphy, RA; Sunpath, H; Tennant, I; Winternheimer, P | 1 |
| Adriaenssen, I; Brogan, AJ; Manuel, SA; Mauskopf, JA; Smets, E | 1 |
| Adapa, SP; Aditya, N; Balija, J; Ravi, PR; Vats, R | 1 |
| Asmelash, A; Currier, J; Hughes, MD; Kaloustian, KW; Lockman, S; Ogwu, A; Salata, R; Sawe, F; Shaffer, D; Zheng, Y | 1 |
| Back, D; Egan, D; Khoo, S; Olagunju, A; Owen, A; Schipani, A; Siccardi, M | 1 |
| Achan, J; Ades, V; Charlebois, ED; Clark, TD; Cohan, D; Dorsey, G; Havlir, DV; Kamya, MR; Luwedde, F; Mwesigwa, J; Natureeba, P; Nzarubara, B; Okong, P; Plenty, A | 1 |
| Antinori, A; Berno, G; D'Arrigo, R; Gori, C; Perno, CF; Pucillo, LP; Tempestilli, M; Zaccarelli, M | 1 |
| Arribas, JR; Bernardino, JI; Estébanez, M; González-García, JJ; Mingorance, J; Montes, ML; Pérez-Valero, I; Stella-Ascariz, N; Zamora, FX | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Cai, J; Xiao, J; Zhang, Q | 1 |
| Benaboud, S; Hirt, D; Illamola, SM; Labat, L; Tréluyer, JM; Tubiana, R; Warszawski, J | 1 |
| Achan, J; Ades, V; Charlebois, ED; Clark, TD; Cohan, D; Havlir, DV; Kamya, MR; Koss, CA; Luwedde, F; Mwesigwa, J; Natureeba, P; Nzarubara, B; Plenty, A; Ruel, T | 1 |
| Chaix, ML; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Ghosn, J; Gupta, RK; Hue, S; Mbisa, JL; Sutherland, KA | 1 |
| Cabellos, C; Cayuela, N; Imaz, A; Izquierdo, C; Niubó, J; Podzamczer, D; Tiraboschi, JM | 1 |
| Arnalich, F; Arribas, JR; Bayón, C; Bernardino, JI; Estébanez, M; González-Baeza, A; González-García, JJ; Hernando, A; Lagarde, M; Monge, S; Montes-Ramírez, ML; Pérez-Valero, I; Pulido, F; Zamora, FX | 1 |
| Dooley, KE; Karlsson, MO; Svensson, EM | 1 |
| Benki-Nugent, S; Eshelman, C; John-Stewart, G; Langat, A; Okinyi, HM; Tapia, K; Wamalwa, D | 1 |
| Anderson, AM; Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Gottlieb, GS; Tchounga, BK; Tegbe, J; Vitoria, M | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Abrams, EJ; Barlow-Mosha, L; Bobat, R; Bwakura-Dangarembizi, M; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Mofenson, LM; Moultrie, H; Palumbo, P; Petzold, E; Sambo, PM; Schimana, W; Violari, A; Zimmer, B | 1 |
| Fraenkel, L; Han, Y; Hsieh, E; Hu, YY; Insogna, K; Li, T; Xia, W; Xie, J; Yin, MT; Zhu, T | 1 |
| Chaix, ML; Cohen Codar, I; Delaugerre, C; Delfraissy, JF; Ghosn, J; Gregson, J; Gupta, RK; Mbisa, JL; Sutherland, KA | 1 |
| Alvarez-Uria, G; Midde, M; Naik, PK; Pakam, R | 1 |
| Camara, S; Goudjo, A; Guillard, E; Peytavin, G; Vasse, M; Zucman, D | 1 |
| Best, BM; Buranabanjasatean, S; Capparelli, EV; Cressey, TR; Jourdain, G; Lallemant, M; Limtrakul, A; Mirochnick, M; Rawangban, B; Sabsanong, P; Stek, A; Treluyer, JM; Urien, S | 1 |
| Brun-Vezinet, F; Costagliola, D; Mokhtari, S; Poizot-Martin, I; Potard, V; Pradier, C; Rey, D; Rozenbaum, W | 1 |
| Bouazza, N; Burger, D; Capparelli, EV; Fauchet, F; Foissac, F; Kiechel, JR; Lallemant, M; Treluyer, JM; Urien, S | 1 |
| Gous, H; Kellermann, T; Kindra, G; McIlleron, H; Moultrie, H; Sawry, S; Van Rie, A; Wiesner, L | 1 |
| Che, J; Chen, X; Cheng, Y; Dong, T; Meng, Q; Qian, X; Tong, B | 1 |
| Farajallah, A; Hardy, H; Kaplita, S; McGrath, SJ; Moyle, GJ; Ward, D | 1 |
| André, P; Cotte, L; Monneret, G; Ramière, C; Ronfort, C; Saison, J; Tardy, JC; Trabaud, MA; Venet, F | 1 |
| Bamford, A; Foster, C; James, M; Walters, S; Xiang, N | 1 |
| Bonfanti, P; d'Arminio Monforte, A; Di Biagio, A; Fortino, I; Galli, M; Gianotti, N; Lazzarin, A; Pan, A; Poli, A; Quirino, T; Rizzardini, G; Soria, A; Viale, P; Viganò, P | 1 |
| Cabrera Figueroa, SE; Domínguez-Gil Hurlé, A; Iglesias Gómez, A; López Aspiroz, E; Valverde Merino, MP | 1 |
| Baldelli, S; Castoldi, S; Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Fucile, S | 1 |
| Freeling, JP; Ho, RJ; Koehn, J; Shu, C; Sun, J | 1 |
| Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L | 1 |
| Achan, J; Ades, V; Charlebois, ED; Clark, TD; Cohan, D; Gandhi, M; Havlir, DV; Kamya, MR; Koss, CA; Luwedde, F; Mwesigwa, J; Natureeba, P; Nzarubara, B; Plenty, A; Ruel, T | 1 |
| Moreira, J | 1 |
| Fukutake, K; Goseki, Y; Hara, S; Kobayashi, M; Kuriiwa, F; Mizukami, H; Takata, Y; Yoshida, K | 1 |
| Alves, M; Guidet, B; Janneau-Magrino, L; Legendre, N; Pateron, D; Yordanov, Y | 1 |
| Berrio-Galan, D; Bravo, I; Clotet, B; Llibre, JM; Miranda, C; Moltó, J; Paredes, R; Pérez-Alvarez, N; Pérez-Alvarez, S; Santos, JR | 1 |
| Rivero, A | 1 |
| Gatell, JM; Zamora, L | 1 |
| Cahn, P; Figueroa, MI; Rolón, MJ; Sued, O | 1 |
| Ortega, FP; Pardo, OB; Sebastián, Mde L | 1 |
| Aldeguer, JL; Tasias, M | 1 |
| Téllez, MJ | 1 |
| Aguirrebengoa, K | 1 |
| Camacho, Á; Rivero, A | 1 |
| Abgrall, S; Cain, LE; Casabona, J; Costagliola, D; Dabis, F; Esteve, A; Fehr, J; Hernán, MA; Jose, S; Justice, A; Logan, R; Meyer, L; Monge, S; Moreno, S; Muga, R; Olson, A; Paparizos, V; Pérez-Hoyos, S; Phillips, A; Reiss, P; Robins, JM; Sabin, C; Seng, R; Sterne, JA; Tate, J; Touloumi, G; van Sighem, A; Vandenhende, MA; Young, J | 1 |
| Duangchaemkarn, K; Lohitnavy, M; Reisfeld, B | 1 |
| Azwa, I; Boettiger, DC; Bui, HV; Durier, N; Heng Sim, BL; Law, M; Nguyen, VK; Ruxrungtham, K | 1 |
| Aweeka, F; Cohn, SE; Cramer, Y; Klingman, KL; Livingston, E; Luque, AE; Park, JG; Watts, DH; Weinberg, A | 1 |
| Antinori, A; Bonora, S; Chiappetta, S; De Battista, D; Di Pietro, M; Galli, L; Lazzarin, A; Malnati, M; Mazzotta, F; Nozza, S; Ottou, S; Pogliaghi, M; Ripa, M; Zaccarelli, M | 1 |
| Chen, H; Chen, J; Guo, C; Huang, X; Li, N; Li, Z; Wu, H; Xu, Y; Yang, Q; Zhang, T | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kerr, SJ; Kumarasamy, N; Losso, MH; Mohapi, L; Molina, JM; Moore, CL; Nwizu, CA; Renjifo, B; Sohn, AH; Teppler, H | 1 |
| Fairlie, L; Meyers, T; Moultrie, H; Pinillos, F; Sawry, S; van Zyl, G; Wong, JY | 1 |
| Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL | 1 |
| Han, Y; Li, T; Li, Y; Qiu, Z; Song, X; Xie, J; Zhu, T | 1 |
| Ayaya, S; Ciaranello, AL; Doherty, K; Essajee, S; Freedberg, KA; Harrison, L; Kelly, K; Lindsey, JC; Losina, E; Muhe, L; Palumbo, P; Penazzato, M; Walensky, RP; Weinstein, MC; Wools-Kaloustian, K | 1 |
| Amogne, W; Assefa, G; Caulk, AW; Getenet, H; Gleason, RL; Parker, I; Seifu, D; Vidakovic, B | 1 |
| Bonjoch, A; Clotet, B; Echeverría, P; Estany, C; Moltó, J; Negredo, E; Ornelas, A; Pérez-Álvarez, N; Puig, J; Santos, JR | 1 |
| Ajose, O; Beanland, RL; Calmy, A; Doherty, M; Ford, N; Irvine, C; Mayer, KH; Rapparini, C; Shubber, Z; Vitoria, M | 1 |
| Barlow-Mosha, L; Cotton, M; Dominguez, K; Ford, N; Penazzato, M | 1 |
| Achan, J; Bacchetti, P; Charlebois, ED; Clark, TD; Cohan, D; Gandhi, M; Havlir, DV; Horng, H; Kamya, MR; Koss, CA; Mwesigwa, J; Natureeba, P; Nzarubara, B; Plenty, A; Ruel, TD | 1 |
| Adeyemo, T; Akanmu, AS; Awolola, A; Bello, FO; Kanki, PJ; Lesi, F; Ogunsola, FT; Okonkwo, P; Okwuegbuna, K; Oloko, K | 1 |
| Dragusha, S; Ejupi, V; El-Mahdy, AF; Kabashima, T; Kai, M; Shibata, T; Yin, S; Yu, Z; Zhu, Q | 1 |
| Donnen, P; Koy, T; Malandala, GL; Mukumbi, H; Wilmet-Dramaix, M | 1 |
| Avettand-Fenoël, V; Cohen-Codar, I; de Goër de Herve, MG; Delfraissy, JF; Ghosn, J; Hendel-Chavez, H; Rouzioux, C; Taoufik, Y; Tran, TA | 1 |
| Arribas, JR; Cabié, A; Crespo, M; Domingo, P; Dronda, F; Estrada, V; Gatell, JM; Girard, PM; Iribarren, JA; Knobel, H; Landman, R; Mallolas, J; Martínez-Rebollar, M; Montero, M; Pich, J; Podzamczer, D; Portilla, J; Pulido, F; Weiss, L; Zamora, FX | 1 |
| Ascoli-Bartoli, T; Bellelli, V; Bianchi, L; Ceccarelli, G; d'Ettorre, G; De Girolamo, G; Giustini, N; Mastroianni, CM; Serafino, S; Vullo, V; Zaccarelli, M | 1 |
| Fairlie, L; Link-Gelles, R; Madhi, S; Mahomed, N; Moultrie, H; Murdoch, D; Sawry, S; Van Rie, A; Verwey, C | 1 |
| Du, X; Fu, Q; Li, T; Liu, Z; Zhang, X | 1 |
| Blanche, S; Delmas, S; Fauchet, F; Hirt, D; Illamola, SM; Lechedanec, J; Lui, G; Mandelbrot, L; Pressiat, C; Treluyer, JM; Tubiana, R; Urien, S; Valade, E; Warszawski, J | 1 |
| Anastos, K; Burk, RD; Dugan, KB; DʼSouza, G; Eltoum, IE; Flowers, L; Lahiri, CD; Massad, LS; Ofotokun, I; Palefsky, JM; Rahangdale, L; Reimers, L; Strickler, HD; Xie, X; Xue, X | 1 |
| Avenant, T; du Plessis, NM; Feucht, UD; Melikian, G; Rossouw, TM; Thomas, W; van Dyk, G | 1 |
| Anderson, J; Barbour, A; Conway, K; Dermont, S; deRuiter, A; Dwyer, E; Flanagan, S; Hawkins, D; Hay, P; McKendry, A; Mulka, L; Perry, ME; Rodgers, M; Roedling, S; Sabin, CA; Sarner, L; Shah, R; Stevenson, J; Taylor, GP; Williams, E; Wood, C | 1 |
| Ananworanich, J; Bacchetti, P; Chokephaibulkit, K; Do, VC; Gandhi, M; Horng, H; Kerr, SJ; Kosalaraksa, P; Kurniati, N; Nguyen, LV; Prasitsuebsai, W; Singtoroj, T; Sohn, AH; Sudjaritruk, T; Teeraananchai, S; Thammajaruk, N; Truong, KH | 1 |
| Aweeka, F; Collier, AC; Dumond, JB; Kashuba, AD; Mollan, K; Rigdon, J; Tierney, C | 1 |
| Begovac, J; Jukić, V; Kolovrat, K; Kozić Dokmanović, S; Laškaj, R; Vrkić, N | 1 |
| Klein, MB; Mucsi, I; Rollet-Kurhajec, KC; Young, J | 1 |
| Arenas-Pinto, A; Atwongyeire, D; Kambugu, A; Lugemwa, A; Musana, H; Musoro, G; Mweemba, A; Paton, NI; Thomason, MJ; Thompson, J; Walker, AS | 1 |
| Gilks, CF; Goodall, R; Gupta, RK; Kaleebu, P; Kapaata, A; Kityo, C; Lyagoba, F; McCormick, A; Parry, CM; Pillay, D; Spyer, M; Sutherland, KA | 1 |
| Abu-Shakra, M; Basok, A; Kiselnik, D; Wolak, A | 1 |
| Clifford, DB; Collier, AC; Croteau, D; Gelman, BB; Grant, I; Heaton, RK; Kao, YT; Letendre, SL; Ma, Q; Marra, CM; McArthur, JC; Morgello, S; Sanders, CA; Simpson, DM; Vaida, F; Wong, J | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kelleher, AD; Losso, M; Madero, JS; Molina, JM; Moore, CL; Renjifo, B; Ruxrungtham, K; Teppler, H; Wolff, M; Wood, R | 1 |
| Blanes, M; Calabuig, E; Cuellar, S; Di Benedetto, N; Lacruz, J; López, J; Montero-Alonso, M; Salavert, M | 1 |
| He, C; Huang, H; Liao, L; Liu, J; Ruan, Y; Shao, Y; Wang, J; Wang, Z; Xing, H; Yang, S; Yue, Y | 1 |
| Decloedt, EH; Maartens, G; McIlleron, H; van der Walt, JS; Wiesner, L | 1 |
| Ayudhaya, OP; Bouazza, N; Cressey, TR; Foissac, F; Ingsrisawang, L; Jittayanun, K; Jourdain, G; Jungpipun, J; Lallemant, M; Le Coeur, S; Ngo-Giang-Huong, N; Puangsombat, A; Sripan, P; Srirompotong, U; Traisathit, P; Tréluyer, JM; Urien, S | 1 |
| Adetokunboh, OO; Balogun, TA; Schoonees, A; Wiysonge, CS | 1 |
| Jones, AK; Klein, CE; Nilius, AM; Patterson, KB; Salem, AH; Santini-Oliveira, M; Taylor, GP | 1 |
| Yogev, R | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Martens, L; Patel, F; Pinillos, F; Shiau, S; Strehlau, R; Tsai, WY | 1 |
| Boissonnault, M; Charest, L; Galanakis, C; Huchet, E; Longpré, D; Machouf, N; Murphy, D; Thomas, R; Trottier, B; Vézina, S | 1 |
| Abach, J; Arenas-Pinto, A; Hakim, J; Hoppe, A; Kambugu, A; Kwobah, C; Mwebaze, R; Paton, NI; Thompson, J; Tumukunde, D; van Oosterhout, JJ; Walker, SA | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Blanche, S; Engebretsen, IMS; Hofmeyr, GJ; Jackson, D; Kankasa, C; Kwagala, M; Lombard, C; Maréchal, V; Meda, N; Mwiya, M; Nagot, N; Ndeezi, G; Neboua, D; Neveu, D; Rekacewicz, C; Rutagwera, D; Singata, M; Siuluta, C; Some, E; Sommerfelt, H; Sunday, A; Traore, H; Tumwine, JK; Tylleskär, T; Vallo, R; Van de Perre, P | 1 |
| Cohen, K; Dave, JA; Levitt, NS; Maartens, G; Micklesfield, LK | 1 |
| Curto, J; Ferrer, E; González, A; Imaz, A; Knobel, H; Niubó, J; Podzamczer, D; Rozas, N; Saumoy, M; Tiraboschi, JM; Vila, A; Villar, J | 1 |
| Arribas, JR; Elbirt, D; Girard, PM; Hadacek, MB; Hill, A; Marcelin, AG; Paton, N; Winston, A | 1 |
| Aghokeng, AF; Bertagnolio, S; Carmona, S; Chua, A; De Oliveira, T; Fitzgibbon, JE; Fokam, J; Frenkel, LM; Gallant, JE; Gupta, RK; Hamers, RL; Hosseinipour, MC; Jordan, MR; Kantor, R; Katzenstein, D; Mukui, I; Ndembi, N; Parkin, N; Raizes, E; Rhee, SY; Richman, DD; Rinke de Wit, TF; Schapiro, JM; Schito, M; Shafer, RW; Tang, M; Van Zyl, GU; Wainberg, MA; Wallis, CL; Wensing, AM; Yang, C; Zeh, C | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
| Arruda, MB; de Brindeiro, RM; Nobre, FF; Raposo, LM | 1 |
| Balogun, K; Banko, N; Loutfy, M; MacGillivray, J; Mohammadi, H; Murphy, KE; Papp, E; Serghides, L; Shah, R; Silverman, M; Walmsley, SL; Yudin, MH | 1 |
| Ande, A; Kumar, A; Kumar, S; Li, J; Li, W; Nookala, AR; Vaidya, NK; Wang, L | 1 |
| Conradie, F; Hughes, J; Maartens, G; McIlleron, H; Pandie, M; Siwendu, S; Variava, E; Wiesner, L | 1 |
| Bravo, I; Cañadas, MP; Clotet, B; García-Rosado, D; Llibre, JM; Moltó, J; Paredes, R; Pérez-Álvarez, N; Santos, JR | 1 |
| Barnes, KI; Cohen, K; Kredo, T; Maartens, G; Mauff, K; Smith, PJ; Van der Walt, JS; Wiesner, L; Workman, L | 1 |
| Basson, AE; Cane, PA; Coovadia, A; Giandhari, J; Hunt, G; Kuhn, L; Morris, L; Parry, CM; Sutherland, K | 1 |
| Norton, M; Thorne, C; Tookey, PA; van Wyk, J | 1 |
| Jin, R; Lu, R; Peng, H; Wang, C; Wang, M; Wang, X; Wu, H; Xia, W; Xie, D; Yao, C; Zhang, H; Zhang, T | 1 |
| Bruce-Keller, AJ; Dasuri, K; Fernandez-Kim, SO; Gupta, S; Keller, JN; Pepping, JK; Scherer, PE | 1 |
| Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP | 1 |
| Srinivas, NR | 1 |
| Durante, W; Durante, ZE; Liu, XM; Peyton, KJ | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Ananworanich, J; Bunupuradah, T; Cremers, S; Kancheva Landolt, N; Kerr, S; Kosalaraksa, P; Thammajaruk, N; Ubolyam, S; Zott, R | 1 |
| Wang, D; Xiao, Q; Yang, J; Yang, W; Yao, C | 1 |
| Chen, J; Dumond, JB; Malone, S; Patterson, KB; Prince, HM | 1 |
| Arnedo, M; Asensi, V; Cruceta, A; del Rio, L; Domingo, P; Estrada, V; Fontdevila, J; Gatell, JM; Imaz, A; Lonca, M; Martínez, E; Miralles, C; Montero, M; Perez, I; Rojas, J | 1 |
| Crespo, M; Curran, A; Domingo, P; Gatell, J; Mallolas, J; Martinez-Rebollar, M; Mateo, GM; Navarro, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Baptiste, D; Gibb, DM; Judd, A; Kekitiinwa, A; Lallemant, M; Mirembe, G; Musiime, V; Nakalanzi, S; Thomason, MJ; Walker, AS | 1 |
| Castel, S; Dandara, C; Kampira, E; Lacerda, M; Mpeta, B; Mpye, KL; Skelton, M; Smith, P; Soko, ND; Wiesner, L | 1 |
| Carvalhal, A | 1 |
| Castro-Iglesias, Á; Cid, P; Grandal, M; Margusino, L; Mena, Á; Pedreira, JD; Pernas, B; Pértega, S; Poveda, E; Tabernilla, A | 1 |
| Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS | 1 |
| Collier, AC; Harrison, LJ; Hosseinipour, MC; Jarocki, B; Kim, P; Kumarasamy, N; La Rosa, AM; Mellors, JW; Taiwo, B; Wallis, CL; Zheng, L | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Abebe, W; Amogne, W; Caulk, AW; Eckard, AR; Gleason, RL; Rosebush, JC; Schwartz, MH; Seifu, D; Shapiro, AM | 1 |
| Avihingsanon, A; Kerr, S; Phanuphak, P; Pussadee, K; Riyaten, P; Ruxrungtham, K; Sapsirisavat, V; Thammajaruk, N; Vongsutilers, V | 1 |
| Cohen, K; Court, R; Gordon, M; Gosnell, B; Maartens, G; Stewart, A; Wiesner, L | 1 |
| Sungkanuparph, S; Wangpatharawanit, P | 1 |
| Arpadi, SM; Coovadia, A; Kaufman, JJ; Kuhn, L; Mbete, N; McMahon, DJ; Patel, F; Shiau, S; Strehlau, R; Yin, MT | 1 |
| Angelidou, K; Archary, M; Barlow-Mosha, L; Barr, E; Chi, BH; Cotton, M; Dittmer, S; Fairlie, L; Jean-Phillipe, P; Kabugho, E; Kamthunzi, P; Kinikar, A; Lindsey, J; Mbengeranwa, T; Mofenson, L; Msuya, L; Palumbo, P; Patel, K; Sambo, P; Violari, A | 1 |
| Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ | 1 |
| Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Baldelli, F; Celesia, BM; Focà, E; Galli, L; Gianotti, N; Lazzarin, A; Lo Caputo, S; Maserati, R; Palvarini, L; Ripamonti, D; Sighinolfi, L; Sterrantino, G | 1 |
| Boroath, B; Canestri, A; Chanroeurn, H; Delfraissy, JF; Limsreng, S; Ly, S; Marcy, O; Ouk, V; Ségéral, O; Thavary, S; Viretto, G | 1 |
| Achan, J; Charlebois, E; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, M; Mwangwa, F; Plenty, A; Ruel, T; Young, S | 1 |
| Abrams, EJ; Castel, S; Coovadia, A; Kuhn, L; Maartens, G; McIlleron, H; Moholisa, RR; Patel, F; Pinillos, F; Schomaker, M; Strehlau, R; Wiesner, L | 1 |
| Aga, E; Bartlett, J; Hosseinipour, MC; Hughes, MD; Kumarasamy, N; Matoga, MM; Ribaudo, HJ | 1 |
| Aurpibul, L; Chokephaibulkit, K; Do, VC; Kerr, SJ; Kosalaraksa, P; Kurniati, N; Nguyen, LV; Prasitsuebsai, W; Singtoroj, T; Sudjaritruk, T; Teerananchai, S; Truong, KH | 1 |
| Giardiello, M; Gurjar, R; Liptrott, NJ; Martin, P; McDonald, TO; Moss, D; Owen, A; Rannard, SP; Siccardi, M; Smith, D | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Post, FA | 1 |
| Asensi-Díez, R; Castaño-Carracedo, MA; Del Rio-Valencia, JC; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Chen, J; Hu, X; Liu, Y; Lu, L; Qin, S; Sun, Y; Tan, N; Wang, Z; Yang, J; Zhan, J; Zhang, C; Zhou, J | 1 |
| Blanche, S; Blume, J; Bouazza, N; Foissac, F; Harper, K; Hirt, D; Illamola, SM; Kankasa, C; Meda, N; Nagot, N; Singata-Madliki, M; Tréluyer, JM; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Claiborne, DT; Collier, DA; Deymier, MJ; Goldstein, RA; Gupta, RK; Hunter, E; Prince, JL; Sutherland, KA | 1 |
| Chaves, GC; Scopel, CT | 1 |
| Amani Bosse, C; Amorissani Folquet, M; Avit, D; Ciaranello, A; Dainguy, E; Desmonde, S; Eboua, FT; Leroy, V; Mea, V; Ngbeché, S; Petit, J; Timite-Konan, M | 1 |
| Barlow-Mosha, L; Borkowsky, W; Chen, J; Chi, BH; Deygoo, N; Duffy, PE; Gabriel, EE; Hobbs, CV; Ilmet, T; Jean Philippe, P; Kamthunzi, P; Kirmse, B; Li, Y; Mofenson, L; Musoke, P; Neal, J; Palumbo, P; Parikh, S; Petzold, E; Prescott, W; Tauzie, J; Tegha, G | 1 |
| Alteri, C; Bernardi, S; Bertoli, A; Liuzzi, G; Manno, EC; Palma, P; Perno, CF; Rossi, P; Tchidjou, HK; Zangari, P | 1 |
| Agüero, F; Ambrosioni, J; Brunet, M; Caballero, M; de Lazzari, E; Gallart, T; Gatell, JM; Guardo, AC; López-Diéguez, M; Manzardo, C; Marcos, MÁ; Miró, JM; Mosquera, MM; Muñoz-Fernández, MÁ; Nicolás, D; Plana, M; Sued, O; Tuset, M | 1 |
| Kaleebu, P; Kapaata, AA; Kasamba, I; Kazooba, P; Lutaakome, J; Lyagoba, F; Mayanja, BN; Munderi, P; Namakoola, I | 1 |
| Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM | 1 |
| Curto, J; Domingo, P; Gatell, JM; Mallolas, J; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M; Tiraboschi, JM | 1 |
| Chadwick, D; Hamzah, L; Jones, R; Jose, S; Nelson, M; Phillips, A; Post, FA; Sabin, CA; Trevelion, R; Williams, DI | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; Celesia, BM; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Galli, M; Gianotti, N; Mussini, C; Pinnetti, C; Spagnuolo, V | 1 |
| Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fortuin-de Smidt, M; Igumbor, EU; Maartens, G; Stinson, K; Technau, KG | 1 |
| López-Montenegro Soria, M; Pelufo-Pellicer, A | 1 |
| Anderson, KN; Blamire, A; Chadwick, TJ; Hynes, AM; Parikh, J; Payne, B; Price, DA; Qian, J; Wilkinson, J | 1 |
| Ananworanich, J; Boonrak, P; Bunupuradah, T; Burger, D; Engchanil, C; Intasan, J; Kosalaraksa, P; Lumbiganon, P; Ruxrungtham, K; Schutz, M | 1 |
| Back, DJ; Cargnel, A; Cordier, L; Cusato, M; Dickinson, L; Duca, P; Khoo, SH; Meraviglia, P; Micheli, V; Orlando, G; Regazzi, M; Rizzardini, G; Viganò, P; Villani, P | 1 |
| Beukel van den Bout-van den, CJ; Bosch, ME; Burger, DM; Koopmans, PP; van der Ven, AJ | 1 |
| Baldelli, F; De Socio, GV; Martinelli, L; Zazzi, M | 1 |
| Andrade-Villanueva, J; De Meyer, S; De Pauw, M; Dejesus, E; Fourie, J; Khanlou, H; Lefebvre, E; Ortiz, R; Spinosa-Guzman, S; van Lunzen, J; Vangeneugden, T; Voronin, E | 1 |
| Ray, AS; Rhodes, GR; Wright, MR | 1 |
| Alfaro, RM; Busse, KH; Formentini, E; Kovacs, JA; Penzak, SR | 1 |
| Calza, L; Chiodo, F; Manfredi, R; Pocaterra, D | 1 |
| Keiser, PH; Nassar, N | 1 |
| Ferrer, A; Galindo, MJ; Gonzalez-Muñoz, M; Polo, R; Verdejo, J | 1 |
| Arribas, JR; Pulido, F | 2 |
| Boue, F; Cohen-Codar, I; Delfraissy, JF; Dellamonica, P; Flandre, P; Marcellin, F; Norton, M; Raffi, F; Spire, B; Van Philippe, N | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Barragan, P; Podzamczer, D | 1 |
| Cohen, C; De Luca, A; Grant, P; Harrington, R; Hawkins, T; Kempf, D; Nadler, J; Rode, R; Shafer, R; Wong, EC; Zolopa, A | 1 |
| Frank, I; Torti, C | 1 |
| Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Thiry, A; Yang, R | 1 |
| Amici, R; Baroncelli, S; Cusato, M; Floridia, M; Galluzzo, CM; Molinari, A; Pinnetti, C; Pirillo, MF; Regazzi, M; Sabbatini, F; Tamburrini, E; Villani, P | 1 |
| Schulz, TR; Street, AC | 1 |
| Chin, BS; Choi, H; Choi, JY; Choi, SH; Han, SH; Jeong, SJ; Kim, CO; Kim, JM; Kim, MS; Lee, HS; Song, YG | 1 |
| Andreoni, M; Narciso, P; Nicastri, E | 1 |
| Barbanoj, MJ; Blanco, A; Clotet, B; Costa, J; Domingo, P; Miranda, C; Moltó, J; Negredo, E; Santos, JR; Valle, M | 1 |
| Amorosa, V; Cramer, YS; Gupta, SK; Hall, SD; Koletar, SL; Rosenkranz, SL; Szczech, LA | 1 |
| Ajana, F; André, P; Bocket, L; Champenois, K; Choisy, P; Cotte, L; Deuffic-Burban, S; Yazdanpanah, Y | 1 |
| Berrisford, AE; Boulle, AM; Jaspan, HB | 1 |
| Bembom, O; Fessel, WJ; Petersen, ML; Rhee, SY; Shafer, RW; Sinisi, SE; van der Laan, MJ | 1 |
| Batterham, M; Chan, DJ; McNally, L; Ray, JE; Smith, DE | 1 |
| Barragán, P; Curto, J; Ferrer, E; Olmo, M; Perulero, N; Podzamczer, D; Saumoy, M | 1 |
| Cohen, MS | 1 |
| Cahn, P; Carr, A; Chaves, R; Gatell, JM; Ritzhaupt, A; Workman, C; Zajdenverg, R; Zhang, W | 1 |
| Barrail-Tran, A; Chaix, ML; Delfraissy, JF; Ghosn, J; Pallier, C; Sahali, S | 1 |
| Busse, KH; Hammer, JH; Kwan, R; Maldarelli, F; Mican, JM; Nieman, L; Pau, AK; Ramanathan, R; Zemskova, M | 1 |
| Boutté, P; Monpoux, F; Pitelet, G; Richelme, C | 1 |
| Colucci, P; Ducharme, MP; Hoepelman, IM; Pottage, JC; Robison, H; Schürmann, D; Turgeon, J | 1 |
| Babiker, AG; Cotton, MF; Gibb, DM; Jean-Philippe, P; Madhi, SA; McIntyre, JA; Steyn, J; Violari, A | 1 |
| Borkowsky, W; Coppi, A; Hobbs, CV; Kirmse, B; Marsh, K; Sinnis, P; Voza, T | 1 |
| Moreno-Celda, V; Valencia-Ortega, ME | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Jean-Philippe, P; King, JR; Kraimer, J; Moye, J; Watson, D; Wiznia, A; Yogev, R | 1 |
| Bierman, WF; Boucher, CA; Danner, SA; Nijhuis, M; van Agtmael, MA | 1 |
| Pitrak, DL | 1 |
| Ameli, N; Anastos, K; Bacchetti, P; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Hyman, CL; Levine, A; Young, M | 1 |
| Guillemi, S; Harrigan, PR; Harris, M; Hull, MW; Lima, V; Montaner, JS | 1 |
| Collada de la Fuente, E; Escobar, I; Granja, V; Moreno, V; Rubio, R; Sáez de la Fuente, J | 1 |
| Burger, DM; Driessen, GJ; Hartwig, NG; van der Flier, M; van der Knaap, LC; van der Lee, M; van Jaarsveld, P; Verweel, G | 1 |
| Estrada, V; Fuster, M | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Antela López, A | 1 |
| García Deltoro, M | 1 |
| Adkison, KK; Berger, D; Bonny, T; Cimoch, P; Lamarca, A; Lazzarin, A; Madison, SJ; McCarty, D; Millard, J; Nichols, WG; Salvato, P; Smaill, FM; Teofilo, E; Yeni, P | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; DeMasi, R; Hill, A; Picchio, G | 1 |
| Barroso, PF; Dias-Neto, E; Estrela, Rde C; Gregório, SP; Ribeiro, FS; Struchiner, CJ; Suarez-Kurtz, G; Tuyama, M | 1 |
| Alvero, CG; Browning, R; Capparelli, E; Chadwick, EG; Hazra, R; Heckman, BE; Hughes, MD; Luzuriaga, K; Palumbo, P; Pinto, J; Purdue, L; Robbins, B; Rodman, J; Serchuck, L; Yogev, R | 1 |
| Dietz, B; Rajagopalan, R; Simpson, KN | 1 |
| Bernstein, B; Cohen, DE; da Silva, BA; Fredrick, L; Gathe, J; Gibbs, S; Loutfy, MR; Marsh, T; Naylor, C; Podzamczer, D; Rubio, R | 1 |
| Baxter, L; Bryant, J; Hird, S | 1 |
| Allavena, C; Cahn, P; Clotet, B; Côté, H; Harris, M; Montaner, J; Negredo, E; Ochoa, C; Raffi, F; Singer, J; Thorne, A; Zala, C | 1 |
| Moreno, V; Valencia, ME | 1 |
| Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN; Strassburger, A | 1 |
| Baghdassarian, A; Neely, MN; Rakhmanina, N; Soldin, S; van den Anker, J; Williams, K | 1 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Bernstein, BM; Campo, RE; Chiu, YL; Cotte, L; Da Silva, BA; Gathe, JC; Gazzard, B; Hicks, CB; King, MS; Klein, CE | 1 |
| Chaves, G; Reis, R; Vieira, MF | 1 |
| Berzins, B; Evans, S; Forand, J; Hafner, R; Murphy, R; Owens, S; Shevitz, A; Tashima, K; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Chaix, ML; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Flandre, P; Ghosn, J; Girard, PM; Gladysz, A; Horban, A; Rouzioux, C; Taburet, AM; Van, PN | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Autran, B; Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Damond, F; Descamps, D; Lascoux-Combes, C; Matheron, S; Peytavin, G; Simon, F; Taieb, A | 1 |
| Arazo, P; Arranz, A; Arribas, JR; Delgado, R; Iribarren, JA; Knobel, H; López-Aldeguer, J; Montes, ML; Muñoz, R; Ocampo, A; Pasquau, J; Pérez-Elias, MJ; Portilla, J; Pulido, F; Rubio, R; Sánchez-Conde, M; Sanz, J | 1 |
| Aarnoutse, RE; Boeree, M; Brinkman, K; Burger, DM; Gras, L; Juttmann, JR; L'homme, RF; Nijland, HM; Prins, JM; van Crevel, R | 1 |
| Azria, E; Bouillon-Pichault, M; Chhun, S; Compagnucci, A; Finkielsztejn, L; Firtion, G; Jullien, V; Krivine, A; Launay, O; Pannier, E; Pons, G; Taulera, O; Treluyer, JM | 1 |
| Aranda, M; Arranz, JA; Blanco, JL; Clotet, B; Cosin, J; Cruceta, A; Dalmau, D; Domingo, P; Ferrer, E; García, I; Gatell, JM; Gutiérrez, F; Knobel, H; Lazzari, Ed; Llibre, JM; Mallolas, J; Martínez, E; Milinkovic, A; Murillas, J; Pedrol, E; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Vidal, F | 1 |
| Finkielsztejn, L; Firtion, G; Jullien, V; Krivine, A; Launay, O; Pannier, E; Rozenberg, F | 1 |
| Butcher, DL; DiRienzo, AG; Garren, KW; Haas, DW; Haubrich, RH; Havlir, DV; Klingman, K; Komarow, L; Mellors, JW; Powderly, WG; Riddler, SA; Rooney, JF | 1 |
| Alabi, A; Corrah, T; Cotten, M; Jallow, S; Janssens, W; Jaye, A; McConkey, SJ; Peterson, K; Rowland-Jones, S; Sarge-Njie, R; Vanham, G; Whittle, H | 1 |
| Brinkman, K; Danner, SA; Geerlings, SE; Hassink, EA; Lips, P; Reiss, P; Ristola, M; Sutinen, J; van Agtmael, MA; van Vonderen, MG | 1 |
| Arranz, A; Arribas, JR; Clotet, B; Delgado, R; Estrada, V; González-García, J; Hernando, A; Miralles, P; Ocampo, A; Pasquau, J; Pérez-Elías, MJ; Pérez-Valero, I; Podzamczer, D; Portilla, J; Pulido, F; Rubio, R | 1 |
| Ananworanich, J; Boonrak, P; Bunupuradah, T; Burger, D; Engchanil, C; Kosalaraksa, P; Lumbiganon, P; Mahanontharit, A; Mengthaisong, T; Puthanakit, T; Ruxrungtham, K; Tompkins, E; van der Lugt, J | 1 |
| Chaix, ML; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Dellamonica, P; Flandre, P; Ghosn, J; Jaeger, H; Norton, M; Raffi, F; Rouzioux, C; Shürmann, D; Taburet, AM; Van, PN | 1 |
| Azria, E; Cabrol, D; Compagnucci, A; Finkielsztejn, L; Firtion, G; Krivine, A; Launay, O; Le Meaux, JP; Moutafoff, C; Pannier, E; Schmitz, T; Taulera, O; Tsatsaris, V | 1 |
| de Béthune, MP; De Meyer, S; De Paepe, E; Dierynck, I; Lathouwers, E; Lefebvre, E; Picchio, G; Spinosa-Guzman, S; Van Baelen, B; Vangeneugden, T | 1 |
| Chen, CY; Grinspoon, SK; Hadigan, CM; Joy, T; Liebau, JG; Makimura, H; Robbins, GK; Stanley, TL; Thomas, BJ; Weise, SB | 1 |
| Brinkman, K; Danner, SA; Geerlings, SE; Hassink, EA; Milinkovic, A; Reiss, P; Ristola, M; van Agtmael, MA; van Eeden, A; van Vonderen, MG | 1 |
| Abeele, CV; Cassetti, I; Dierynck, I; Girard, PM; Jayaweera, D; Lavreys, L; Mills, AM; Nelson, M; Ruxrungtham, K; Sekar, V; Workman, C | 1 |
| Bernstein, BM; Brown, TT; da Silva, BA; King, MS; McComsey, GA; Qaqish, RB | 1 |
| Edamoto, Y; Kamimura, M; Kikuchi, Y; Kobayakawa, M; Mihara, F; Oka, S; Teruya, K; Watanabe, K | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Feinberg, J | 1 |
| Arribas López, JR; Pulido Ortega, F | 1 |
| Arranz Caso, JA | 1 |
| Llenas-García, J; Pulido Ortega, F | 1 |
| López Aldeguer, J | 1 |
| Clotet, B; Moltó, J | 1 |
| Arribas López, JR | 1 |
| Pérez Valero, I | 1 |
| Delgado, R | 1 |
| Escobar Rodríguez, I; Esteban Alba, C | 1 |
| Pasquau Liaño, J | 1 |
| Abecasis, AB; Cabanas, J; Camacho, RJ; Carvalho, AP; Palma, AC; Vandamme, AM; Vercauteren, J | 1 |
| la Porte, C; Mitchell, CD; Parker, J; Rongkavilit, C; van Heeswijk, R; Zhang, G | 1 |
| Andrade, A; Eshleman, SH; Flanigan, T; Flexner, C; Gross, R; Hogg, E; Lalama, C; Mildvan, D; Reisler, R; Rosenkranz, S; Salomon, N; Santana, J; Tierney, C; Wiggins, I | 1 |
| Blanco, F; Jiménez-Nácher, I; Morello, J; Rodríguez-Nóvoa, S; Rubio, AJ; Soriano, V | 1 |
| Calvez, V; Hill, A; Marcelin, AG | 1 |
| Bierman, WF; Boucher, CA; de Jong, D; Fun, A; Jaspers, CA; Kagan, R; Nijhuis, M; Schurink, KA; van Agtmael, MA; Wensing, AM | 1 |
| Khachi, H; Ladenheim, D; O'Connell, R; Orkin, C | 1 |
| Chaubey, SK; Falhammar, H; Phillips, E; Russell, DB; Sinha, AK | 1 |
| Alonso-Villaverde, C; Barrufet, P; Bonjoch, A; Clotet, B; Cucurull, J; Domingo, P; Estany, C; Force, L; Garrabou, G; Masabeu, A; Miró, O; Morén, C; Negredo, E; Pérez-Alvarez, N; Rodríguez-Santiago, B | 1 |
| Chaix, ML; Cohen-Codar, I; Delfraissy, JF; Dellamonica, P; Flandre, P; Ghosn, J; Girard, PM; Ngovan, P; Norton, M; Raffi, F | 1 |
| Pacios, E | 1 |
| Chachad, S; Gogtay, J; Malhotra, G; Purandare, S | 1 |
| Ananworanich, J; Boonrak, P; Bunupuradah, T; Burger, D; Gorowara, M; Jupimai, T; Pancharoen, C; Phasomsap, C; Puthanakit, T; Ruxrungtham, K; van der Lugt, J | 1 |
| Chen, J; Chen, L; Gurley, E; Hylemon, PB; Pandak, WM; Sanyal, AJ; Studer, E; Sun, L; Wang, G; Wang, JY; Wang, X; Wu, X; Zha, W; Zhang, L; Zhou, H | 1 |
| Chetchotisakd, P | 1 |
| Rackley, RJ | 1 |
| Chang, SC; Chang, SY; Chen, MY; Hsieh, SM; Hung, CC; Sheng, WH | 1 |
| Bergerat, JP; Herbrecht, R; Levêque, D; Pavillet, J; Santucci, R | 1 |
| Castelnuovo, B; Colebunders, R; Kambugu, AD; Lutwama, F; Piloya, T; Shihab, HM | 1 |
| Sankawa, Y | 1 |
| Abbara, C; Antonini, T; Bonhomme-Faivre, L; Desbois, D; Duclos-Vallée, JC; Samuel, D; Teicher, E; Vittecoq, D | 1 |
| Ashkin, D; Boulanger, C; Espinoza, LA; Farrell, K; Graham, JJ; Hollender, E; Maasen, D; Peloquin, CA; Rivero, RO; Stambaugh, JJ; Symes, S | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Cavassini, M; Fux, CA; Guenthard, HF; Hirschel, B; Rickenbach, M; Vernazza, P; Young, J | 1 |
| Fox, MP; Ive, P; Long, L; Maskew, M; Sanne, I | 1 |
| Albrecht, H; Jorgensen, P; Marcus, U; Schürmann, D; Suttorp, N | 1 |
| Elens, L; Haufroid, V; Lison, D; Vandercam, B; Wallemacq, P; Yombi, JC | 1 |
| Bangsberg, DR | 1 |
| Boonrak, P; Chokephaibulkit, K; Gorowara, M; Leawsrisuk, P; Puthanakit, T; Ruxrungtham, K; Suntarattiwong, P; Suwanlerk, T | 1 |
| Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Sabin, C; Stöhr, W; Winston, A | 1 |
| Bouillon-Pichault, M; Chhun, S; Dupin, N; Jullien, V; Krivine, A; Launay, O; Lortholary, O; Morini, JP; Piketty, C; Pons, G; Salmon, D; Treluyer, JM; Viard, JP; Weiss, L | 1 |
| Ananworanich, J; Avihingsanon, A; Burger, D; Gorowara, M; Lange, J; Phanuphak, P; Ruxrungtham, K; Sealoo, S; van der Lugt, J | 1 |
| Girard, PM; Lacombe, K; Meynard, JL; Morand-Joubert, L; Poirier, JM; Slama, L; Valantin, MA | 1 |
| Anceschi, MM; Ascenzi, P; Ivanovic, J; Mattia, E; Narciso, P; Nicastri, E; Notari, S; Pisani, G; Pucillo, LP; Signore, F; Tempestilli, M; Vallone, C | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Cruttenden, K; DiCenzo, R; DiFrancesco, R; Donnelly, J; Schifitto, G | 1 |
| Hills-Nieminen, C; Houston, S; Hughes, CA; Shafran, SD | 1 |
| Gorny, M; Läer, S; Morali, N; Niehues, T; Röhm, S | 1 |
| Bravo, I; Carosi, G; Clotet, B; del Arco, A; Echeverría, P; Gálvez, J; Gómez, JL; López, JC; López-Blazquez, R; Mariño, A; Moreno, A; Negredo, E; Ocampo, A; Pedrol, E; Pérez-Alvarez, N; Portilla, J; Prieto, A; Rubio, R; Viladés, C | 1 |
| Cocohoba, J | 1 |
| Aweeka, FT; Best, BM; Burchett, SK; Capparelli, EV; Hermes, A; Holland, D; Hu, C; Mirochnick, M; Read, J; Stek, A | 1 |
| Belgum, T; Christensen, K; Dash, A; Destache, CJ; Sharma, A; Shibata, A | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Altice, FL; Springer, SA | 1 |
| Andrade-Villanueva, J; Barnard, RJ; Berger, DS; Cooper, DA; Dejesus, E; Dinubile, MJ; Eron, JJ; Fätkenheuer, G; Kumar, PN; Leavitt, R; Miller, MD; Nguyen, BY; Rodgers, AJ; Shaughnessy, MA; Sklar, P; Walker, ML; Workman, C; Xu, X; Youle, M; Young, B; Zajdenverg, R | 1 |
| Barroso, PF; de Cássia Estrela, R; Kohlrausch, FB; Suarez-Kurtz, G | 1 |
| Neely, MN; Rakhmanina, NY | 1 |
| Antuna-Puente, B; Belaunzarán-Zamudio, F; Crabtree-Ramírez, B; Gutiérrez-Escolano, F; Juárez-Kasusky, I; Lima, V; Magana-Aquino, M; Méndez, P; Montaner, J; Mosqueda-Gómez, JL; Pérez-Saleme, L; Ramos-Santos, C; Rangel-Frausto, S; Sierra-Madero, J; Soto-Ramírez, LE; Torres-Escobar, I; Villasis-Keever, A | 1 |
| Cohen, CJ; Greenblatt, DJ; Hellinger, JA; Rhee, MS; Sheble-Hall, S | 1 |
| Andrade-Villanueva, J; Badal-Faesen, S; Bernstein, BM; Fredrick, LM; Gathe, J; Gaultier, IA; Mingrone, H; Podsadecki, TJ; Woodward, WC; Zajdenverg, R | 1 |
| Kaiser, R; Kemper, I; Knops, E; Pfister, H; Schülter, E; Verheyen, J | 1 |
| Acosta, EP; Kim, G; Klebert, M; Mondy, KE; Overton, ET; Rodriguez, M; Royal, M; Spitz, T; Tschampa, JM | 1 |
| Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N | 1 |
| Aberg, J; Andrade, A; Dehlinger, M; Eshleman, SH; Ferguson, E; Flexner, C; Gross, R; Kashuba, A; Kmack, A; Lalama, C; Mildvan, D; Parsons, T; Rosenkranz, SL; Sanne, I; Tierney, C | 1 |
| Abrams, EJ; Coovadia, A; Ko, S; Kuhn, L; Meyers, T; Reitz, C; Sherman, G; Strehlau, R | 1 |
| Bloch, M; Calmy, A; Carr, A; Cooper, DA; Delhumeau, C; Finlayson, R; Hirschel, B; Norris, R; Rafferty, M; Wand, H | 1 |
| Avettand-Fenoel, V; Chaix, ML; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Flandre, P; Ghosn, J; Ngovan, P; Raffi, F; Rouzioux, C | 1 |
| Burger, DM; Faraj, D; Gelinck, L; Kroon, F; Kuks, PF; Richter, C; Van der Ende, ME; Van der Ven, A; van Luin, M; Van Schaik, RH; Visser, M; Wit, FW | 1 |
| Bellón, JM; de José, MI; Gutiérrez, MD; Larru, B; Lorente, R; Micheloud, D; Muñoz-Fernández, MA; Palladino, C; Polo, R; Resino, S | 1 |
| Coveney, PV; Kenway, OA; Sadiq, SK; Wright, DW | 1 |
| Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS | 1 |
| Abe, E; Alvarez, JC; de Truchis, P; Dinh, A; Greder-Belan, A; Ledu, D; Mathez, D | 1 |
| Palasanthiran, P; Walls, T; Yeong, MM; Ziegler, JB | 1 |
| Andersson, LM; Andersson, O; Edén, A; Flamholc, L; Gisslén, M; Josephson, F; Nilsson, S; Ormaasen, V; Säll, C; Sönnerborg, A; Svedhem, V; Tunbäck, P | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| De Meyer, M; Goffin, E; Kanaan, N; Morelle, J; Mourad, M; Wallemacq, P; Yombi, JC | 1 |
| Chen, L; Demasi, R; Girard, PM; Lavreys, L; Nelson, M; Sekar, V; Smets, E | 1 |
| Bucher, HC; Nadal, D; Rickenbach, M; Rudin, C; Wolbers, M | 1 |
| Elsherbiny, D; Maartens, G; McIlleron, H; Ren, Y; Simonsson, US | 1 |
| Crawford, KW; Flexner, C; Kalayjian, RC; Landay, A; Lederman, MM; Parsons, T; Pollard, R; Spritzler, J; Stocker, V | 1 |
| Chirayus, S; Cressey, TR; Jourdain, G; Kongpanichkul, R; Lallemant, M; Ngo-Giang-Huong, N; Pattarakulwanich, S; Rawangban, B; Sabsanong, P; Varadisai, S; Voramongkol, N; Yuthavisuthi, P | 1 |
| Burger, DM; Burgers, PC; de Groot, R; Dekker, LJ; Gruters, RA; Hartwig, NG; Luider, TM; Osterhaus, AD; Reedijk, ML; van der Ende, IE; van Kampen, JJ | 1 |
| Burger, DM; Dekker, LJ; Gruters, RA; Hartwig, NG; Luider, TM; Meesters, RJ; Osterhaus, AD; Reedijk, ML; Scheuer, RD; van Kampen, JJ | 1 |
| Best, BM; Burchett, SK; Capparelli, EV; Hu, C; Li, H; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM | 1 |
| Altice, FL; Andrews, L; Bruce, RD; Fang, WB; Friedland, GH; Lin, SN; Ma, Q; Moody, DE; Morse, GD | 1 |
| Bernstein, B; Cohen, D; da Silva, B; Fredrick, L; González-García, J; Johnson, M; Naylor, C; Sloan, L | 1 |
| Hagelberg, NM; Laine, K; Neuvonen, M; Neuvonen, PJ; Nieminen, TH; Olkkola, KT; Saari, TI | 1 |
| Gerstoft, J; Hansen, AB; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Back, DJ; Boyle, N; Breiden, J; Brennan, M; Connor, EO; Coulter-Smith, S; Dickinson, L; Else, LJ; Fleming, C; Gibbons, S; Jackson, V; Khoo, SH; Lambert, JS | 1 |
| Benabdelmoumen, G; Bouvet, E; Christian, B; Muller, P; Peyrouse, E; Prazuck, T; Quertainmont, Y; Rabaud, C; Tosini, W | 1 |
| Cavassini, M; Cusini, A; Decosterd, LA; Fux, C; Günthard, HF; Gutmann, C; Hirschel, B; Vernazza, PL; Yerly, S | 1 |
| Fätkenheuer, G; Gatell, J; Katlama, C; Ledergerber, B; Lundgren, JD; Mocroft, A; Parczewski, M; Reekie, J; Reiss, P; Sedlacek, D | 1 |
| Benhamou, Y; Bricaire, F; Dominguez, S; Ghosn, J; Guiguet, M; Katlama, C; Murphy, R; Peytavin, G; Tubiana, R; Valantin, MA | 1 |
| Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Sherman, G; Stehlau, R; Tsai, WY | 1 |
| Arribas, JR; Perez-Valero, I; Pulido, F; Zamora, FX | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Croxtall, JD; Perry, CM | 1 |
| Aweeka, F; Cohn, SE; Kamemoto, L; Klingman, KL; Park, JG; Patterson, K; Vogler, MA; Watts, H | 1 |
| Baillat, V; Bonnard, P; Bouteloup, V; Cabie, A; Chene, G; Girard, PM; Izopet, J; Kolta, S; Landman, R; Mercie, P; Meynard, JL; Taburet, AM | 1 |
| D'Avolio, A; Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Verhofstede, C; Watson, V; Yilmaz, A | 1 |
| Bernasconi, E; Bucher, HC; Cavassini, M; Decosterd, LA; Dell-Kuster, S; Evison, J; Flepp, M; Hasse, B; Hirschel, B; Magenta, L; Richter, WO; Vernazza, P; Young, J | 1 |
| Calza, L; Colangeli, V; Erario, A; Grossi, G; Manfredi, R; Mosca, L; Piergentili, B; Pocaterra, D; Verucchi, G; Viale, P | 1 |
| Auclair, M; Bastard, JP; Boccara, F; Capeau, J; Caron-Debarle, M; Lefèvre, C; Vigouroux, C | 1 |
| Baran, R; Dietz, B; Hornberger, J; Podsadecki, T; Shewade, A; Simpson, K | 1 |
| Alston-Smith, B; Asmelash, A; Atwine, D; Chipato, T; Conradie, F; Currier, JS; Eshleman, S; Hakim, J; Hogg, E; Hosseinipour, MC; Hughes, MD; Kanyama, C; Lockman, S; McIntyre, J; Mellors, JW; Mngqibisa, R; Mohapi, L; Purcelle-Smith, E; Rahim, S; Rooney, J; Salata, RA; Sawe, F; Schooley, RT; Shaffer, D; Siika, A; Stringer, E; Walawander, A; Wools-Kaloustian, K; Zheng, Y | 1 |
| Abrams, EJ; Bobat, R; Bwakura-Dangarembizi, M; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Lindsey, JC; Meyers, T; Millar, L; Mofenson, LM; Musoke, P; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A | 1 |
| Bruce-Keller, AJ; Domingue, M; Gupta, S; Ingram, DK; Keller, JN; Kheterpal, I; Knight, AG; Pistell, PJ; Ruiz, C; Uranga, RM | 1 |
| Bagnarelli, P; Bonora, S; Carli, T; Colao, G; Corsi, P; De Luca, A; Di Giambenedetto, S; Ghisetti, V; Gismondo, MR; Meini, G; Monno, L; Pecorari, M; Prosperi, MC; Punzi, G; Zazzi, M | 1 |
| Gruber, S; Petersen, ML; Porter, KE; van der Laan, MJ; Wang, Y | 1 |
| Doroshyenko, O; Fätkenheuer, G; Frank, D; Fuhr, U; Hein, W; Jetter, A; Kirchheiner, J; Klaassen, T; Schömig, E; Seeringer, A; Wyen, C | 1 |
| Estes, R; Linnares-Diaz, M; Novak, RM; Pitrak, DL; Tschampa, JM | 1 |
| Alteri, C; Cella, E; Ciccozzi, M; Ciotti, M; Drašković, N; Fabeni, L; Lai, A; Laušević, D; Lo Presti, A; Marjanovic, A; Mugoša, B; Santoro, MM; Vratnica, Z; Vujošević, D; Zehender, G | 1 |
| Absalon, J; Johnson, M; McGrath, D; Sheppard, L; Squires, KE; Uy, J; Yang, R | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Ananworanich, J; Bunupuradah, T; Burger, D; Kosalaraksa, P; Lumbiganon, P; Mengthaisong, T; Pancharoen, C; Phanuphak, P; Puthanakit, T; Wongsabut, J | 1 |
| Curto, J; del Rio, L; Domingo, P; Ferrer, E; Gatell, JM; Martínez, E; Negredo, E; Ordóñez, J; Podzamczer, D; Ribera, E; Rosales, J; Saumoy, M | 1 |
| Allegri, G; Hemmett, L; Hjelmgren, J; Moeremans, K; Smets, E | 1 |
| Burger, DM; de Wolf, F; Franssen, EJ; Kroon, F; Richter, C; Rigter, IM; Smit, C; van Luin, M; Wit, FW | 1 |
| Boué, F; Briot, K; Cohen-Codar, I; Delfraissy, JF; Flandre, P; Knysz, B; Kolta, S; Morlat, P; Norton, M; Pintado, C; Rode, R; Roux, C; Valantin, MA; Van, PN | 1 |
| Acosta, EP; Easley, KA; Eaton, ME; Lennox, JL; Long, MC; Masalovich, SE; Ofotokun, I; Ritchie, JC | 1 |
| Alvarez, SM; de Jesús Asencio Montiel, I; Flores, RA; Martínez, JG; Mata Marín, JA | 1 |
| Alaeus, A; Heeg, B; Lescrauwaet, B; Neubauer, A; Sennfält, K; Thuresson, PO | 1 |
| Cramer, Y; Currier, JS; Fletcher, CV; Hermes, AE; Park, JG; Umeh, OC | 1 |
| Arenas-Pinto, A; Arribas, J; Girard, PM; Meynard, JL; Paton, NI; Pulido, F | 1 |
| Decloedt, E; Gandhi, M; Huang, Y; Maartens, G; Malavazzi, C; McIlleron, H; Nachega, JB; Smith, P; van der Merwe, L; van Mens, TE; van Zyl, GU; Zeier, M | 1 |
| Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H | 1 |
| Harrison, C | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Chu, J; Ciaranello, AL; Conradie, F; Currier, J; Freedberg, KA; Holmes, CB; Hughes, M; Lockman, S; Losina, E; McIntyre, J; Pillay, S; Walensky, RP; Wood, R | 1 |
| Alvero, CG; Capparelli, EV; Chadwick, EG; Hazra, R; Heckman, BE; Hughes, MD; Palumbo, PE; Pinto, JA; Robbins, BL; Yogev, R | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Borrull, A; Espiau, M; Figueras, C; Soler-Palacín, P | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Meyers, T; Morris, L; Sherman, G; Strehlau, R; Taylor, BS | 1 |
| Chen, J; Liu, XQ; Lu, HZ; Sun, JJ; Yao, YM; Zhang, LJ | 1 |
| Caswell, RJ; Chaponda, M; Ghanem, M; Gibbons, S; Jackson, V; Khoo, SH; Lambert, JS; Phillips, D; Poulton, M; Taylor, GP; Welch, J | 1 |
| Back, DJ; Costello, S; de Ruiter, A; Dickinson, L; Else, LJ; Lechelt, M; Lyons, F; Magaya, V; Mullen, J; O'shea, S | 1 |
| Boibieux, A; Charpiat, B; Ferry, T; Gagnieu, MC; Planus, C; Puech, R; Tod, M | 1 |
| Camacho, RJ; Detsika, MG; Hatzakis, A; Imbrechts, S; Lazanas, M; Lu, L; Magiorkinis, E; Magiorkinis, G; Molla, A; Paraskevis, D; Pilot-Matias, T; Van Laethem, K; Vandamme, AM | 1 |
| Avettand-fenoel, V; Blanche, S; Briand, N; Chaix, ML; Frange, P; Mahlaoui, N; Moshous, D; Rouzioux, C; Veber, F | 1 |
| Delfraissy, JF; Dulioust, A; Ferradini, L; Fournier, I; Hak, C; Lerolle, N; Mean, CV; Nerrienet, E; Ngin, S; Nouhin, J; Ouk, V; Segeral, O | 1 |
| López-Segura, N; López-Vílchez, MA; Mur-Sierra, A | 1 |
| Dolgin, E | 1 |
| Avihingsanon, A; Burger, D; Chaithongwongwatthana, S; Gorowara, M; Kerr, SJ; Phanuphak, N; Phanuphak, P; Ramautarsing, RA; Ruxrungtham, K; van der Lugt, J | 1 |
| Decloedt, EH; Maartens, G; McIlleron, H; Merry, C; Orrell, C; Smith, P | 1 |
| Cotton, M; Eley, B; Fairlie, L; Maartens, G; McIlleron, H; Merry, C; Meyers, T; Nuttall, J; Rabie, H; Ren, Y; Smith, PJ | 1 |
| Burger, DM; de Kanter, CT; Keuter, M; Koopmans, PP; van der Lee, MJ | 1 |
| Phung, BC; Yeni, P | 1 |
| Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Ledwaba, J; Maldarelli, FM; Morris, L; Pau, AK; Sangweni, P; Somaroo, H | 1 |
| Brown, TT; Dobs, AS; Kingsley, LA; Monroe, AK; Palella, FJ; Witt, MD; Xu, X | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Bavoux, F; Benhammou, V; Blanche, S; Czernichow, P; Firtion, G; Foissac, F; Kariyawasam, D; Laborde, K; Layouni, I; Le Chenadec, J; Munzer, M; Polak, M; Simon, A; Tréluyer, JM; Warszawski, J | 1 |
| Gruber, S; van der Laan, MJ | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Kuhn, L; Meyers, TM; Moultrie, H; Yotebieng, M | 1 |
| Azzoni, L; Firnhaber, C; Foulkes, AS; Fox, L; Glencross, DK; Gross, R; Hunt, G; Montaner, LJ; Morris, L; Sanne, I; Schulze, D; Stevens, W; Van Amsterdam, D; Yin, X | 1 |
| Gordish-Dressman, HA; Neely, MN; Rakhmanina, NY; Soldin, SJ; van den Anker, JN; Van Schaik, RH; Williams, KD | 1 |
| Blanche, S; Chaix, ML; Foissac, F; Frange, P; Hirt, D; Treluyer, JM; Urien, S | 1 |
| Ajana, F; Baras, A; Bocket, L; Champenois, K; Choisy, P; Melliez, H; Yazdanpanah, Y | 1 |
| Gatanaga, H; Kikuchi, Y; Nagata, N; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Bierman, WF; Burger, DM; Danner, SA; Reiss, P; van Agtmael, MA; van Vonderen, MG; Veldkamp, AI | 1 |
| Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP | 1 |
| Amole, CD; Brisebois, C; Brown Ripin, DH; Essajee, S; Koehler, E; Levin, AD; Moore, MC; Sickler, JJ; Singh, IR | 1 |
| Calis, JC; de Wit, TF; Geelen, SP; Sigaloff, KC; van Vugt, M | 1 |
| Best, BM; Capparelli, EV; Diep, H; Farrell, MJ; Lee, G; Rakhmanina, N; Rossi, SS; van den Anker, JN; Williams, E | 1 |
| Ackad, N; Andrade-Villanueva, J; Bortolozzi, R; Cahn, P; Casiró, AD; Cassetti, I; Junod, P; Krolewiecki, A; Longo, N; Lupo, SH; Montaner, J; Patterson, P; Rampakakis, E; Sampalis, JS; Sierra-Madero, J | 1 |
| Cabrera Figueroa, S; Domínguez-Gil Hurlé, A; García Sánchez, MJ; López Aspiroz, E; López Galera, RM; Ribera Pascuet, E; Santos Buelga, D | 1 |
| Alvarez Del Vayo Benito, C; Falcon-Neyra, L; León Leal, JA; Lopez-Cortes, LF; Neth, O; Obando, I; Ruiz-Valderas, R | 1 |
| Butcher, DL; Direnzo, G; Garren, KW; Haubrich, RH; Havlir, DV; Klingman, KL; Mellors, JW; Ribaudo, H; Riddler, SA; Rooney, JF | 1 |
| Abraham, B; Bélec, L; Charpentier, C; Dandy, M; De Dieu Longo, J; Grésenguet, G; Matta, M; Mbelesso, P; Moussa, S; Péré, H | 1 |
| Chaix, ML; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Flandre, P; Galimand, J; Ghosn, J; Raffi, F; Rouzioux, C | 1 |
| Ashton, M; Ekvall, H; Flamholc, L; Gisslén, M; Ormaasen, V; Röshammar, D; Simonsson, US; Vesterbacka, J; Wallmark, E | 1 |
| Andrade-Villanueva, J; Cheng, AK; Chuck, SL; Clotet, B; Clumeck, N; Lamarca, A; Liu, YP; Margot, N; Molina, JM; Zhong, L | 1 |
| Ananworanich, J; Avihingsanon, A; Burger, DM; Gorowara, M; Khongpetch, C; Lange, JM; Phanuphak, P; Ramautarsing, RA; Ruxrungtham, K; van der Lugt, J; Wongsabut, J | 1 |
| Furrer, H; Rauch, A; Wandeler, G | 1 |
| Back, DJ; Dickinson, L; Douglas, M; Else, LJ; Khoo, SH; Taylor, GP | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Cozzi-Lepri, A; Dunn, D; Kjær, J; Lundgren, JD; Paredes, R; Phillips, AN; Pillay, D; Prosperi, MC; Sabin, CA | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Chipato, T; Cole, SR; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, M; Hughes, MD; Lockman, S; McCarthy, JS; Meshnick, SR; Poole, C; Porter, KA; Salata, R; Sawe, FK; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E; Zheng, Y | 1 |
| Decloedt, E; Denti, P; Karlsson, MO; Maartens, G; McIlleron, H; Simonsson, US; Zhang, C | 1 |
| Abrams, EJ; Arpadi, S; Coovadia, A; Kuhn, L; Martens, L; Meyers, T; Strehlau, R | 1 |
| Baran, RW; Dietz, B; Kirbach, SE; Simpson, KN | 1 |
| Bergin, C; Hennessy, M; Hopkins, S; Kennedy, A; Mulcahy, F; Spiers, JP | 1 |
| Allan, S; Back, D; Fidler, S; Fisher, M; Gilleran, G; Heald, L; Jayasuriya, A; Owen, A; Smit, E; Taylor, S; Wilkins, E | 1 |
| Camp, R; Connick, E; Daar, ES; Degruttola, V; Del Rio, C; Fiscus, SA; Hare, CB; Hogan, CM; Kallungal, B; Little, S; Macatangay, B; Markowitz, M; Morton, T; Sun, X; Tashima, KT | 1 |
| Conway, B; Tossonian, H | 1 |
| Borkhardt, A; Lankisch, P; Laws, HJ; Neubert, J; Niehues, T; Wingen, AM | 1 |
| Asboe, D; Bansi, L; Barber, TJ; Dunn, D; Gilson, R; Harrison, L; Kirk, S; Pillay, D; Williams, I | 1 |
| Borderi, M; Calza, L; Colangeli, V; Grossi, G; Manfredi, R; Motta, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Denti, P; Karlsson, MO; McIlleron, H; Ren, Y; Simonsson, US; van der Walt, JS; Zhang, C | 1 |
| Cabrera Figueroa, SE; Domínguez-Gil Hurlé, A; García Sánchez, MJ; López Aspiroz, E | 1 |
| Ananworanich, J; Burger, D; Gorowara, M; Kerr, S; Klinklom, A; Pancharoen, C; Phasomsap, C; Puthanakit, T; Ruxrungtham, K; Sriheara, C | 1 |
| Arnaiz, JA; Clotet, B; Cruceta, A; Dalmau, D; Diaz-Brito, V; Domingo, P; García, F; Gatell, JM; Knobel, H; León, A; Peraire, J | 1 |
| Bedimo, R; Drechsler, H; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Gruters, R; Hooff, GP; Luider, TM; Meesters, RJ; van Kampen, JJ | 1 |
| Brigido, LF; Collares, JK; Ferreira, JL; Fonseca, BA; Lanca, AM; Lima, DM; Rodrigues, R | 1 |
| Asahchop, EL; Brenner, BG; Doualla-Bell, F; Grossman, Z; Lisovsky, I; Martinez-Cajas, JL; Mendelson, E; Moisi, D; Oliveira, M; Wainberg, MA | 1 |
| Bánhegyi, D; da Cunha, CA; De Meyer, S; Katlama, C; Rachlis, A; Schneider, S; Tomaka, F; Van De Casteele, T; Vandevoorde, A; Workman, C | 1 |
| Chiarella, J; DeGrosky, M; Kozal, M; Lataillade, M; Moreno, E; Seekins, D; Simen, B; St John, E; Uy, J; Yang, R | 1 |
| Arribas, JR; Estébanez, M | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Feng, M; Ji, C; Kao, E; Lau, MY; Shinohara, M | 1 |
| Bango, F; Decloedt, EH; Maartens, G; McIlleron, H; Merry, C; Smith, P | 1 |
| Cotton, MF; Holgate, SL; Rabie, H; Smith, P | 1 |
| Boer, K; Godfried, MH; Nellen, J; Scherpbier, H; van Hoog, S | 1 |
| McIntyre, J; Nachman, S | 1 |
| Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY | 1 |
| Clotet, B; Domingo, P; Galindo, MJ; Imaz, A; Iribarren, JA; Llibre, JM; Mariño, A; Miralles, C; Moreno, S; Ornelas, A; Santos, JR; Schapiro, JM | 1 |
| Ascenzi, P; Ivanovic, J; Montesano, C; Narciso, P; Notari, S; Pucillo, LP; Sergi, M | 1 |
| Back, DJ; Boffito, M; Davies, G; Dickinson, L; Egan, D; Khoo, SH; Owen, A; Schipani, A; Youle, M | 1 |
| Back, D; Boffito, M; Byakika-Kibwika, P; Khoo, S; Lamorde, M; Mayito, J; Merry, C; Nabukeera, L; Ogwal-Okeng, J; Ryan, M; Tjia, J | 1 |
| Butterworth, AS; Chipato, T; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, MC; Lockman, S; McCarthy, JS; Meshnick, SR; Porter, KA; Salata, R; Sawe, F; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E | 1 |
| Beron, J; Da Silva, B; Fredrick, L; Nilius, A; Norton, M; Patwardhan, M; Tschampa, J; Woodward, WC; Zachry, W | 1 |
| Bruzzone, B; Calzi, A; Di Biagio, A; Nicco, E; Parisini, A; Schenone, E; Secondo, G; Sticchi, L; Viscoli, C | 1 |
| Alvero, CG; Capparelli, EV; Chadwick, EG; Hughes, MD; Luzuriaga, K; Palumbo, PE; Persaud, D; Yogev, R; Ziemniak, C | 1 |
| Du, X; Fu, Q; Han, Y; Kou, H; Li, T; Xie, J; Ye, M; Zhu, Z | 1 |
| Blaszczyk, AT; Vouri, SM | 1 |
| Boro, J; Cheung, MC; Ezzat, HM; Harris, M; Hicks, LK; Leitch, HA; Lima, VD; Montaner, JS | 1 |
| Apostoli, A; Bigoni, S; Calabresi, A; Carvalho, AC; Cusato, M; Dal Zoppo, S; El-Hamad, I; Marcantoni, C; Matteelli, A; Regazzi, M; Villani, P | 1 |
| Abrams, EJ; Barlow-Mosha, L; Bobat, R; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Millar, L; Mofenson, LM; Moultrie, H; Mujuru, HA; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A | 1 |
| Alston-Smith, B; Amod, F; Asmelash, A; Chibowa, M; Chipato, T; Currier, J; Halvas, E; Hogg, E; Hosseinipour, M; Hughes, M; Kimaiyo, S; Lockman, S; McIntyre, J; Mellors, J; Mohapi, L; Rassool, M; Sawe, F; Schooley, R; Shaffer, D; Smith, L; Ssali, F; Zheng, Y | 1 |
| Burgos, R; Goldstein, DA; Huesgen, E; Jarrett, OD; Max, B | 1 |
| Calvez, V; Carret, S; Charpentier, C; Cohen Codar, I; Costagliola, D; Delaugerre, C; Ferre, V; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Montes, B; Morand-Joubert, L; Perrot, V; Peytavin, G; Plantier, JC; Soulie, C | 1 |
| Jaye, A; Oko, F; Okomo, U; Peterson, I; Peterson, K; Togun, T; Townend, J | 1 |
| Cotton, M; Gibb, D; Penazzato, M; Prendergast, A; Tierney, J | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Kaleebu, P; Kasirye, R; Kikaire, B; Mambule, I; Musana, H; Pillay, D; Reid, A; Robertson, V; Spyer, M; Ssali, F; Walker, AS; Yirrell, D | 1 |
| Ananworanich, J; Avihingsanon, A; Burger, DM; Gorowara, M; Lange, JM; Phanuphak, P; Ramautarsing, RA; Ruxthungtham, K; Sophonphan, J; van der Lugt, J | 1 |
| Abel, F; Behrens, G; Domingo, P; Maserati, R; Pearce, G; Rieger, A; Wang, H | 1 |
| Biollaz, J; Buclin, T; Cavassini, M; Cruchon, S; Decosterd, LA; Eap, CB; Fayet-Mello, A; Grawe, C; Gremlich, E; Guignard, N; Martinez de Tejada, B; Popp, KA; Schmid, F; Telenti, A | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Chokephaibulkit, K; Cressey, TR; Lapphra, K; Nuntarukchaikul, M; Phongsamart, W; Vanprapar, N; Wittawatmongkol, O | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Valcour, V | 1 |
| Calza, L; Manfredi, R | 1 |
| Cavassini, M; Cusini, A; Decosterd, LA; Fux, CA; Gaudenz, R; Günthard, HF; Gutmann, C; Hirschel, B; Klimkait, T; Ledergerber, B; Opravil, M; Rohrbach, J; Vernazza, PL; Widmer, N; Yerly, S; Zenger, F | 1 |
| Bénard, A; Brun-Vezinet, F; Charpentier, C; Chene, G; Damond, F; Descamps, D; Larrouy, L; Matheron, S; Visseaux, B; Vivot, A | 1 |
| Gandhi, RT; Kuritzkes, DR; Marconi, VC; Murphy, RA; Sunpath, H | 1 |
| Cavassini, M; Cusini, A; Du Pasquier, RA; Fux, CA; Günthard, HF; Gutmann, C; Jilek, S; Kalubi, M; Vernazza, PL; Yerly, S | 1 |
| Hofmeyr, J; Kankasa, C; Karamagi, C; Meda, N; Nagot, N; Neveu, D; Nikodem, C; Sommerfelt, H; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Amin, T; Kesselheim, AS | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Butler, K; Doerholt, K; Donegan, K; Gibb, DM; Judd, A; Lyall, H; Menson, E; Riordan, A; Shingadia, D; Tookey, P; Tudor-Williams, G; Walker, AS | 1 |
| DeJesus, E; Khanlou, H; Lathouwers, E; Lefebvre, E; Opsomer, M; Orkin, C; Stoehr, A; Supparatpinyo, K; Tomaka, F; Van de Casteele, T | 1 |
| Blanc, P; D'Annunzio, M; Galli, L; Gallotta, G; Hasson, H; Lazzarin, A; Merli, M; Morsica, G; Neri, V; Sollima, S; Uberti-Foppa, C | 1 |
| Cabie, A; Charpentier, C; Chene, G; Colin de Verdiere, N; Descamps, D; Fagard, C; Grondin, C; Joly, V; Raffi, F; Tabuteau, S; Yazdanpanah, Y; Yeni, P | 1 |
| Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL | 1 |
| Aragones, AM; Cano, SM; Castello, A; Gomez-Arbones, X; Porcel, JM; Puig, T; Schoenenberger, JA | 1 |
| Achan, J; Aweeka, F; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Nsanzabana, C; Rosenthal, PJ; Ruel, T | 1 |
| Ananworanich, J; Bunupuradah, T; Chobkarjing, U; Chuanjaroen, T; Kosalaraksa, P; Lumbiganon, P; Pancharoen, C; Phanuphak, P; Pinyakorn, S; Puthanakit, T | 1 |
| Abrams, EJ; Arpadi, S; Coovadia, A; Kuhn, L; Martens, L; Patel, F; Shiau, S; Strehlau, R | 2 |
| Dumond, JB; Hudgens, MG; Jenkins, AJ; Kashuba, AD; Malone, S; Patterson, KB; Prince, HA; Scarsi, KK; Wang, R | 1 |
| Abrams, EJ; Coovadia, A; Kuhn, L; Martens, L; Strehlau, R; Teasdale, CA | 1 |
| Cau, P; Cremer, J; Dellamonica, P; Faucher, O; Kaspi, E; Lacarelle, B; Lévy, N; Micallef, J; Nicolino-Brunet, C; Perrin, S; Poizot-Martin, I; Reynes, J; Robaglia-Schlupp, A; Roll, P; Solas, C; Stretti, C; Tamalet, C; Tamalet, CN | 1 |
| Belshan, M; Date, AA; Destache, CJ; Goede, M; McMullen, E; Pham, A; Sanford, B; Shibata, A; Zhou, Y | 1 |
| Ananworanich, J; Bunupuradah, T; Chokephaibulkit, K; Fahey, P; Fong, SM; Hansudewechakul, R; Huy, BV; Kariminia, A; Khanh, TH; Kumarasamy, N; Kurniati, N; Lumbiganon, P; Puthanakit, T; Razali, K; Saphonn, V; Sohn, AH; Sudjaritruk, T; Yusoff, NK | 1 |
| Bierhoff, M; Boucher, CA; Fibriani, A; Ten Kate, RW | 1 |
| Arribas, JR; Arrizabalaga, J; Bernardino, JI; Domingo, P; Martinez, E; Muñoz, J; Ocampo, A; Portilla, J; Pulido, F; Torres, R | 1 |
| Carli, T; Corsi, P; Di Pietro, M; Gonnelli, A; Peduzzi, C; Romano, L; Valensin, PE; Venturi, G; Zazzi, M | 1 |
| James, JS | 2 |
| Burger, D; Droste, J; Jurriaans, S; Lange, JM; Prins, JM; Sankatsing, SU; Van Praag, RM | 1 |
| Breilh, D; Dabis, F; Dupon, M; Fleury, H; Lavignolle, V; Lawson-Ayayi, S; Masquelier, B; Morlat, P; Neau, D; Ragnaud, JM | 1 |
| Gallant, JE | 1 |
| Arnaudo, I; Back, DJ; Boffito, M; Bonora, S; Di Garbo, A; Di Perri, G; Hoggard, PG; Raiteri, R; Reynolds, HE; Sinicco, A | 1 |
| Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Lucchini, A; Maiello, A | 1 |
| Fusco, G; Liao, Q; Paulsen, D; Ross, L; Shaefer, M; St Clair, M | 1 |
| Caetano, MR; Chequer-Fernandez, SL; Couto-Fernandez, JC; Eyer-Silva, WA; Morais-De-Sá, CA; Morgado, MG; Pinto, JF | 1 |
| Back, DJ; Boffito, M; Dal Conte, I; Di Perri, G; Hoggard, PG; Lucchini, A; Maiello, A | 1 |
| Bernstein, B; Brun, SC; Isaacson, JD; Kempf, DJ; King, MS; Richards, B; Rode, R; Sun, E; Sylte, J | 1 |
| Leibovich, M | 1 |
| Bini, T; Bongiovanni, M; Cicconi, P; d'Arminio Monforte, A; Melzi, S; Repetto, D; Rusconi, S; Sollima, S; Tordato, F | 1 |
| Bernstein, B; Bertz, R; Brun, S; Foit, C; Granneman, GR; Hsu, A; Isaacson, J; Kempf, DJ; King, M; Lam, W; Richards, B; Rode, R; Rynkiewicz, K; Sun, E | 1 |
| Gazzard, BG; Gilleece, YC; Mandalia, S; Morlese, JF; Nelson, MR; Pozniak, AL; Qazi, NA | 1 |
| Allen, U; Arpadi, S; Bernstein, B; Bertz, RJ; Cahn, P; Castrejón, MM; Chadwick, E; Deetz, CO; Gomez, P; Handelsman, E; Heuser, RS; Hsu, AF; Kempf, DJ; Pelton, S; Ramilo, O; Renz, CL; Rode, RA; Sáez-Llorens, X; Sun, E; Violari, A | 1 |
| Gilleece, Y; Mandalia, S; Nelson, M; Parmar, D | 1 |
| Badiou, S; Baillat, V; Cristol, JP; De Boever, CM; Dupuy, AM; Reynes, J | 1 |
| Crabb, C | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Casau, NC; Glesby, MJ; Gulick, RM; Paul, S | 1 |
| Ershov, FI; Kas'ianova, NV; Vasil'ev, AN | 1 |
| Chappey, C; Parkin, NT; Petropoulos, CJ | 1 |
| Zolopa, AR | 1 |
| Back, DJ; Boffito, M; Bonora, S; Caci, A; Di Perri, G; Hoggard, PG; Khoo, S; Raiteri, R; Reynolds, HE; Sinicco, A | 1 |
| Mauboussin, JM; Peyrière, H; Rouanet, I; Vincent, D | 1 |
| Badiou, S; Baillat, V; Cristol, JP; Dupuy, AM; Merle De Boever, C; Reynes, J | 1 |
| Phillips, E; Rachlis, A; Sullivan, JR | 1 |
| Gill, MJ; Mah Ming, JB | 1 |
| Bartlett, JG; Celentano, DD; Lai, H; Lai, S; Lima, JA; Margolick, J; Ren, S; Vlahov, D | 1 |
| Calza, L; Chiodo, F; Farneti, B; Manfredi, R | 1 |
| Burger, DM; la Porte, CJ; Rockstroh, JK; Schneider, K; Wasmuth, JC | 1 |
| Atzori, C; Cargnel, A; Maruzzi, M; Regazzi, M; Villani, P | 1 |
| Esteban, A; Gutiérrez, F; Hernández, I; Martin-Hidalgo, A; Masiá, M; Navarro, A; Padilla, S; Ramos, J | 1 |
| Bertz, R; Maroldo-Connelly, L; Patterson, JB; Rapaport, S; Stevens, RC | 1 |
| Friedland, G; Jatlow, P; McCance-Katz, EF; Rainey, PM | 1 |
| Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B | 1 |
| Elston, R; Paulsen, D; Ross, L; Snowden, W; Tisdale, M | 1 |
| Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Cargnel, A; Chiesa, E; Cicconi, P; Cordier, L; d'Arminio Monforte, A; Landonio, S; Meraviglia, P; Rusconi, S; Tordato, F | 1 |
| Larder, B; Wang, D | 1 |
| Eghtesad, B; Fung, JJ; Jain, AB; Marcos, A; Rafail, AB; Ragni, M; Shapiro, R; Venkataramanan, R | 1 |
| Allan, J; Boulassel, MR; Gilmore, N; Klein, M; Lalonde, RG; LeBlanc, R; MacLeod, J; Murphy, T; René, P; Routy, JP; Smith, GH | 1 |
| Ajana, F; Caron, J; Cheret, A; Gerard, Y; Guerroumi, H; Mouton, Y; Viget, N; Yazdanpanah, Y | 1 |
| Blanco, F; Garcia-Benayas, T; González de Requena, D; González-Lahoz, J; Jiménez-Nácher, I; Soriano, V | 1 |
| Moyle, GJ | 1 |
| Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Khoo, SH; Milia, MG; Raiteri, R; Sinicco, A | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; d'Arminio Monforte, A; Riva, A | 1 |
| Huff, B | 1 |
| Bauer, E; Bernstein, B; Brun, S; Cernohous, P; Gu, K; Hsu, A; Kempf, DJ; King, MS; Moseley, J; Sun, E | 1 |
| Klinker, H; Langmann, P; Schubert, J; Tollmann, F; Weissbrich, B; Winzer, R; Zilly, M | 1 |
| Bernstein, B; Bertz, R; Carpio, FF; Eron, JJ; Feinberg, J; Horowitz, HW; Kessler, HA; King, MS; Mildvan, D; Ruane, P; Sun, E; Wheeler, DA; Witt, MD; Yangco, BG | 1 |
| Belarbi, L; Bouchaud, O; Guillevin, L; Launay, O; Lortholary, O; Louchahi, K; Mémain, N; Petitjean, O; Robineau, M; Tod, M | 1 |
| Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Khoo, SH; Lindup, WE; Sinicco, A | 1 |
| Bulgheroni, E; Chou, TC; Citterio, P; Croce, F; Galli, M; Lo Cicero, M; Rusconi, S; Soster, F; Viganò, O | 1 |
| Koepke, JI; Kovari, LC; Logsdon, BC; Martin, P; Merigan, TC; Proteasa, G; Terlecky, SR; Vickrey, JF; Wawrzak, Z; Winters, MA | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; Monforte, Ad | 1 |
| de Mendoza, C; González de Requena, D; González-Lahoz, J; Martin-Carbonero, L; Soriano, V; Valer, L | 1 |
| Allegre, T; Dhiver, C; Drogoul, MP; Durand, A; Lacarelle, B; Lafeuillade, A; Lepeu, G; Mokhtari, M; Moreau, J; Petit, N; Poizot-Martin, I; Ravaux, I; Solas, C | 1 |
| Adorni, F; Bini, T; Bongiovanni, M; Chiesa, E; Cicconi, P; Monforte d'Arminio, A | 1 |
| Arroyo, JA; Baldovi, F; de Lazzari, E; Domingo, P; Galindo, MJ; Gatell, JM; Larrousse, M; León, A; Martínez, E; Milinkovic, A | 1 |
| Gallego, J; Gutiérrez, F; Hernández, I; Martin-Hidalgo, A; Masiá, M; Navarro, A; Padilla, S; Ramos, JM | 1 |
| Carter, M | 3 |
| Kaiser, R; Mauss, S; Rockstroh, JK; Schmutz, G; Vogel, M; Voigt, E; Wasmuth, JC | 1 |
| Barrail, A; Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM; Vincent, I | 1 |
| Benson, C; Brun, SC; Eron, JJ; Gulick, RM; Hicks, C; Kessler, HA; King, KR; King, MS; Murphy, RL; White, AC | 1 |
| Katzenstein, D | 1 |
| Bellón, JM; Cabrero, E; De José, MI; Galán, I; González-Rivera, M; Gurbindo, MD; Jiménez, JL; Mellado, MJ; Muñoz-Fernández, MA; Navarro, ML; Ramos, JT; Resino, S | 1 |
| Carosi, G; De Luca, A; Di Giambenedetto, S; Lo Caputo, S; Micheli, V; Patroni, A; Quiros-Roldan, E; Regazzi-Bonora, M; Torti, C; Villani, P | 1 |
| Doco-Lecompte, T; Garrec, A; May, T; Rabaud, C; Thomas, L; Trechot, P | 1 |
| Dauer, B; Harder, S; Klauke, S; Kourbeti, I; Kurowski, M; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; von Hentig, N | 1 |
| Boeri, E; Castagna, A; Danise, A; Gianotti, N; Hasson, H; Lazzarin, A; Nozza, S; Seminari, E | 1 |
| Beijnen, JH; Crommentuyn, KM; Huitema, AD; Mulder, JW; Schellens, JH; Sparidans, RW | 1 |
| Conradie, F; Eron, J; Sanne, I; Venter, W | 1 |
| Baldini, F; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Hoetelmans, RM | 1 |
| Gallego, O; González de Requena, D; Jiménez-Nácher, I; Soriano, V; Valer, L | 1 |
| Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Hartwig, NG; Korn, K; Neubert, J; Niehues, T; Schroten, H; van Rossum, AM | 1 |
| Wehr, A | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Bernstein, BM; Brun, SC; Cernohous, P; Feinberg, J; King, MS; Montaner, JS; Sanne, I; Sherer, R; Sun, E; Walmsley, SL | 1 |
| DeSilva, KE; Guest, JL; Rimland, D; Ruffin, C; Tschampa, JM | 1 |
| Bertz, RJ; Eron, JJ; Gaedigk, A; Kashuba, AD; Lim, ML; Min, SS; Robinson, M | 1 |
| Gutiérrez, F; Hernández, I; Masiá, M; Navarro, A; Padilla, S | 1 |
| Back, DJ; Cane, P; Drake, SM; Gibbons, SE; Isaac, A; Khoo, S; Smit, E; Taylor, S; White, DJ | 1 |
| Angarano, G; Carosi, G; Lo Caputo, S; Mazzotta, F; Monno, L; Patroni, A; Quiros-Roldan, E; Saracino, A; Tinelli, C; Tirelli, V; Torti, C | 1 |
| González-Lahoz, J; González-Requena, D; Jiménez-Nacher, I; Núñez, M; Soriano, V | 1 |
| Callens, S; Colebunders, R; De Schacht, C; Vanwolleghem, T | 1 |
| Deeks, SG; Friend, J; Liegler, T; Martin, JN; Parkin, N | 1 |
| Berthoin, K; Breilh, D; Budzinski, H; Fleury, HJ; Munck, M; Pellegrin, I; Pellegrin, JL; Rouzés, A; Saux, MC; Xuereb, F | 1 |
| Angeli, E; Bini, T; Bongiovanni, M; Cargnel, A; Castagna, A; Danise, A; Duca, P; Hasson, H; Landonio, S; Meraviglia, P; Moioli, MC; Schiavini, M; Viganò, P | 1 |
| Blanche, S; Chaix, ML; Delaugerre, C; Jullien, V; Rouzioux, C; Teglas, JP; Treluyer, JM; Vaz, P; Veber, F | 1 |
| Alexander, CS; Asselin, JJ; Guillemi, S; Harrigan, PR; Harris, M; McNabb, K; Montaner, JS; Ting, L | 1 |
| Boeri, E; Castagna, A; Danise, A; Galli, L; Gianotti, N; Hasson, H; Hoetelmans, R; Lazzarin, A; Nauwelaers, D | 1 |
| Harrigan, PR; Hogg, RS; Loutfy, MR; Montaner, JS; Raboud, JM; Saskin, R; Thompson, CA; Walmsley, SL | 1 |
| Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM | 1 |
| Christian, MD; Walmsley, S | 1 |
| Azuaje, C; Clotet, B; Crespo, M; Diaz, M; Falcó, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I; Ruiz, L | 1 |
| Cruttenden, K; DiCenzo, R; Gelbard, H; Morse, G; Peterson, D; Riggs, G; Schifitto, G | 1 |
| Beijnen, JH; Crommentuyn, KM; Huitema, AD; Mairuhu, AT; Meenhorst, PL; Mulder, JW; van Gorp, EC | 1 |
| Antoniou, T; Boyle, E; Park-Wyllie, L | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
| Calza, L; Chiodo, F; Manfredi, R | 1 |
| Bellón, JM; Cabrero, E; Martín-Fontelos, P; Muñoz-Fernández, MA; Navarro, ML; Ramos, JT; Resino, S | 1 |
| Burger, D; Clotet, B; Côté, H; López, S; Martínez, E; Miró, O; Moltó, J; Montaner, J; Negredo, E; Puig, J; Rey-Joly, C; Ribalta, J; Ruiz, L; Salazar, J | 1 |
| Antoniades, D; Kioses, V; Kolokotronis, A; Miteloudis, G; Valagouti, D; Vritsali, E; Zaraboukas, T | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Azoulay, S; Créminon, C; Dellamonica, P; Durant, J; Duval, D; Garraffo, R; Grassi, J; Guedj, R; Heripret, L; Nevers, MC | 1 |
| Cargnel, A; Carosi, G; De Luca, A; Maggi, P; Moretti, F; Orani, A; Patroni, A; Pierotti, P; Quiros-Roldan, E; Regazzi-Bonora, M; Tirelli, V; Torti, C | 1 |
| Bonora, S; Canta, F; D'Avolio, A; De Rosa, FG; Di Perri, G; Marrone, R; Sciandra, M; Sinicco, A | 1 |
| Béguinot, I; Burty, C; Christian, B; Grandidier, M; Jeanmaire, H; May, T; Penalba, C; Rabaud, C | 1 |
| Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 2 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Brun, S; Kempf, DJ; King, K; King, MS; Mo, H; Molla, A | 1 |
| Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA | 1 |
| Badri, S; Conover, CS; Jacobson, LP; Li, X; Margolick, JB; Riddler, SA; Witt, MD | 1 |
| Campo, RE; Fontaine, L; Jayaweera, DT; Kolber, MA; Lalanne, R; Rodriguez, AE; Tanner, TJ | 1 |
| Dalmau, D; Ferrer, E; Gatell, JM; Iniguez, D; Knobel, H; Leon, A; Niubo, J; Podzamczer, D; Polo, C; Ruiz, I | 1 |
| Antela, A; Arribas, JR; Barros, C; Berenguer, J; Cepeda, C; Condes, E; Dronda, F; González-García, JJ; Miralles, P; Montes, ML; Navas, E; Peña, JM; Pérez, S; Pulido, F; Rubio, R; Sanz, J; Vázquez, JJ; Zapata, A | 1 |
| Dailly, E; Jolliet, P; Raffi, F; Reliquet, V | 1 |
| Fuchs, D; Gisslén, M; Hagberg, L; Ståhle, L; Svennerholm, B; Yilmaz, A | 1 |
| Cua, E; Dellamonica, P; Dunais, B; Fontas, E; Garraffo, R; Lavrut, T; Pradier, C; Valerio, L | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Bourbeau, M; Cameron, DW; Garber, GE; Giguere, P; Seguin, I; van Heeswijk, RP | 1 |
| Bergmann, JF; Chaffaut, C; Chevret, S; David, F; Fournier, S; Gérard, L; Lascoux, C; Loze, B; Maillard, A; Molina, JM; Oksenhendler, E; Sereni, D; Timsit, J | 1 |
| Alvaro-Meca, A; de José, MI; Gurbindo, MD; Martin-Fontelos, P; Muñoz-Fernández, MA; Ramos, JT; Resino, S | 1 |
| Biasi, P; Bini, T; Bongiovanni, M; Capetti, A; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; Di Biagio, A; Meraviglia, P; Tordato, F | 1 |
| Cuadrado, JM; Jover, F; Martínez-Baltanás, A; Roig, P | 1 |
| Brodard, V; Calvez, V; Chaix, ML; Chauvin, JP; Cohen-Codar, I; Colson, P; Cottalorda, J; Descamps, D; Guillevic, E; Izopet, J; Kempf, DJ; King, MS; Kohli, E; Lamotte, C; Mackiewicz, V; Marcelin, AG; Morand-Joubert, L; Palmer, P; Peigue-Lafeuille, H; Peytavin, G; Ritter, J; Ruffault, A; Schmuck, A; Schneider, V; Segondy, M | 1 |
| Arnedo, M; Biglia, MA; Blanco, JL; García, F; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Pumarola, T | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; Cicconi, P; Di Biagio, A; Landonio, S; Meraviglia, P; Monforte, Ad; Testa, L; Tordato, F | 1 |
| Brun, SC; Kempf, DJ; King, MS | 1 |
| Capparelli, EV; Durelle, J; Ellis, R; Gragg, B; Holland, D; Letendre, S; Marquie-Beck, J; Okamoto, C; van den Brande, G | 1 |
| Bellón, JM; Cabrero, E; de José, MI; Fontelos, PM; Galán, I; Gutiérrez, MD; Muñoz-Fernández, MA; Pérez, A; Ramos, JT; Resino, S | 1 |
| Rockstroh, JK; Vogel, M | 1 |
| Blok, WL; Burger, DM; Kauffmann, RH; Koopmans, PP; Kroon, FP; la Porte, CJ; Schippers, EF; van der Ende, ME | 1 |
| Allavena, C; Bentata, M; Brunet-François, C; Dailly, E; Delfraissy, JF; Ferré, V; Lafeuillade, A; Launay, O; Michelet, C; Poizot-Martin, I; Raffi, F; Valantin, MA | 1 |
| Armignacco, O; Bonfanti, P; Carradori, S; Magnani, C; Martinelli, C; Parruti, G; Quirino, T; Ricci, E | 1 |
| Hicks, CB; Kaplan, SS | 2 |
| Murphy, RL | 1 |
| Bini, T; Bonfanti, P; Cristina, G; Miccolis, S; Orofino, G; Penco, G; Quirino, T; Ricci, E; Sfara, C | 1 |
| Carini, E; Castagna, A; Danise, A; Dorigatti, F; Galli, L; Gentilini, G; Hasson, H; Lazzarin, A; Seminari, E; Soldarini, A | 1 |
| Brun, S; Cernohous, P; Da Silva, B; Omachi, JH; Rouster, SD; Sherman, KE; Shire, NJ | 1 |
| Beijnen, JH; Crommentuyn, KM; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Meenhorst, PL; Mulder, JW; van Gorp, EC | 1 |
| Angeles Muñoz-Fernández, M; Bellón, JM; Luis Jiménez, J; Martinez-Colom, A; Resino, S | 1 |
| Caumes, E; Duvivier, C; Ghosn, J; Katlama, C; Tubiana, R | 1 |
| Benetucci, J; Bruun, JN; Castagna, A; Dragsted, UB; Fox, Z; Gazzard, B; Gerstoft, J; Hill, A; Jayaweera, DT; Losso, M; Lundgren, JD; Rieger, A; Walmsley, S; Youle, M | 1 |
| Cabrero, E; De José, MI; Dueñas, J; Fortuny, C; González-Montero, R; Mellado, MJ; Muñoz-Fernández, MA; Mur, A; Navarro, M; Otero, C; Pocheville, I; Ramos, JT | 1 |
| Ananworanich, J; Bergshoeff, A; Burger, D; Engchanil, C; Hill, A; Kosalaraksa, P; Pancharoen, C; Ruxrungtham, K; Siangphoe, U | 1 |
| Bini, T; Bongiovanni, M; Capetti, A; Di Biagio, A; Monforte, Ad; Tordato, F; Trovati, S | 1 |
| Adler, E; Cohen, C; Fessel, WJ; Gladysz, A; Gonzalez-Garcia, J; McGovern, R; McLaren, C; Nieto-Cisneros, L; Zala, C | 1 |
| Arranz, A; Arribas, JR; Carcas, A; Cepeda, C; Costa, JR; Delgado, R; Gaya, F; González-García, JJ; Hervás, R; Lorenzo, A; Miralles, P; Montes, ML; Paño, JR; Peña, JM; Pulido, F | 1 |
| Cattarossi, G; Corona, G; Sartor, I; Toffoli, G; Vaccher, E | 1 |
| Hill, A | 1 |
| Hicks, CB | 1 |
| Carosi, G; De Luca, A; Gargiulo, F; Lapadula, G; Manca, N; Patroni, A; Pierotti, P; Quiros-Roldan, E; Regazzi, M; Tinelli, C; Tirelli, V; Torti, C; Uccelli, MC | 1 |
| Antoniou, T; Giguere, P; Phillips, EJ; Tseng, AL; van Heeswijk, RP; Walker, SE | 1 |
| Allavena, C; Dailly, E; Gagnieu, MC; Jolliet, P; Raffi, F | 1 |
| Jiménez, V; Mansinho, K; Rodés, B; Sheldon, JA; Soriano, V; Toro, C | 1 |
| Battegay, M; Elzi, L; Hirsch, HH | 1 |
| Baker, A; Crawford, W; Jassen, A; Jooste, JP; Van Zyl, AJ | 1 |
| Allan, J; Brouillette, MJ; Delisle, MS; Sheehan, NL | 1 |
| Jäger, H; Theobald, T | 1 |
| Tachikawa, N | 1 |
| Bellón, JM; Muñoz-Fernández, MA; Resino, S | 1 |
| Bernard, M; Bouhour, D; Boulliat, J; Fleury, J; Laurent-Coriat, C; Tilikete, C; Vighetto, A | 1 |
| Guéry, B; Yazdanpanah, Y | 1 |
| Adorni, F; Biasi, P; Bini, T; Bongiovanni, M; Chiesa, E; Cicconi, P; Di Biagio, A; Landonio, S; Meraviglia, P; Monforte, AD; Testa, L; Tordato, F | 1 |
| Arribas, J; Brun, SC; Causemaker, SJ; Cepeda, C; DaSilva, B; García Cabanillas, JA; Li, J; Lorenzo, A; Peng, JZ; Pulido, F | 1 |
| Billaud, E; Dailly, E; Jolliet, P; Raffi, F; Wateba, MI | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Biollaz, J; Buclin, T; Cavassini, M; Colombo, S; Decosterd, LA; Franc, C; Guignard, N; Khonkarly, M; Rochat, B; Tarr, PE; Telenti, A | 1 |
| Aliyu, SH; Roberts, MT | 1 |
| Burger, DM; de Wolf, F; Galama, JM; Gras, L; Hoefnagel, JG; Jurriaans, S; Koopmans, PP; Schuurman, R; van der Lee, MJ; van Sighem, AI | 1 |
| Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L | 1 |
| Caliendo, AM; Difrancesco, R; Flanigan, TP; Kurpewski, J; Martin, TM; Morse, GD; Tashima, KT | 1 |
| Bassetti, M; Dentone, C; Di Biagio, A; Gatti, G; Gattinara, GC; Giaquinto, C; Martino, AM; Merlo, M; Rampon, O; Rosso, R; Viganò, A; Viscoli, C | 1 |
| Barroso, PF; Cerbino-Neto, J; Estrela, RC; Schechter, M; Suarez-Kurtz, G; Vergara, TR | 1 |
| Antoniadou, A; Giamarellou, H; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Poulakou, G; Tsiodras, S | 1 |
| Chan-Tack, KM; Edozien, A | 1 |
| Azuaje, C; Crespo, M; Curran, A; Diaz, M; Feijoo, M; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E | 1 |
| Beller, CL; Louet, AL; Piketty, C; Touzot, F; Touzot, M | 1 |
| Freedberg, KA; Holmes, CB; Martinson, NA; Walensky, RP; Zheng, H | 1 |
| Dicenzo, R; Larppanichpoonphol, P; Luque, A; Reichman, R | 1 |
| Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A | 1 |
| Harder, S; Klauke, S; Kurowski, M; Lutz, T; Müller, A; Rottmann, C; Staszewski, S; von Hentig, N | 1 |
| Oldfield, V; Plosker, GL | 1 |
| Chen, HJ; DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, D; Klein, LL; Marsh, KC; Masse, S; Mo, HM | 1 |
| Burger, D; de Groot, R; van der Lee, M; Verweel, G | 1 |
| Hansen, AB; Justesen, US; Mathiesen, S; Von Lüttichau, HR | 1 |
| DeJesus, E; Eron, J; Estrada, V; Gathe, J; Katlama, C; Lackey, P; Patel, L; Shaefer, M; Staszewski, S; Sutherland-Phillips, D; Vavro, C; Wannamaker, P; Yau, L; Yeni, P; Yeo, J; Young, B | 1 |
| Gatanaga, H; Genka, I; Honda, M; Kikuchi, Y; Kimura, S; Oka, S; Tachikawa, N; Tanuma, J; Teruya, K; Ueda, A; Yazaki, H | 1 |
| Belohradsky, BH; Eberle, J; Friese, K; Gingelmaier, A; Grubert, TA; Kästner, R; Kurowski, M; Mylonas, I | 1 |
| Adkison, KK; Berrey, MM; Fang, L; Lou, Y; Otto, VR; Piscitelli, SC; Shachoy-Clark, A | 1 |
| Harris, M; Hogg, RS; Montaner, JS; Moore, DM; Wood, E; Yip, B | 1 |
| Brun, SC; Chiu, YL; Gathe, JC; Hanna, GJ; Johnson, MA; King, MS; Molina, JM; Naylor, CT; Podsadecki, TJ; Podzamczer, D | 1 |
| Babacan, E; Carlebach, A; Dauer, B; Gute, P; Haberl, A; Hermschulte, Y; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Antinori, A; Bongiovanni, M; Cauda, R; Ciardi, M; Cicconi, P; Cozzi-Lepri, A; De Luca, A; Di Giambenedetto, S; Grisorio, B; Marconi, P; Monforte, Ad; Resta, F; Zaccarelli, M | 1 |
| Arribas, JR; Escobar, I; García, MP; Hernando, A; Pérez, E; Pulido, F | 1 |
| Best, BM; Burchett, SK; Capparelli, E; Cotter, A; Elgie, C; Holland, DT; Hu, C; Mirochnick, M; Read, JS; Smith, E; Stek, AM; Tuomala, R | 1 |
| Johnson, M | 1 |
| Biollaz, J; Buclin, T; Colombo, S; Décosterd, LA; Eap, CB; Furrer, H; Lee, BL; Telenti, A | 1 |
| Burger, DM; Koopmans, PP; la Porte, CJ; van der Leur, MR | 1 |
| Boeri, E; Castagna, A; Danise, A; Galli, L; Gianotti, N; Hasson, H; Lazzarin, A | 1 |
| Arribas, JR; Delgado, R; McKinnon, JE; Mellors, JW; Pulido, F | 1 |
| Daar, ES | 1 |
| Manfredi, R; Sabbatani, S | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Chan-Tack, KM; Fantry, LE; Gilliam, BL; Qaqish, RB; Redfield, RR; Rode, RA | 1 |
| Bini, T; Bongiovanni, M; Casana, M; Cicconi, P; Monforte, AD; Tordato, F | 1 |
| Baeza, MT; Boix, V; Climent, E; Merino, E | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| Chauchard, M; Choudat, L; Fabre, A; Houzé, S; Lidove, O; Males, S; Matheron, S; Papo, T; Peigne, V; Rousseau, A; Trinh-Khac, JP | 1 |
| Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN | 1 |
| Zuger, A | 1 |
| Chêne, G; Clavel, F; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM | 1 |
| Barbanoj, MJ; Blanco, A; Clotet, B; Costa, J; DelaVarga, M; Domingo, P; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Tural, C; Valle, M; Vilaró, J | 1 |
| Arvieux, C; Bentué-Ferrer, D; Chapplain, JM; Maillard, A; Michelet, C; Ruffault, A; Tattevin, P; Tribut, O | 1 |
| Allavena, C; Brunet-François, C; Chêne, G; Cuzin, L; Dellamonica, P; Le Moing, V; Lewden, C; Masquelier, B; Raffi, F; Spire, B; Taieb, A | 1 |
| Bassett, R; Brizz, B; Collier, AC; Dehlinger, M; Demeter, LM; Feinberg, JE; Fischl, MA; Garren, K; Giuliano, M; Mukherjee, AL; Tebas, P | 1 |
| Tan, D; Walmsley, S | 1 |
| Taéron, C | 1 |
| Albrecht, M; Benson, C; da Silva, BA; Eron, J; Glesby, M; Gulick, R; Hanna, GJ; Hicks, C; Kessler, H; King, MS; Landay, A; McMillan, FI; Murphy, R; Thompson, M; White, AC; Wolfe, P | 1 |
| DiFrancesco, R; Fischl, MA; Gripshover, B; Hochreitter, J; Keil, K; Morse, GD; Reichman, RC; Zingman, BS | 1 |
| Johnson, MA; Lampe, FC; Phillips, AN; Sabin, CA; Smith, CJ; Tsintas, R; Tyrer, M; Youle, MS | 1 |
| Al-Sharqui, A; Manavi, K; McDonald, A | 1 |
| Brazeau, D; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, BM; Ma, Q; Morse, GD; Reichman, RC; Slish, JC; Venuto, CS; Zingman, BS | 1 |
| Amoroso, A; Chan-Tack, KM; Kopack, AM; Polk, C | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V | 1 |
| Becker, S; Bernstein, B; Calhoun, D; Cameron, DW; da Silva, B; Foit, C; Hanna, GJ; King, MS; Klein, C; Tokimoto, D | 1 |
| Andrews, KT; Gardiner, DL; Kelly, M; McCarthy, JS; Ray, J; Redmond, AM; Skinner-Adams, T | 1 |
| Calles, NR; Ilie, M; Kline, MW; Matusa, RF; Rugina, S; Schwarzwald, HL; Schweitzer, AM | 1 |
| Huttner, A; Lüthi, B; Mueller, NJ; Speck, RF | 1 |
| De Ruiter, A; Lechelt, M; Lyons, F | 1 |
| Kanmaz, TJ; Rode, RA; Sarlo, JA; Shuter, J; Zingman, BS | 1 |
| von Hentig, N | 1 |
| Awni, W; Brun, S; Chiu, YL; King, KR; Klein, CE; Naylor, C; Woodward, WC | 1 |
| Nunes, EP; Schechter, M | 1 |
| Back, DJ; Gibbons, SE | 1 |
| Capparelli, E; Diamond, C; Goicoechea, M; Haubrich, R; Kemper, C; Rigby, A; Vidal, A; Witt, MD | 1 |
| Brizz, B; Collier, AC; Evans, S; Feinberg, J; Fischl, MA; Sattler, F; Shevitz, A; Shikuma, C; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Laurence, J | 1 |
| Calvez, V; Chaix, ML; Delaugerre, C; Girard, PM; Katlama, C; Marcelin, AG; Morand-Joubert, L; Soulié, C | 1 |
| Clotet, B; Miranda, C; Moltó, J; Negredo, E; Santos, JR; Videla, S | 1 |
| Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN | 2 |
| Kurowski, M; Reinke, P; Schürmann, D; Suttorp, N; Wesselmann, H | 1 |
| Calvez, V; Cohen-Codar, I; Hanna, GJ; Kempf, DJ; King, MS; Marcelin, AG; Rode, R | 1 |
| Anderson, PL; Aquilante, CL; Bushman, LR; Carten, ML; Delahunty, T; Fletcher, CV; King, TM; Kiser, JJ; Wolfe, P | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Acosta, EP; Binongo, JN; Chuck, SK; Lennox, JL; Ofotokun, I; Palau, M | 1 |
| Banhegyi, D; Berger, D; de Béthune, MP; De Pauw, M; Lefebvre, E; Madruga, JV; McMurchie, M; Norris, D; Ruxrungtham, K; Spinosa-Guzman, S; Suter, F; Tomaka, F; Vangeneugden, T | 1 |
| Bergonzi, S; Manfredi, R; Sabbatani, S | 1 |
| Abad, J; Amorós-Quiles, I; Belda, A; Borrás-Blasco, J; Casterá, E; Rosique-Robles, D | 1 |
| Bergshoeff, AS; Burger, DM; de Groot, R; Driessen, G; Hartwig, NG; Sheehan, NL; van der Knaap, LC; Verweel, G; Warris, A | 1 |
| Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM | 1 |
| Kuritzkes, DR | 1 |
| Bacarelli, A; Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Gatti, G; Pinnetti, C; Prosperi, M | 1 |
| Agarwal, R; Considine, RV; Dubé, MP; Gupta, SK; Mather, KJ; Saha, CK | 1 |
| Blanco, JL; De Lazzari, E; Gatell, JM; Laguno, M; Larrousse, M; León, A; Lonca, M; López, Y; Mallolas, J; Martinez, E; Milincovic, A; Sarasa, M | 1 |
| Back, D; Boffito, M; Bonora, S; D'Avolio, A; Else, L; Gazzard, B; Mandalia, S; Moyle, G; Nelson, M; Pozniak, A; Waters, LJ | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Battegay, M; Blick, G; Kraft, M; Neubacher, D; Opravil, M; Raffi, F; Rusconi, S; Sabo, JP; Steigbigel, RT | 1 |
| Chrysos, G; Kokkoris, S; Kontochristopoulos, G; Mikros, S; Pastelli, A | 1 |
| Farthing, C; Khanlou, H; Valdes-Sueiras, M | 1 |
| Bonfanti, P; Carradori, S; De Socio, GV; Gianelli, E; Madeddu, G; Martinelli, C; Orofino, G; Penco, G; Quirino, T; Ricci, E; Rizzardini, G | 1 |
| Beusterien, KM; Davis, EA; Dziekan, K; Flood, E; Flood, R; Schrader, S; Shearer, A | 1 |
| Alonso-Socas, Mdel M; Delgado, R; García-Bujalance, S; Garriga, C; Menéndez-Arias, L; Nájera, R; Pérez-Elías, MJ; Pumarola, T; Ruiz, L | 1 |
| Boston, NS; Brazeau, D; Catanzaro, L; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, B; Ma, Q; Morse, GD; Reichman, RC; Slish, J; Zingman, BS | 1 |
| Cahn, P; Castagna, A; Clumeck, N; Dragsted, UB; Fox, Z; Gerstoft, J; Justesen, US; Losso, M; Lundgren, JD; Obel, N; Pedersen, C; Peters, B | 1 |
| Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D | 1 |
| Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C | 1 |
| Chang, CH; Lin, HC; Lu, PL | 1 |
| Barreiro, P; Blanco, F; de Mendoza, C; García-Gasco, P; González-Lahoz, J; Martín-Carbonero, L; Morello, J; Rivas, P; Rodríguez-Novoa, S; Ruiz-Sancho, A; Soriano, V; Vispo, E | 1 |
| Bäumer, A; Burger, D; de Groot, E; Fätkenheuer, G; Koopmans, P; Kroon, F; Reiss, P; Rockstroh, J; Sankatsing, R; Schippers, E; Stroes, E; van der Lee, M; van der Ven, A; Vogel, M; Wyen, C | 1 |
| Asensi, M; Bellón, JM; de José, MI; Fortuny, C; Gurbindo, MD; Larrú, B; Léon, JA; Mellado, MJ; Muñoz-Fernández, MA; Navarro, ML; Ramos, JT; Resino, S; Soler Palacín, P | 1 |
| Boucher, CA; Cotte, L; Hicks, CB; Meier, U; Rusconi, S; Valdez, H; Walmsley, SL; Ward, DJ | 1 |
| Díaz-Curiel, M; Fernández-Guerrero, ML; García-Delgado, R; Górgolas, M; Goyenechea, A; Rivas, P | 1 |
| Arranz, A; Arribas, JR; Cabrero, E; Delgado, R; González-García, J; Iribarren, JA; Norton, M; Pasquau, J; Pérez-Elias, MJ; Portilla, J; Pulido, F; Rubio, R | 1 |
| Ackermans, M; Blümer, RM; Danner, SA; Hassink, E; Reiss, P; Sauerwein, HP; Sutinen, J; van Agtmael, MA; van Vonderen, MG; Yki-Jarvinen, H | 1 |
| Capparelli, EV; Chadwick, EG; Chen, J; Hughes, M; Palumbo, P; Pinto, JA; Robbins, B; Rodman, JH; Serchuck, L; Smith, E; Yogev, R | 1 |
| Corral, A; de Mendoza, C; Garrido, C; Soriano, V; Zahonero, N | 1 |
| Domingo, P; Hairrell, JM; Hanna, GJ; Johnson, MA; King, MS; Molina, JM; Myers, R; Podsadecki, TJ; Rode, RA; Wilkin, A | 1 |
| Aarnoutse, RE; Abdulrazik, F; Burger, DM; Doroshyenko, O; Fätkenheuer, G; Frank, D; Fuhr, U; Hein, W; Jetter, A; Kirchheiner, JC; Klaassen, T; Lazar, A; Lehmann, C; Schmeisser, N; Schömig, E; Seeringer, A; Wyen, C | 1 |
| Hanna, GJ; Podsadecki, TJ; Rode, RA; Tousset, EP; Vrijens, BC | 1 |
| Asenjo, MA; Barrufet, P; Domingo, P; Gatell, JM; Gutiérrez, F; Knobel, H; Mallolas, J; Pedrol, E; Peñaranda, M; Peraire, J; Pich, J; Vidal, F | 1 |
| Chauvin, JP; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Flandre, P; Ghosn, J; Girard, PM; Horban, A; Norton, M; Rouzioux, C; Taburet, AM; Van, PN | 1 |
| Egbers, C; Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ | 1 |
| Andres, DA; Coffinier, C; Farber, EA; Fong, LG; Hrycyna, CA; Hudon, SE; Lee, R; Miner, JH; Nobumori, C; Spielmann, HP; Young, SG | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; De Luca, A; Gianotti, N; Lorenzini, P; Maggiolo, F; Mussini, C; Nasto, P; Perno, CF; Torti, C; Trotta, MP | 1 |
| Babacan, E; Doerr, HW; Lötsch, J; Staszewski, S; Stürmer, M; von Hentig, N | 1 |
| Banno, K; Hirano, A; Kaneda, T; Kudaka, Y; Okumura, N; Takahashi, M | 1 |
| Barrail-Tran, A; Chêne, G; Clavel, F; Dam, E; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM | 1 |
| Barroso, PF; Estrela, RC; Santoro, AB; Suarez-Kurtz, G; Tuyama, M | 1 |
| Bay, MB; Jeffman, MW; Lazzaretti, RK; Mattevi, VS; Sprinz, E | 1 |
| Diaz, RS; Ferreira, PA; Tenore, S | 1 |
| Arranz, A; Arribas, JR; Delgado, R; González-García, J; Hernando, A; Miralles, P; Pérez-Valero, I; Pulido, F | 1 |
| Bresson, JL; Chaix, ML; Cohen-Codar, I; Delfraissy, JF; Galimand, J; Ghosn, J; Girard, PM; Peytavin, G; Raffi, F; Rouzioux, C | 1 |
| Cosín, J; Domingo, P; Galindo, MJ; García Alcalde, ML; Garrido, M; Geijo, P; Gonzalez, J; Lacalle, JR; Lopez-Aldeguer, J; Lozano, F; Muñoz, A; Ribera, E; Roca, B; Sanchez, T; Suárez-Lozano, I; Teira, R; Terrón, A; Torres, F; Vergara, A; Viciana, P; Vidal, F | 1 |
| Delgado, O; Murillas, J; Riera, M; Ventayol, P | 1 |
| Bacarelli, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Navarra, P; Ragazzoni, E; Regazzi, M; Villani, P | 1 |
| Burri, M; Nadal, D; Rode, R; Rudin, C; Shen, Y | 1 |
| Antoniou, T; Balla, S; Du Mont, J; Husson, H; Loutfy, MR; Macdonald, S; Myhr, T; Rachlis, A | 1 |
| Diaz, RS; Hayden, RL; Palácios, R; Sucupira, MC; Tenore, S; Turcato, G; Vasconcelos, L | 1 |
| Bulgin-Coleman, D; Fath, M; Fontaine, L; Kantor, C; Mieras, J; Pierone, G; Shearer, J | 1 |
| Bertilsson, L; Böttiger, Y; Diczfalusy, U; Flamholc, L; Gisslén, M; Josephson, F; Ormaasen, V; Sönnerborg, A | 1 |
| Galegov, GA | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Brizz, B; DiRienzo, AG; Garren, KW; George, T; Haubrich, R; Havlir, D; Klingman, KL; Lalloo, UG; Mellors, JW; Murphy, RL; Peeples, L; Powderly, WG; Riddler, SA; Rooney, JF; Swindells, S | 1 |
| Calmy, A; Hirschel, B | 1 |
| Henney, JE | 1 |
| Miller, JL | 1 |
| Faulds, D; Hurst, M | 1 |
| Benson, C; Bertz, R; Brun, S; Eron, JJ; Gulick, R; Hammer, S; Hicks, C; Hsu, A; Japour, A; Kessler, HA; King, M; Murphy, RL; Sun, E; Thompson, M; White, AC | 1 |
| Mascolini, M | 1 |
| Caumes, E; Deray, G; Izzedine, H; Launay-Vacher, V; Legrand, M; Lieberherr, D | 1 |
| Brothers, CH; Scott, TR; Stein, AJ | 1 |
| Gilden, D | 1 |
| Schouten, J | 1 |
| Slovick, J | 1 |
| Bertocchi, M; Lascaux, AS; Lesprit, P; Levy, Y | 1 |
| Genka, I; Hachiya, A; Kikuchi, Y; Kimura, S; Matsuoka, S; Oka, S; Tachikawa, N; Teruya, K; Tsuchiya, K; Yasuoka, A | 1 |
| Bernstein, BM; Brun, SC; Isaacson, JD; Japour, AJ; Kempf, DJ; King, MS; Real, K; Rode, RA; Sun, E; Xu, Y | 1 |
| Mazzullo, JM; Piliero, PJ | 1 |
| Burger, D; Fätkenheuer, G; Kamps, R; Römer, K; Salzberger, B | 1 |
| Kuschak, D; Mauss, S; Schmutz, G | 1 |
| Edmunds-Ogbuokiri, J | 1 |
| Murphy, MJ | 1 |
| Benson, CA; Brun, SC; Deeks, SG; Eron, JJ; Feinberg, J; Gulick, RM; Hicks, C; Hsu, A; Japour, AJ; Kempf, D; Kessler, HA; King, M; Murphy, RL; Real, K; Riddler, S; Sax, PE; Stryker, R; Sun, E; Thompson, M; Wheeler, D | 1 |
| Morlese, JF; Pozniak, AL; Qazi, NA | 1 |
| Eyer-Silva, WA; Morais-De-Sá, CA; Neves-Motta, R; Pinto, JF | 1 |
| Back, DJ; Barry, M; Bergin, C; Boyle, N; Clarke, S; Mulcahy, F; Reynolds, H | 1 |
| Brill, M; Farthing, C; Graham, E; Khanlou, H | 1 |
| Alexander, C; Harris, M; Montaner, JS; O'Shaughnessy, M | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Han, L; Hsu, A; Kempf, DJ; Lin, CT; Mo, H; Molla, A; Vasavanonda, S | 1 |
| Hammer, SM | 1 |
| Arribas, J; Beall, G; Bernstein, B; Brun, S; Japour, A; Johnson, D; Johnson, M; King, M; Lalonde, R; Ruane, P; Sun, E; Walmsley, S | 1 |
69 review(s) available for lopinavir and HIV Coinfection
| Article | Year |
|---|---|
Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua.
Topics: Anti-HIV Agents; Child; Decidua; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lopinavir; Placenta; Pregnancy; Progesterone; Protease Inhibitors; Ritonavir | 2022 |
Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Betaretrovirus; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis, Biliary; Lopinavir; Malus; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2022 |
Population pharmacokinetics of ethambutol in African children: a pooled analysis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Child, Preschool; Ethambutol; HIV Infections; Humans; Infant, Newborn; Lopinavir; Ritonavir | 2022 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Artemether, Lumefantrine Drug Combination; Body Weight; Computer Simulation; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Lumefantrine; Malaria; Male; Middle Aged; Monte Carlo Method; Ritonavir; Young Adult | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Lopinavir; Pharmaceutical Preparations; Tuberculosis | 2020 |
Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
Topics: Animals; Clinical Trials as Topic; COVID-19 Drug Treatment; Drug Combinations; Drug Repositioning; HIV Infections; Humans; Lopinavir; Ritonavir; SARS-CoV-2 | 2021 |
Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices.
Topics: COVID-19 Drug Treatment; Drug Compounding; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Ritonavir | 2022 |
Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications.
Topics: Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; HIV Infections; Humans; Infant, Newborn; Lopinavir; Malnutrition; Ritonavir | 2022 |
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Network Meta-Analysis; Prospective Studies; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir | 2017 |
Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2017 |
Regression of human immunodeficiency virus-associated oral Kaposi sarcoma with combined antiretroviral therapy: A case report and literature review.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mouth Neoplasms; Ritonavir; Sarcoma, Kaposi; Zidovudine | 2019 |
Clinical pharmacokinetics of antiretroviral drugs in older persons.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; Guidelines as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lamivudine; Liver; Lopinavir; Middle Aged; Oligopeptides; Pyridines; Young Adult | 2013 |
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Induction Chemotherapy; Infant; Infectious Disease Transmission, Vertical; Lopinavir; Maintenance Chemotherapy; Nevirapine; Ritonavir | 2014 |
Antiretroviral therapy response among HIV-2 infected patients: a systematic review.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Female; HIV Infections; HIV-2; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Ritonavir; Treatment Outcome | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
[Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection].
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Therapeutic Equivalency | 2014 |
[Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Therapies, Investigational | 2014 |
[Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
Topics: AIDS Dementia Complex; Chemical and Drug Induced Liver Injury; Drug Combinations; Hepatitis, Viral, Human; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lopinavir; Renal Insufficiency; Reverse Transcriptase Inhibitors; Ritonavir; Subarachnoid Space | 2014 |
[Lopinavir/ritonavir in human immunodeficiency virus-infected women].
Topics: Anti-HIV Agents; Body Size; Drug Combinations; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Meta-Analysis as Topic; Multicenter Studies as Topic; Patient Selection; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sex Characteristics | 2014 |
Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.
Topics: Adult; Anti-HIV Agents; Birth Weight; Cholesterol; Databases, Factual; Female; HIV Infections; Humans; Infant, Newborn; Lopinavir; Pregnancy; Premature Birth; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome | 2015 |
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Tenofovir; World Health Organization | 2015 |
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Nevirapine; Post-Exposure Prophylaxis; Pregnancy; Prospective Studies; Randomized Controlled Trials as Topic; Ritonavir; Zidovudine | 2015 |
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Ritonavir; Stavudine | 2015 |
Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Topics: Atazanavir Sulfate; Cerebrospinal Fluid; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome | 2016 |
Prediction of area under the concentration-time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir-ritonavir therapy.
Topics: Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Forecasting; HIV Infections; HIV Protease Inhibitors; Humans; Linear Models; Lopinavir; Ritonavir | 2016 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
Topics: Antiretroviral Therapy, Highly Active; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Patient Compliance; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir | 2008 |
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
[Safety and tolerability of darunavir].
Topics: Adult; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Lopinavir; Male; Multicenter Studies as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
[Resistance to darunavir].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Male; Multicenter Studies as Topic; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Phenotype; Point Mutation; Pyridazines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
Non-occupational postexposure prophylaxis for HIV: a systematic review.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Databases, Bibliographic; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Lopinavir; Premedication; Pyrimidinones; Ritonavir; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Unsafe Sex; Zidovudine | 2009 |
[Monotherapy in treatment-naïve patients].
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load; Virus Replication | 2008 |
[Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cost Control; Developing Countries; Drug Combinations; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Multicenter Studies as Topic; Pilot Projects; Prospective Studies; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load; Viremia; Virus Replication | 2008 |
[Lopinavir/ritonavir monotherapy. Possible indications].
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Mitochondria; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load; Virus Replication | 2008 |
[Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
Topics: Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Practice Guidelines as Topic; Pyrimidinones; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Virus Replication | 2008 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
[Prognostic factors of virological response in patients treated with lopinavir/ritonavir monotherapy].
Topics: Anemia; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Combinations; Hemoglobins; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Patient Compliance; Pilot Projects; Prospective Studies; Pyrimidinones; Randomized Controlled Trials as Topic; Risk Factors; Ritonavir; Treatment Outcome; Viral Load | 2008 |
[Lopinavir/ritonavir monotherapy for the treatment of HIV-1 infection: the emergence of resistance].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Mutation, Missense; Pilot Projects; Point Mutation; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Viremia | 2008 |
[Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Cost Control; Cost-Benefit Analysis; Direct Service Costs; Drug Combinations; Drug Costs; Drug-Related Side Effects and Adverse Reactions; European Union; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Prescription Fees; Pyrimidinones; Ritonavir; Treatment Outcome | 2008 |
[Penetration in reservoirs].
Topics: Anti-HIV Agents; Drug Combinations; Female; Genitalia, Male; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Lymphocytes; Lymphoid Tissue; Male; Organ Specificity; Pyrimidinones; Ritonavir; Tissue Distribution; Virus Replication | 2008 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.
Topics: Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2010 |
Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.
Topics: Drug Administration Schedule; Drug Combinations; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Practice Guidelines as Topic; Pyrimidinones; Ritonavir | 2010 |
Darunavir: an effective protease inhibitor for HIV-infected patients.
Topics: Darunavir; Drug Administration Routes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2011 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Latin America; Lopinavir; Male; Mutation; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2011 |
[New strategies in the optimisation of lopinavir/ritonavir doses in human immunodeficiency virus-infected patients].
Topics: Drug Combinations; HIV Infections; Humans; Lopinavir; Practice Guidelines as Topic; Ritonavir | 2013 |
Protease inhibitor monotherapy: what is its role?
Topics: Adipose Tissue; Bone Density; Carbamates; Drug Combinations; Drug Resistance, Viral; Furans; HIV Infections; Humans; Lopinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides | 2012 |
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Ritonavir | 2012 |
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Maintenance Chemotherapy; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone.
Topics: Administration, Inhalation; Adult; Androstadienes; Antiviral Agents; Asthma; Biological Availability; Cushing Syndrome; Cytochrome P-450 Enzyme Inhibitors; Drug Therapy, Combination; Fluticasone; Glucocorticoids; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir | 2003 |
Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
Topics: Carbamates; Drug Resistance, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Boosted PIs: competition hots up.
Topics: Atazanavir Sulfate; Drug Administration Schedule; HIV Infections; Humans; Indinavir; Lopinavir; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Saquinavir | 2003 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
The role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.
Topics: Adult; Animals; Anti-Retroviral Agents; HIV Infections; Humans; Lopinavir; Pyrimidinones | 2003 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
Safety of lopinavir/ritonavir for the treatment of HIV-infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Approval; Drug Interactions; HIV Infections; Humans; Lopinavir; Pyrimidinones; Safety | 2005 |
Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2005 |
Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
Topics: Administration, Oral; CD4 Lymphocyte Count; Contraindications; Cytochrome P-450 CYP3A Inhibitors; Dosage Forms; Drug Approval; Drug Combinations; Drug Interactions; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Viral Load | 2005 |
[Protease inhibitors].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2005 |
[Antiretroviral drugs in severe acute respiratory syndrome].
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Pyrimidinones; Ribavirin; Ritonavir; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Viral Fusion Proteins | 2006 |
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2006 |
Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
Topics: Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2007 |
Lopinavir/ritonavir: appraisal of its use in HIV therapy.
Topics: Animals; Drug Combinations; Drug Evaluation, Preclinical; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2007 |
Monotherapy with lopinavir/ritonavir.
Topics: Drug Combinations; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2007 |
Lopinavir/ritonavir (ABT-378/r).
Topics: Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones | 2002 |
368 trial(s) available for lopinavir and HIV Coinfection
| Article | Year |
|---|---|
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
Topics: Adolescent; Anti-HIV Agents; Child; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome | 2008 |
Brief Report: No Differences Between Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297).
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Parasitemia; Plasmodium falciparum; Reverse Transcriptase Inhibitors; Ritonavir | 2022 |
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Infant, Newborn; Lamivudine; Lopinavir; Ritonavir | 2022 |
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lopinavir; Nevirapine; RNA; Viral Load | 2023 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Chromatography, Liquid; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Lopinavir; Medication Adherence; Organophosphates; Polyphosphates; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies; Ritonavir; Tenofovir | 2020 |
Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Rifampin; Ritonavir | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Child; Child, Preschool; Dental Caries; Drug Therapy, Combination; Female; Gingivitis; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Oral Health; Outcome Assessment, Health Care; Prevalence; Quality of Life; Ritonavir; Tooth Eruption; Uganda | 2020 |
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Topics: Africa South of the Sahara; Anti-HIV Agents; Area Under Curve; Child, Preschool; Chromatography, Liquid; Cohort Studies; Drug Combinations; Drug Elimination Routes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Patient Safety; Ritonavir; Severe Acute Malnutrition; Tandem Mass Spectrometry; Zidovudine | 2021 |
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
Topics: Anti-HIV Agents; Burkina Faso; Chemoprevention; Child; Child Development; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Neuropsychological Tests; Ritonavir; South Africa; Surveys and Questionnaires; Uganda; Zambia | 2021 |
Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Bone Density; Breast Feeding; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Postpartum Period; Ritonavir; Tenofovir; Young Adult | 2021 |
Vitamin D status and associated factors among HIV-infected children and adolescents on antiretroviral therapy in Kampala, Uganda.
Topics: Calcifediol; Child; Child, Preschool; Female; HIV Infections; HIV-1; Humans; Infant; Lopinavir; Male; Ritonavir; Uganda; Vitamin D Deficiency | 2021 |
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Topics: Adult; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Rifabutin; Rifampin; Ritonavir; Tuberculosis | 2021 |
Understanding the acceptability and adherence to paediatric antiretroviral treatment in the new formulation of pellets (LPV/r): the protocol of a realist evaluation.
Topics: Administration, Oral; Anti-HIV Agents; Caregivers; Child; Culture; Data Collection; Delivery of Health Care; Drug Combinations; HIV Infections; Humans; Kenya; Lopinavir; Medication Adherence; Patient Satisfaction; Ritonavir; Socioeconomic Factors; Tablets | 2017 |
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Maraviroc; Medication Adherence; Post-Exposure Prophylaxis; Ritonavir; Triazoles; Young Adult | 2017 |
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infant; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; RNA, Viral; Treatment Outcome | 2017 |
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Burkina Faso; Child, Preschool; Cote d'Ivoire; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Public Health; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Lopinavir; Male; Neurocognitive Disorders; Reverse Transcriptase Inhibitors; Uganda | 2017 |
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.
Topics: Area Under Curve; Body Weight; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Pharmacogenomic Testing; Practice Guidelines as Topic; Ritonavir; Viral Load; World Health Organization | 2018 |
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Post-Exposure Prophylaxis; Prospective Studies; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Tenofovir | 2017 |
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; HIV Infections; HIV-1; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Ritonavir; Uganda | 2018 |
Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Chromatography, High Pressure Liquid; Developing Countries; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Plasma; Retrospective Studies; Treatment Outcome | 2018 |
Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).
Topics: Adult; Anti-Retroviral Agents; Female; France; HIV Infections; HIV-1; Hospitals, University; Humans; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2018 |
Decreased bone turnover in HIV-infected children on antiretroviral therapy.
Topics: Absorptiometry, Photon; Alkynes; Benzoxazines; Bone Density; Bone Remodeling; Child; Child, Preschool; Collagen Type I; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Peptides; Ritonavir; South Africa | 2018 |
Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.
Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Ritonavir; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult | 2018 |
Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunity, Cellular; Inflammation; Lopinavir; Lymphocyte Activation; Male; Middle Aged; Pilot Projects; Proof of Concept Study; Raltegravir Potassium; RNA, Viral; Viremia; Virus Replication | 2018 |
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Quality of Life; Reproducibility of Results; Ritonavir; Spain; Surveys and Questionnaires; Treatment Outcome; Viral Load | 2018 |
Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Data Interpretation, Statistical; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2018 |
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
Topics: Adult; Africa; Developing Countries; Drug Resistance, Viral; Female; Genotyping Techniques; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Randomized Controlled Trials as Topic; Treatment Failure | 2019 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Treatment Outcome; Viral Load | 2019 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
Topics: Adult; Age Factors; Anti-HIV Agents; Antitubercular Agents; Biological Availability; Child, Preschool; Cohort Studies; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Infant; Lopinavir; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Rifampin; Ritonavir; Tuberculosis | 2013 |
Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Gels; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Young Adult | 2013 |
Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2013 |
Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Drug Therapy, Combination; Female; Glucosides; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Plant Extracts; Ritonavir; Solanum tuberosum; Young Adult | 2013 |
Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lopinavir; Male; Pregnancy; Pregnancy Complications, Infectious; Ritonavir | 2013 |
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Nucleosides; Nucleotides; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome | 2013 |
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA Stability; RNA, Viral; Tenofovir; Viral Load | 2013 |
Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.
Topics: Absorptiometry, Photon; Adult; Argentina; Bone Density; Bone Diseases, Metabolic; Female; Femur; HIV Infections; HIV Protease Inhibitors; Humans; India; Lopinavir; Lumbar Vertebrae; Malaysia; Male; Osteoporosis; Prevalence; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; South Africa; Thailand; Treatment Outcome | 2013 |
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Eruptions; Drug Substitution; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Ritonavir; Uganda; World Health Organization | 2013 |
Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.
Topics: Adult; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Rifabutin; Ritonavir; Young Adult | 2013 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load | 2013 |
Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biological Availability; Breast Feeding; Cyclopropanes; Dried Blood Spot Testing; Drug Combinations; Drug Therapy, Combination; Female; Hair; HIV Infections; Humans; Lopinavir; Malnutrition; Medication Adherence; Middle Aged; Nutritional Status; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Uganda; Young Adult | 2014 |
Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Hair; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Milk, Human; Plasma; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Uganda | 2013 |
A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prenatal Care; Protease Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipodystrophy; Logistic Models; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Viral Load; Virus Replication | 2013 |
A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Netherlands; Odds Ratio; Patient Satisfaction; Quality of Life; Ritonavir; Zidovudine | 2014 |
Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lopinavir; Malaria; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Uganda; Viral Load | 2014 |
Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; Humans; Immune System; Lopinavir; Male; Middle Aged; Ritonavir; Time Factors; Treatment Outcome | 2014 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Diseases; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Risk Factors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Topics: Adult; Antibiotics, Antitubercular; Area Under Curve; Asian People; Biological Availability; Chemical and Drug Induced Liver Injury; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis; Vietnam | 2014 |
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Nevirapine; Ritonavir; Sex Factors; South Africa; Treatment Outcome | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Pressure; Body Mass Index; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cholesterol, HDL; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Linear Models; Logistic Models; Lopinavir; Multivariate Analysis; Nevirapine; Organophosphonates; Prospective Studies; Risk Factors; Ritonavir; RNA, Viral; Tenofovir; Triglycerides | 2014 |
Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pregnancy; Ritonavir; Young Adult | 2014 |
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment.
Topics: Adult; Case-Control Studies; Chemistry, Pharmaceutical; Coinfection; Drug Combinations; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Lopinavir; Male; Middle Aged; Ritonavir; Treatment Outcome; Viral Load | 2014 |
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Malaria; Male; Nevirapine; Parasitemia; Quinolines; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Uganda | 2014 |
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomise
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Young Adult | 2014 |
Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biological Availability; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Ritonavir; Young Adult | 2014 |
Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Treatment Outcome; Viral Load; Viremia | 2014 |
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Biological Availability; Child; Child, Preschool; Cohort Studies; Confidence Intervals; Cross-Over Studies; Drug Compounding; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Ritonavir; Tablets; Uganda; World Health Organization | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Nevirapine; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome | 2014 |
Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Lopinavir; Malaria; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult | 2014 |
Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Cytokines; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Lopinavir; Male; Middle Aged; Ritonavir; Sulfonamides; Viremia | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Lopinavir; Male; Pregnancy; Premature Birth; Risk Factors; Ritonavir; Uganda; Young Adult | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Ritonavir; Tuberculosis; Young Adult | 2014 |
Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child Development; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Kenya; Lopinavir; Male; Nevirapine; Ritonavir | 2015 |
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
Topics: Africa South of the Sahara; Anti-HIV Agents; Child, Preschool; Female; HIV Infections; HIV-1; Humans; Incidence; India; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lopinavir; Male; Nevirapine; Ritonavir; Treatment Outcome | 2014 |
Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Peptides; Ritonavir; Tenofovir; Young Adult | 2015 |
[Lack of bioavailability of generic lopinavir/ritonavir not prequalified by WHO marketed in Africa (Congo Brazzaville)].
Topics: Africa; Commerce; Congo; Developing Countries; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; HIV-1; Humans; Lopinavir; Ritonavir; Therapeutic Equivalency; World Health Organization | 2015 |
Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Body Weight; Clinical Trials as Topic; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Monte Carlo Method; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Ritonavir; Thailand; Treatment Outcome; United States; Young Adult | 2015 |
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis | 2015 |
Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Double-Blind Method; Drug Combinations; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Peptide Fragments; Peptides; Ritonavir | 2014 |
Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Viral Load | 2014 |
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Black People; Coinfection; Cross-Over Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Lamivudine; Lopinavir; Male; Neutropenia; Rifabutin; South Africa; Stavudine; Tuberculosis; Uveitis | 2014 |
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lopinavir; Malaria; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Uganda; Viral Load | 2015 |
Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the
Topics: Adolescent; Contraceptives, Oral, Synthetic; Delayed-Action Preparations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Medroxyprogesterone Acetate; Middle Aged; Ovulation; Progesterone; Ritonavir; Young Adult | 2015 |
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Maraviroc; Prospective Studies; Ritonavir; Treatment Outcome; Triazoles; Viral Load | 2015 |
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
Topics: Adult; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Raltegravir Potassium; Ritonavir; Secondary Care | 2015 |
Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Tenofovir | 2015 |
Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; T-Lymphocyte Subsets; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a random
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2015 |
Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.
Topics: Adult; Anti-HIV Agents; Female; Genotyping Techniques; HIV Infections; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Young Adult | 2015 |
Effect of Extra Virgin Olive Oil on Biomarkers of Inflammation in HIV-Infected Patients: A Randomized, Crossover, Controlled Clinical Trial.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Atherosclerosis; Biomarkers; C-Reactive Protein; Cross-Over Studies; Drug Combinations; Food Handling; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation Mediators; Lopinavir; Male; Middle Aged; Olive Oil; Ritonavir; Single-Blind Method; Young Adult | 2015 |
Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.
Topics: Adult; Africa South of the Sahara; Alcohol Abstinence; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Isoniazid; Logistic Models; Lopinavir; Male; Middle Aged; Peripheral Nervous System Diseases; Raltegravir Potassium; Ritonavir; RNA, Viral; Smoking; Tuberculosis, Pulmonary; Viral Load | 2016 |
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.
Topics: Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Mutation; Phenotype; Ritonavir; Treatment Failure | 2015 |
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Ritonavir; South Australia; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Disease Progression; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Lopinavir; Male; Ritonavir; South Africa | 2015 |
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Thailand; Viral Load; Zidovudine | 2016 |
No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Pregnancy; Pregnancy Trimester, Third; Ritonavir; Tablets; Tandem Mass Spectrometry; Viral Load | 2016 |
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Male; Nevirapine; South Africa; Viral Load | 2015 |
Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.
Topics: Adolescent; Anti-HIV Agents; Child; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; CD4 Lymphocyte Count; Cognition; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Neurocognitive Disorders; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2016 |
Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pre-Exposure Prophylaxis; Ritonavir | 2016 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal Fluid; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Prospective Studies; Ritonavir; Semen; Viral Load; Young Adult | 2016 |
The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
Topics: Adult; Anti-HIV Agents; Artemether; Artemisinins; Drug Interactions; Ethanolamines; Female; Fluorenes; HIV Infections; HIV-1; Humans; Lopinavir; Lumefantrine; Male; Ritonavir | 2016 |
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
Topics: Amino Acid Substitution; Child, Preschool; Drug Resistance, Viral; Female; Gene Expression; Gene Products, gag; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Mutagenesis, Site-Directed; Mutation; Phenotype; Ritonavir; Treatment Failure | 2016 |
Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.
Topics: Adolescent; Adult; Drug Interactions; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Maleimides; Middle Aged; Peptides; Ritonavir; Treatment Outcome; Young Adult | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
High Variability of Hormonal Levels and No Clinically Relevant Interaction Between Ethinyl Estradiol, Desogestrel and Lopinavir/Ritonavir in a Small Sample of HIV-positive Adolescents.
Topics: Adolescent; Anti-HIV Agents; Contraceptive Agents, Female; Desogestrel; Drug Combinations; Drug Interactions; Ethinyl Estradiol; HIV Infections; Humans; Lopinavir; Pilot Projects; Prospective Studies; Ritonavir; Treatment Outcome | 2016 |
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
Topics: Adipogenesis; Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Extremities; Female; Gene Expression Regulation; HIV Infections; Humans; Lipid Metabolism; Lipids; Lopinavir; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome | 2016 |
Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bone Density; Bone Diseases; CD4 Lymphocyte Count; Drug Substitution; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load | 2016 |
Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cross-Over Studies; HIV Infections; Humans; Infant; Lopinavir; Patient Acceptance of Health Care; Tablets; Taste; Viral Load | 2016 |
Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Amenorrhea; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Metrorrhagia; Prospective Studies; Ritonavir; Young Adult; Zidovudine | 2016 |
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Drug Resistance, Viral; Health Resources; Health Services Accessibility; HIV Infections; HIV-1; Humans; India; Lopinavir; Malawi; Male; Medically Underserved Area; Peru; Raltegravir Potassium; Reverse Transcriptase Inhibitors; RNA, Viral; Thailand; Viral Load | 2016 |
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Efavirenz is associated with higher bone mass in South African children with HIV.
Topics: Absorptiometry, Photon; Alkynes; Anti-Retroviral Agents; Benzoxazines; Bone and Bones; Bone Development; CD4 Lymphocyte Count; Child; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Ritonavir; South Africa; Treatment Outcome; Viral Load | 2016 |
Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Male; Nevirapine; Ritonavir; Severity of Illness Index; Treatment Failure; Treatment Outcome; Viral Load | 2016 |
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia.
Topics: Adult; Cambodia; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipoproteins, LDL; Lopinavir; Male; Middle Aged | 2016 |
Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy.
Topics: Anti-Retroviral Agents; Body Height; Body Weight; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Male; Ritonavir | 2016 |
Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line Antiretroviral Therapy in Asia.
Topics: Adolescent; Anti-Retroviral Agents; Asia; Child; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Viral Load | 2016 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Costs of Care of HIV-Infected Children Initiating Lopinavir/Ritonavir-Based Antiretroviral Therapy before the Age of Two in Cote d'Ivoire.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cote d'Ivoire; Female; Follow-Up Studies; Health Care Costs; HIV Infections; Humans; Infant; Lopinavir; Lost to Follow-Up; Male; Outcome Assessment, Health Care; Prospective Studies; Ritonavir; Survival Rate | 2016 |
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Malaria, Falciparum; Malawi; Male; Nevirapine; Plasmodium falciparum; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2016 |
Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclosporine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Ritonavir; Young Adult | 2017 |
Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Lamivudine; Lipid Metabolism; Lipids; Lipoproteins, LDL; Lopinavir; Male; Viral Load | 2017 |
Does efavirenz replacement improve neurological function in treated HIV infection?
Topics: Adult; Alkynes; Benzoxazines; Brain Chemistry; Cognition; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Neuropsychological Tests; Proton Magnetic Resonance Spectroscopy; Ritonavir; Treatment Outcome; Young Adult | 2017 |
Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Topics: Anti-HIV Agents; Blood Chemical Analysis; CD4 Lymphocyte Count; Child; Cholesterol; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Saquinavir; Thailand; Treatment Refusal; Triglycerides; Viral Load | 2008 |
Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
Topics: Adult; Area Under Curve; Body Weight; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Liver Function Tests; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Risk Factors; Ritonavir; Spectrophotometry, Ultraviolet; Ultrafiltration; Ultrasonography | 2008 |
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Weight Gain | 2008 |
Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Viral Load | 2008 |
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; Diarrhea; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease; HIV-1; Humans; Hypertriglyceridemia; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome | 2008 |
Metabolic changes in protease inhibitor-naive patients treated for 1 year with lopinavir/ritonavir.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Insulin Resistance; Lipids; Lopinavir; Male; Pyrimidinones; Risk Factors; Ritonavir | 2008 |
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pyrimidinones; Quality of Life; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A king in the CASTLE? Optimum initial HIV protease inhibitor.
Topics: Atazanavir Sulfate; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Tablets; Viral Load | 2008 |
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2008 |
Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
Topics: Adult; Cross-Sectional Studies; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Models, Biological; Pyrimidinones; Ritonavir | 2008 |
CASTLE data show no gender differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Sex Factors; Viral Load | 2008 |
Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
Topics: Adiponectin; Adult; Body Composition; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Lopinavir; Male; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2008 |
Early antiretroviral therapy and mortality among HIV-infected infants.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Treatment Failure; Zidovudine | 2008 |
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Capsules; Cytochrome P-450 CYP3A; Drug Combinations; Drug Therapy, Combination; Enzyme Induction; Female; Gelatin; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Tablets | 2009 |
Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir/ritonavir antiretroviral in HIV-infected patients.
Topics: Adult; Aged; Drug Combinations; Female; Gastrointestinal Tract; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir | 2009 |
[Darunavir in treatment-naïve patients. The ARTEMIS study].
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2008 |
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Topics: Adult; Aged; Benzoates; Diketopiperazines; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Piperazines; Pyrimidinones; Receptors, CCR5; Ritonavir; RNA, Viral; Spiro Compounds; Young Adult | 2009 |
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Protease Inhibitors; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
Topics: Area Under Curve; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.
Topics: Adult; Capsules; Drug Administration Schedule; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Tablets | 2009 |
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2009 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Medication Adherence; Plasma; Pyrimidinones; Ritonavir; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Intra-Abdominal Fat; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Radiography, Abdominal; Stavudine; Thigh; Viral Load; Zidovudine | 2009 |
Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
Topics: Adult; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Medication Adherence; Pilot Projects; Predictive Value of Tests; Prognosis; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load | 2009 |
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Middle Aged; Nucleosides; Pyrimidinones; Ritonavir | 2009 |
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Atazanavir Sulfate; Drug Resistance, Viral; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lipids; Liver; Lopinavir; Male; Middle Aged; Mutation; Oligopeptides; Pyridines; Pyrimidinones; Safety | 2009 |
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
Topics: Absorptiometry, Photon; Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Osteoporosis; Pyrimidinones; Ritonavir; Young Adult; Zidovudine | 2009 |
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
Topics: Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome; Zidovudine | 2009 |
Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Viral Load | 2009 |
Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lopinavir; Male; Middle Aged; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2009 |
Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Composition; Glucose; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Pyrimidinones; Zidovudine | 2009 |
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; Humans; Inflammation Mediators; Lamivudine; Lopinavir; Male; Middle Aged; Osteoporosis; Prospective Studies; Pyrimidinones; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Risk Factors; Ritonavir; Zidovudine | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Retrospective Studies; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2009 |
Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Topics: Adult; Algorithms; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Logistic Models; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; RNA, Viral; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; DNA, Mitochondrial; Drug Therapy, Combination; Electron Transport Complex IV; Extremities; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2009 |
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Topics: Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Lopinavir; Male; Medication Adherence; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Zidovudine | 2010 |
Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Plasma; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation.
Topics: Adult; Anti-Retroviral Agents; Cyclosporine; Dose-Response Relationship, Drug; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Immunosuppressive Agents; Liver Failure; Liver Transplantation; Lopinavir; Male; Middle Aged; Peptide Fragments; Pyrimidinones; Ritonavir; Tacrolimus; Treatment Outcome | 2009 |
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antiviral Agents; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Rifabutin; Ritonavir; Tuberculosis | 2009 |
Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Prospective Studies; Pyrimidinones | 2009 |
Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Organophosphonates; Pyrimidinones; Ritonavir; Self Administration; Stavudine; Tenofovir; Treatment Outcome | 2009 |
Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
Topics: Adult; Drug Administration Schedule; Drug Combinations; Drugs, Generic; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidinones; Ritonavir; Tablets | 2009 |
Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults.
Topics: Adult; Area Under Curve; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Linear Models; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; Time Factors; Virus Replication | 2009 |
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Withholding Treatment | 2010 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viremia | 2010 |
Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mexico; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral | 2010 |
Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Nausea; Pyrimidinones; Ritonavir; Viral Load; Young Adult | 2010 |
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome | 2010 |
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.
Topics: Anti-Retroviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Proportional Hazards Models; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Child, Preschool; Drug Therapy, Combination; Ethionamide; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Isoniazid; Kaplan-Meier Estimate; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; RNA, Viral; South Africa; Tuberculosis, Pulmonary; Viral Load | 2010 |
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.
Topics: Absorptiometry, Photon; Adiposity; Adult; Anti-Retroviral Agents; Anticholesteremic Agents; Dideoxynucleosides; Drug Therapy, Combination; Extremities; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Pravastatin; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Uridine | 2010 |
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.
Topics: Anti-HIV Agents; Blood Cells; DNA, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Polymerase Chain Reaction; Pyrimidinones; Ritonavir; Viral Load | 2010 |
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
Topics: Adult; Aged; Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Uganda | 2010 |
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2010 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
Topics: Adult; Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Medication Adherence; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load | 2010 |
Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.
Topics: Adult; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Pregnancy; Pregnancy Trimester, Third; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Thailand; Viral Load; Young Adult; Zidovudine | 2010 |
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized t
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Organophosphonates; Pyrimidinones; Ritonavir; Tenofovir | 2010 |
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.
Topics: Adult; Analgesics, Opioid; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Finland; HIV Infections; HIV Protease Inhibitors; Humans; Linear Models; Lopinavir; Male; Oxycodone; Pain; Pyrimidinones; Reference Values; Ritonavir; Time Factors; Young Adult | 2010 |
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Topics: Absorptiometry, Photon; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; Young Adult | 2011 |
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.
Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Semen; Time Factors; Treatment Failure; Viral Load | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Maternal Exposure; Nevirapine; Protease Inhibitors; Pyrimidinones; RNA, Viral; Stavudine; Treatment Outcome; Viremia | 2010 |
Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
Topics: Adolescent; Adult; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Estrogens; Ethinyl Estradiol; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Middle Aged; Norgestrel; Oximes; Pyrimidinones; Ritonavir; Transdermal Patch; United States | 2010 |
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; France; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Topics: Adult; Albumins; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System Infections; Cross-Over Studies; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immunoglobulin G; Lopinavir; Male; Maraviroc; Middle Aged; Neopterin; Peptide Fragments; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Triazoles; Viral Load; Viremia; Virus Replication | 2010 |
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Clinical Protocols; Cohort Studies; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Mothers; Nevirapine; Pregnancy; Pyrimidinones; Research Design; Ritonavir; Zidovudine | 2011 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Linear Models; Lopinavir; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; Statistics, Nonparametric; Tenofovir; Treatment Failure; Young Adult | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Lopinavir; Male; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Failure | 2010 |
Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Sex Factors | 2011 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Body Fat Distribution; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.
Topics: Adult; Anti-HIV Agents; Area Under Curve; CD4-Positive T-Lymphocytes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Orosomucoid; Prospective Studies; Protein Binding; Ritonavir; RNA, Viral | 2011 |
Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
Topics: Adolescent; Adult; Area Under Curve; Capsules; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Sex Factors; Tablets; Young Adult | 2011 |
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Lopinavir; Male; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load | 2011 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Treatment Outcome; Viral Load | 2011 |
Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; Tablets | 2011 |
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Lopinavir; Male; Mutation; Ritonavir; RNA, Viral; South Africa; Treatment Failure; Viral Load | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; HIV Infections; Lamivudine; Lopinavir; Protease Inhibitors; Ritonavir; Stavudine; Zidovudine | 2011 |
Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Ritonavir; Treatment Outcome; Young Adult | 2011 |
Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.
Topics: Adolescent; Anti-HIV Agents; Child; Cross-Over Studies; Drug Combinations; Female; HIV Infections; Humans; Lopinavir; Male; Ritonavir; Tablets; Treatment Outcome | 2011 |
Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Precision Medicine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Young Adult | 2011 |
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; DNA Fingerprinting; Drug Resistance, Viral; Female; Genetic Variation; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load; Young Adult; Zidovudine | 2012 |
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Limit of Detection; Lopinavir; Male; Middle Aged; Nonlinear Dynamics; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Viral Load | 2011 |
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; Atazanavir Sulfate; CD4 Lymphocyte Count; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Therapeutic Equivalency | 2012 |
Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
Topics: Adolescent; Anti-HIV Agents; Biological Availability; Capsules; Cohort Studies; Dose-Response Relationship, Drug; Female; Gelatin; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Tablets; Viral Load; Young Adult | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Malaria; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; Lipids; Lopinavir; Male; Ritonavir; South Africa; Treatment Outcome | 2012 |
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2012 |
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Oligopeptides; Post-Exposure Prophylaxis; Pyridines; Ritonavir; Zidovudine | 2012 |
HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Prospective Studies; Treatment Outcome; Viral Load; Viral Tropism | 2012 |
Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2012 |
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Topics: Alanine Transaminase; Anti-HIV Agents; Body Height; Body Weight; Chi-Square Distribution; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Male; Medication Adherence; Nevirapine; Ritonavir; Statistics, Nonparametric; Time Factors; Viral Load | 2012 |
Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Dietary Fats; Drug Administration Schedule; Eating; Fasting; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Uganda | 2012 |
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Nevirapine; Ritonavir | 2012 |
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Ritonavir; RNA, Viral; Zidovudine | 2012 |
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
Topics: Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Death; Drug Resistance, Viral; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lopinavir; Medication Adherence; Mutation; Nevirapine; Ritonavir | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; Gambia; HIV Infections; HIV-1; HIV-2; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Topics: Adult; Africa; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 2012 |
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV; HIV Infections; Humans; Lamivudine; Lipids; Lopinavir; Male; Medication Adherence; Middle Aged; Organophosphorus Compounds; Ritonavir; Treatment Outcome | 2012 |
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Plasma; Ritonavir; Tablets; Treatment Outcome; Viral Load | 2012 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy.
Topics: Amyloid beta-Peptides; Antiretroviral Therapy, Highly Active; Astrocytes; Biomarkers; Enzyme-Linked Immunosorbent Assay; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Neopterin; Peptide Fragments; Ritonavir; S100 Proteins; Switzerland; tau Proteins; Thailand | 2013 |
Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
Topics: Africa; Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Pregnancy; Ritonavir; Treatment Outcome | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Protease Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2013 |
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Prospective Studies; Ritonavir; Young Adult | 2012 |
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immune Tolerance; Lopinavir; Male; Organophosphonates; Peptide Fragments; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Infant; Lactation; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2013 |
Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Topics: Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Infant; Kaplan-Meier Estimate; Lopinavir; Malaria; Male; Reverse Transcriptase Inhibitors; Ritonavir; Secondary Prevention; Uganda | 2012 |
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; South Africa; Stavudine | 2013 |
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
Topics: Aging; Atazanavir Sulfate; Carbamates; Cross-Sectional Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Leukocytes, Mononuclear; Longitudinal Studies; Lopinavir; Male; Nuclear Proteins; Oligopeptides; Protein Precursors; Pyridines; Ritonavir; Sulfonamides; Viral Load | 2012 |
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Atrophy; Body Composition; Chemistry, Pharmaceutical; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Intention to Treat Analysis; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2013 |
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Combinations; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Models, Biological; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy | 2002 |
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Topics: Drug Resistance, Viral; Drug Therapy, Combination; Genes, Viral; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Logistic Models; Lopinavir; Mutation; Phenotype; Pyrimidinones; Ritonavir; RNA, Viral; Time Factors; Viral Load | 2002 |
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Logistic Models; Lopinavir; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2003 |
The efficacy of lopinavir in individuals experiencing protease inhibitor failure.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Protease Inhibitors; Pyrimidinones; Ritonavir; Treatment Failure | 2003 |
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
Topics: Administration, Oral; Biological Availability; Chemistry, Pharmaceutical; Child; Child, Preschool; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Lopinavir; Male; Maximum Tolerated Dose; Multivariate Analysis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2003 |
The safety and tolerability of switching from a non-failing antiretroviral regimen to lopinavir.
Topics: Adult; CD4 Lymphocyte Count; Cholesterol; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Triglycerides; Viral Load | 2003 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Cholesterol, LDL; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Triglycerides | 2003 |
Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.
Topics: Adult; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lipid Metabolism; Lipids; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Time Factors; Triglycerides | 2003 |
Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Proportional Hazards Models; Pyrimidinones; Ritonavir; Salvage Therapy; Viremia | 2003 |
Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Interleukin-7; Lopinavir; Lymphocyte Count; Male; Prospective Studies; Pyrimidinones; Ritonavir; T-Lymphocytes; Viral Load | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2003 |
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Topics: Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Global Health; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Nelfinavir; Patient Compliance; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; Viral Load | 2004 |
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Patient Compliance; Pyrimidinones; Ritonavir | 2004 |
Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women.
Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Indinavir; Lopinavir; Protein Binding; Pyrimidinones; Vagina | 2004 |
Lopinavir protein binding in vivo through the 12-hour dosing interval.
Topics: Adult; Area Under Curve; Blood Proteins; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Protein Binding; Pyrimidinones; Ritonavir; Ultrafiltration | 2004 |
Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mutation; Patient Selection; Phenotype; Predictive Value of Tests; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2004 |
Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.
Topics: Adipose Tissue; Anti-HIV Agents; Area Under Curve; Body Composition; Body Mass Index; Body Weight; CD4 Lymphocyte Count; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir; Salvage Therapy; Tomography, X-Ray Computed | 2004 |
Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Microbial Sensitivity Tests; Middle Aged; Pharmacogenetics; Probability; Prospective Studies; Pyrimidinones; Risk Assessment; Ritonavir; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
Topics: Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Biological Availability; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Middle Aged; Probability; Pyrimidinones; Risk Assessment; Ritonavir; Salvage Therapy; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Sulfonamides; Survival Rate; Treatment Outcome; Viral Load | 2004 |
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Stavudine; Time Factors | 2004 |
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Lipids; Lopinavir; Male; Metabolic Diseases; Pyrimidinones; Reproducibility of Results | 2004 |
Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides | 2004 |
Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome | 2004 |
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Nelfinavir; Predictive Value of Tests; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Sex Characteristics; Stavudine; Viral Load | 2004 |
Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.
Topics: Adult; Anticonvulsants; Cytochrome P-450 Enzyme System; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pharmacogenetics; Phenytoin; Pyrimidinones; Ritonavir; Seizures | 2004 |
Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
Topics: Adult; Area Under Curve; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Mass Spectrometry; Middle Aged; Pyrimidinones; RNA, Viral; Semen; Viral Load | 2004 |
The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
Topics: Adult; CD4 Lymphocyte Count; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Microbial Sensitivity Tests; Multivariate Analysis; Phenotype; Pyrimidinones; Ritonavir; Viral Load | 2004 |
Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Topics: Adult; Aged; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load | 2004 |
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Topics: Adult; Area Under Curve; Body Weight; Capsules; Drug Therapy, Combination; Excipients; Female; Gelatin; Hepatitis, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Saquinavir; Sex Characteristics; Treatment Failure; Viral Load | 2004 |
A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.
Topics: Adult; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Pyrimidinones; Retrospective Studies; Ritonavir; Treatment Outcome; Triglycerides; Viral Load | 2004 |
Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
Topics: Amino Acid Sequence; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Drug Resistance, Viral; Drug Therapy, Combination; Genes, Viral; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Pyrimidinones; Ritonavir; Salvage Therapy; Viral Load | 2004 |
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Middle Aged; Mitochondria; Nevirapine; Prospective Studies; Pyrimidinones; Ritonavir; Safety | 2005 |
Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Salvage Therapy; Substance Abuse, Intravenous | 2004 |
Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Viral Load; Zidovudine | 2005 |
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome | 2005 |
Boosted Reyataz comparable to Kaletra.
Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Oligopeptides; Probability; Pyridines; Pyrimidinones; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sequence Analysis | 2005 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Pyrimidinones; RNA, Viral; Tenofovir; Time Factors; Treatment Failure; Viremia | 2005 |
Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipids; Lopinavir; Male; Middle Aged; Pyrimidinones; Risk Factors; Ritonavir; Triglycerides | 2005 |
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.
Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors | 2005 |
Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Neopterin; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load | 2004 |
Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2005 |
Lopinavir/r versus nelfinavir as salvage therapy.
Topics: Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Nelfinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Salvage Therapy; Viral Load | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Topics: Adult; Aged; Drug Combinations; Drug Monitoring; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Linear Models; Lopinavir; Male; Middle Aged; Mutation; Predictive Value of Tests; Pyrimidinones; Ritonavir; RNA, Viral | 2005 |
Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
Topics: Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Odds Ratio; Patient Compliance; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Viral Load | 2005 |
Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunologic Memory; Infant; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Salvage Therapy; T-Lymphocyte Subsets; Thymus Gland; Treatment Outcome | 2005 |
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Drug Tolerance; Female; France; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oxazines; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Safety | 2005 |
Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 1999 |
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load | 2005 |
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Saquinavir; Treatment Outcome | 2005 |
Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Salvage Therapy; Treatment Outcome | 2005 |
Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Treatment Outcome | 2005 |
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Cholesterol, LDL; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides | 2005 |
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).
Topics: Adult; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pilot Projects; Pyrimidinones; Ritonavir; RNA, Viral; Spain | 2005 |
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
Topics: Adult; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Predictive Value of Tests; Pyrimidinones; RNA, Viral; Salvage Therapy | 2006 |
Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypertriglyceridemia; Indinavir; Lopinavir; Male; Metabolic Clearance Rate; Pyrimidinones | 2005 |
No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach.
Topics: Administration, Oral; Adult; Bayes Theorem; Capsules; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Gels; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Clearance Rate; Pyrimidinones; Regression Analysis; Retrospective Studies; Ritonavir; Saquinavir | 2005 |
Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
Topics: Child; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy | 2006 |
Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.
Topics: Adult; Area Under Curve; Biological Availability; Drug Combinations; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Lopinavir; Male; Middle Aged; Pyrimidinones; Radioligand Assay; Ritonavir | 2006 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Topics: Adult; Atazanavir Sulfate; Blood Proteins; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Protein Binding; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome | 2006 |
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Plasma; Pyrimidinones; Ritonavir | 2006 |
Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
Topics: Adolescent; Adult; Anti-HIV Agents; Bilirubin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; HIV Infections; Humans; Indinavir; Lopinavir; Male; Middle Aged; Multivariate Analysis; Pyrimidinones | 2006 |
Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Zidovudine | 2006 |
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Topics: Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Safety | 2006 |
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Topics: Adult; Aged; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Salvage Therapy; Saquinavir; Viral Load | 2006 |
[Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients].
Topics: Adult; Cost-Benefit Analysis; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2006 |
Reduced lopinavir exposure during pregnancy.
Topics: Adolescent; Adult; Area Under Curve; Case-Control Studies; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Puerperal Infection; Pyrimidinones; Ritonavir | 2006 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides | 2007 |
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome | 2007 |
Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; London; Lopinavir; Male; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load | 2007 |
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Saquinavir; Zidovudine | 2007 |
A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring.
Topics: Adult; Algorithms; Alkynes; Anti-Retroviral Agents; Artificial Intelligence; Bayes Theorem; Benzoxazines; California; Computer Systems; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Expert Systems; Female; Fuzzy Logic; HIV Infections; Humans; Lopinavir; Male; Models, Biological; Practice Guidelines as Topic; Prospective Studies; Pyrimidinones; Reproducibility of Results | 2007 |
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
Topics: Adult; Algorithms; Analysis of Variance; Cohort Studies; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral | 2007 |
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Topics: Adenine; Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Drug Interactions; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transport Protein 1; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2008 |
Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
Topics: Adenine; Adult; Area Under Curve; Capsules; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2007 |
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides | 2007 |
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2007 |
Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Topics: Adult; Double-Blind Method; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Saquinavir; Treatment Failure | 2007 |
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load | 2007 |
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; CD4 Lymphocyte Count; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Pyrimidinones; RNA, Viral; Treatment Outcome | 2008 |
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nucleosides; Pyrimidinones; Ritonavir; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2008 |
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Topics: Adiponectin; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Glucose; Glycerol; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Insulin Resistance; Lamivudine; Lipid Metabolism; Lipids; Lopinavir; Male; Middle Aged; Pyrimidinones; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
Topics: Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Child, Preschool; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Treatment Outcome; United States | 2008 |
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Patient Compliance; Pyrimidinones; Ritonavir; Viral Load | 2007 |
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir | 2008 |
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.
Topics: Adult; Aged; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Refusal; Viral Load; Viremia | 2007 |
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Zidovudine | 2008 |
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Phenotype; Prognosis; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Prospective Studies; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Outcome | 2008 |
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Topics: Adult; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Genitalia, Male; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Plasma; Pyrimidinones; Ritonavir; RNA, Viral; Semen; Time Factors; Virus Shedding; Zidovudine | 2008 |
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Kaplan-Meier Estimate; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Withholding Treatment | 2008 |
Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil.
Topics: Brazil; CD4 Lymphocyte Count; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Time; Time Factors; Treatment Outcome | 2008 |
An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2008 |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxycholesterols; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2008 |
Class-sparing regimens for initial treatment of HIV-1 infection.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure | 2008 |
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Viral Load | 2001 |
Preliminary pharmacokinetic data on ABT-378 encouraging.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir | 1998 |
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome | 2002 |
Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
Topics: Adult; Analgesics, Opioid; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Methadone; Opioid-Related Disorders; Pyrimidinones; Ritonavir; RNA, Viral; Substance Withdrawal Syndrome | 2002 |
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nelfinavir; Proportional Hazards Models; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Survival Analysis; Viral Load | 2002 |
769 other study(ies) available for lopinavir and HIV Coinfection
| Article | Year |
|---|---|
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
Topics: Atazanavir Sulfate; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Outcome | 2008 |
Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.
Topics: Adolescent; Adult; Area Under Curve; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Pyrimidinones; Ritonavir; Thailand; Treatment Outcome; Young Adult | 2009 |
Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
Topics: Anti-HIV Agents; Blotting, Western; Cell Line; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; HIV-2; Human Immunodeficiency Virus Proteins; Humans; Macrophages; Microscopy, Electron, Transmission; Molecular Structure; Polymerase Chain Reaction; Viral Regulatory and Accessory Proteins; Virion; Virus Release; Virus Replication | 2010 |
Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Base Sequence; DNA, Viral; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genes, gag; Genes, Viral; HIV Infections; HIV Protease; HIV-1; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Recombinant Proteins; Succinates; Triterpenes | 2010 |
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Cells, Cultured; Codon; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones | 2010 |
Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
Topics: Drug Resistance, Multiple; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Protein Conformation | 2013 |
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Topics: Benzothiazoles; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Docking Simulation; Pyrans; Structure-Activity Relationship; Sulfonamides | 2017 |
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
Topics: Crystallography, X-Ray; Darunavir; Dipeptides; Drug Design; Furans; HEK293 Cells; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship | 2020 |
Drug interactions in HIV-infected children undergoing treatment with antiretrovirals.
Topics: Administration, Inhalation; Anti-HIV Agents; Anti-Inflammatory Agents; Child, Preschool; Drug Combinations; Drug Interactions; Fluticasone; HIV Infections; Humans; Lopinavir; Male; Rhinitis, Allergic; Ritonavir | 2021 |
Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C.
Topics: Bayes Theorem; Cohort Studies; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation | 2021 |
Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir.
Topics: Animals; Anti-HIV Agents; Biological Availability; Biological Products; Dogs; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Lopinavir; Ritonavir; Tablets | 2021 |
Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Ethiopia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Ritonavir; Viral Load | 2022 |
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.
Topics: Animals; HIV Infections; Lopinavir; Lymphatic System; Ritonavir; Tenofovir | 2022 |
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
Topics: Drug Combinations; HIV Infections; Humans; Lopinavir; Lymphatic System; Models, Biological; Nanoparticles; Tenofovir | 2022 |
The administration of lopinavir/ritonavir via an enteral feeding tube.
Topics: Enteral Nutrition; HIV Infections; Humans; Lopinavir; Ritonavir | 2021 |
Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.
Topics: Emtricitabine; Female; HIV; HIV Infections; Humans; Humeral Head; Lopinavir; Middle Aged; Osteonecrosis; Ritonavir; Tenofovir | 2021 |
Comparison of the Ivermectin and Lopinavir/Ritonavir Treatment Outcomes among COVID-19 Mild to Moderate Cases in Kaduna State.
Topics: COVID-19 Drug Treatment; Cross-Sectional Studies; HIV Infections; Humans; Ivermectin; Lopinavir; Nigeria; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
Topics: Animals; COVID-19 Drug Treatment; Cricetinae; HIV Infections; HIV Protease Inhibitors; Lopinavir; Lung; Mesocricetus; Nelfinavir; Ritonavir; RNA, Viral; SARS-CoV-2 | 2022 |
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study.
Topics: Child; COVID-19; COVID-19 Drug Treatment; HIV Infections; Humans; Lopinavir; Ritonavir; Systemic Inflammatory Response Syndrome | 2022 |
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
Topics: Adult; Cobicistat; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Treatment Outcome | 2022 |
Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Lopinavir; Quality of Life; Ritonavir; South Africa | 2022 |
Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Maleimides; Peptides; Ritonavir; Viral Load | 2022 |
A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
Topics: Anti-Retroviral Agents; HIV; HIV Infections; Humans; Latent Tuberculosis; Lopinavir; Models, Biological; Rifampin; Ritonavir; Tuberculosis | 2022 |
Menthol augmented niosomes for enhanced intestinal absorption of lopinavir.
Topics: Animals; HIV Infections; Intestinal Absorption; Liposomes; Lopinavir; Menthol; Particle Size; Rabbits | 2022 |
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Fluorenes; HIV Infections; Humans; Lopinavir; Lumefantrine; Malaria; Malaria, Falciparum; Nevirapine; Ritonavir; Uganda | 2023 |
Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Rifampin; Ritonavir; Thailand; Tuberculosis | 2022 |
Method validation and clinical application for the quantification of lopinavir, efavirenz, and ritonavir in breast milk using liquid chromatography tandem mass spectrometry.
Topics: Anti-Retroviral Agents; Chromatography, Liquid; Female; HIV Infections; Humans; Lopinavir; Milk, Human; Ritonavir; Tandem Mass Spectrometry | 2022 |
Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Lopinavir; Mutation; Nevirapine; Reverse Transcriptase Inhibitors | 2023 |
Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
Topics: Anti-HIV Agents; Child; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Rifampin; Ritonavir | 2023 |
Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy.
Topics: Animals; Child; Digestion; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lipids; Lopinavir; Milk; Ritonavir; Scattering, Small Angle; X-Ray Diffraction | 2023 |
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study.
Topics: Anti-HIV Agents; Cohort Studies; HIV Infections; Humans; Lopinavir; Retrospective Studies; Rilpivirine | 2023 |
Short-term toxicity assessment of combined use of zidovudine, lamivudine and lopinavir/ritonavir in vitro and in vivo.
Topics: Animals; Anti-HIV Agents; Female; HIV Infections; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Mammals; Mice; Rats; Ritonavir; Zidovudine | 2023 |
Co-administration of rimonabant prevents glucose intolerance in Sprague-Dawley rats treated chronically with lopinavir/ritonavir and zidovudine: an experimental study design.
Topics: Adult; Animals; Anti-HIV Agents; Cannabinoids; Glucose Intolerance; HIV Infections; Humans; Lopinavir; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Rimonabant; Ritonavir; Zidovudine | 2023 |
Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
Topics: Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Lesotho; Lopinavir; Male; Nevirapine; Retrospective Studies; Ritonavir; Viral Load | 2023 |
Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lopinavir; Rifampin; Ritonavir; Tuberculosis | 2023 |
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
Topics: COVID-19; COVID-19 Drug Treatment; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; SARS-CoV-2 | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis | 2023 |
A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2.
Topics: Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; HIV Infections; Humans; Iraq; Lopinavir; Pandemics; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2023 |
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.
Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Understanding acceptance of and adherence to a new formulation of paediatric antiretroviral treatment in the form of pellets (LPV/r)-A realist evaluation.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Caregivers; Child, Preschool; Drug Implants; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Patient Acceptance of Health Care; Ritonavir; Viral Load | 2019 |
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Topics: Aged; Animals; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Caco-2 Cells; Carbamates; Drug Interactions; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Imidazoles; Intestines; Lopinavir; Male; Maraviroc; Middle Aged; Pyrrolidines; Rats; Rats, Wistar; Ritonavir; Saquinavir; Valine; Zidovudine | 2019 |
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.
Topics: Adult; Biomarkers; Female; HIV Infections; Humans; Inflammation; Lopinavir; Male; Middle Aged; Randomized Controlled Trials as Topic; Ritonavir; Time Factors; Treatment Outcome | 2019 |
Lopinavir-Ritonavir Impairs Adrenal Function in Infants.
Topics: Anti-HIV Agents; Burkina Faso; Child; Female; HIV Infections; Humans; Infant; Lopinavir; Pregnancy; Ritonavir; South Africa; Steroid 21-Hydroxylase | 2020 |
Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Asian People; Beijing; Benzoxazines; Case-Control Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Female; HIV Infections; Hospitals, University; Humans; Lipids; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome | 2019 |
Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir.
Topics: Adolescent; Adult; Antimalarials; Coinfection; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Middle Aged; Models, Biological; Quinine; Ritonavir; Young Adult | 2020 |
Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Reverse Transcriptase Inhibitors; Viral Load | 2020 |
Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Medication Adherence; Nevirapine; Pregnancy; Retrospective Studies; South Africa; Tertiary Care Centers; Treatment Outcome | 2020 |
Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy.
Topics: Anti-HIV Agents; Cabo Verde; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2020 |
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Topics: Adult; Age Factors; CD4 Lymphocyte Count; Databases, Factual; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Lost to Follow-Up; Male; Medication Adherence; Middle Aged; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir; Treatment Failure; Viral Load; World Health Organization; Zidovudine | 2019 |
Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101.
Topics: Animals; Anti-HIV Agents; Drug Combinations; HIV Infections; Lopinavir; Pharmaceutical Preparations; Ritonavir | 2020 |
Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Developing Countries; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Treatment Outcome | 2020 |
Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
Topics: Anti-HIV Agents; Antitubercular Agents; Biological Availability; Child; Child, Preschool; Dideoxynucleosides; Drug Combinations; Drug Interactions; HIV Infections; Humans; Lopinavir; Prospective Studies; Rifampin; Ritonavir; Tuberculosis, Pulmonary | 2020 |
Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Topics: Anti-HIV Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Testing; Diabetes Mellitus, Type 2; Drug Combinations; gamma-Globulins; HIV; HIV Infections; Humans; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Darunavir does not prevent SARS-CoV-2 infection in HIV patients.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Darunavir; HIV Infections; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Republic of Korea; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2 | 2020 |
Pyromellitic dianhydride crosslinked soluble cyclodextrin polymers: Synthesis, lopinavir release from sub-micron sized particles and anti-HIV-1 activity.
Topics: Benzoates; Cell Line; Cell Survival; Cyclodextrins; Drug Liberation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Solubility | 2020 |
Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART.
Topics: Adult; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Ritonavir; Treatment Failure; Viral Load | 2020 |
Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz.
Topics: Alkynes; Benzoxazines; Bone Remodeling; Child; Cyclopropanes; HIV Infections; Humans; Lopinavir; Ritonavir | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment.
Topics: Adult; Anti-Retroviral Agents; Atherosclerosis; Female; Fibroblast Growth Factors; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Factors; Ritonavir; Tenofovir; Young Adult | 2020 |
Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies.
Topics: Animals; Betacoronavirus; Cells, Cultured; Clinical Trials as Topic; Coculture Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Decidua; Disease Models, Animal; Drug Repositioning; Drug Therapy, Combination; Embryo Implantation; Endometrium; Female; HIV Infections; Humans; Lopinavir; Maternal Exposure; Mice; Pandemics; Placentation; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Primary Cell Culture; SARS-CoV-2; Trophoblasts; Vascular Remodeling | 2020 |
Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cote d'Ivoire; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Integrase Inhibitors; HIV-2; Humans; Lopinavir; Middle Aged; Mutation; Ritonavir; Viral Load | 2020 |
Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Protective Factors; Retrospective Studies; Risk Factors; SARS-CoV-2; Severity of Illness Index; Spain; Sustained Virologic Response; Viral Load | 2020 |
Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Protease Inhibitors; Ritonavir; Texas; Time Factors; Vitamin D Deficiency | 2021 |
Prevalence and predictors of bone health among perinatally HIV-infected adolescents.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Bone Density; Cross-Sectional Studies; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Male; Prevalence; Puberty; Ritonavir; Viral Load | 2020 |
Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
Topics: Anti-HIV Agents; Antibodies, Neutralizing; Antibody-Dependent Cell Cytotoxicity; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; HIV Antibodies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Ritonavir; Viral Load; Zidovudine | 2020 |
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Malaria; Male; Middle Aged; Nevirapine; Nigeria; Ritonavir; Treatment Outcome; Young Adult | 2020 |
High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Namibia; Prevalence; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Young Adult | 2020 |
Suppression of HIV-1 Viral Replication by Inhibiting Drug Efflux Transporters in Activated Macrophages.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cells, Cultured; Ethanol; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Macrophages; Male; Membrane Transport Proteins; Middle Aged; Virus Replication | 2021 |
Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.
Topics: Adolescent; Adult; Child; Coinfection; HIV Infections; Humans; Lopinavir; Rifabutin; Ritonavir; Tuberculosis | 2021 |
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
Topics: COVID-19; COVID-19 Drug Treatment; HIV Infections; Humans; Lopinavir; Pre-Exposure Prophylaxis; Ritonavir; RNA; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |
Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.
Topics: Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV-1; Humans; Hydrogen Bonding; Kinetics; Lopinavir; Molecular Dynamics Simulation; Mutation; Protein Stability; Recombinant Proteins; Thermodynamics; Treatment Failure | 2021 |
Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates.
Topics: Adult; Anti-Retroviral Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dehydroepiandrosterone Sulfate; Drug Combinations; HIV Infections; HIV-1; Humans; Infant, Newborn; Lopinavir; Molecular Conformation; Oxidation-Reduction; Ritonavir | 2021 |
Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Ritonavir; Self Report; Treatment Outcome; Viral Load | 2021 |
Persistently lower bone mass and bone turnover among South African children living with well controlled HIV.
Topics: Biomarkers; Bone Density; Bone Remodeling; Child; HIV Infections; Humans; Lopinavir; Ritonavir | 2021 |
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis | 2021 |
Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Immunoenzyme Techniques; Limit of Detection; Lopinavir; Medication Adherence; Oxazines; Piperazines; Point-of-Care Testing; Pyridones; Reproducibility of Results; Rural Population; South Africa | 2021 |
Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; COVID-19; Drug Combinations; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Ritonavir; United States; United States Food and Drug Administration | 2021 |
Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; Female; Guidelines as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Inappropriate Prescribing; Lopinavir; Middle Aged; Protease Inhibitors; Rifampin; Ritonavir; Treatment Outcome; Tuberculosis; Uganda; Young Adult | 2021 |
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Registries; Regression Analysis; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2017 |
Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
Topics: Adolescent; CD4 Lymphocyte Count; CD4-CD8 Ratio; Child; Child, Preschool; Cohort Studies; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Host-Pathogen Interactions; Humans; Infant; Infant, Newborn; Lopinavir; Male; Mutation; Ritonavir; Spain; Treatment Outcome; Viral Load; Viremia | 2017 |
Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cohort Studies; Coinfection; Drug Combinations; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Lamivudine; Lopinavir; Male; Models, Immunological; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Ribavirin; Ritonavir; Time-to-Treatment; Zidovudine | 2017 |
Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Prospective Studies; Ritonavir | 2017 |
Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Male; Ritonavir; Sustained Virologic Response; Viral Load | 2017 |
Assessing the Efficacy of Second-Line Antiretroviral Treatment for HIV Patients Failing First-Line Antiretroviral Therapy in Iran: A Cohort Study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Drug Combinations; Female; HIV Infections; Humans; Iran; Longitudinal Studies; Lopinavir; Male; Ritonavir; Treatment Failure; Viral Load; Weight Gain | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Neurocognitive development in HIV-positive children is correlated with plasma viral loads in early childhood.
Topics: Adolescent; Anti-HIV Agents; Child; Child Development; Cognition; Cognition Disorders; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Intelligence; Intelligence Tests; Lopinavir; Male; Neuropsychological Tests; Prospective Studies; Retrospective Studies; Ritonavir; Viral Load | 2017 |
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Topics: Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Retrospective Studies; Ritonavir; South Africa; Stavudine; Treatment Outcome; Viral Load | 2017 |
Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
Topics: Adolescent; Alkynes; Asian People; Benzoxazines; Child; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Polymorphism, Single Nucleotide; Retrospective Studies; Ritonavir | 2017 |
Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy.
Topics: Adolescent; Anti-HIV Agents; Asian People; CD4 Lymphocyte Count; Child; Drug Monitoring; Female; Hair; HIV Infections; Humans; Indonesia; Longitudinal Studies; Lopinavir; Male; Medication Adherence; Predictive Value of Tests; Thailand; Vietnam; Viral Load; Viremia | 2017 |
Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; C-Reactive Protein; Child; Child, Preschool; Cholesterol; Creatinine; Cyclopropanes; Cystatin C; Drug Monitoring; Europe; Female; Fibrin Fibrinogen Degradation Products; HIV Infections; Humans; Inflammation; Interleukin-6; Kidney; Lipopolysaccharide Receptors; Liver; Lopinavir; Male; North America; Reverse Transcriptase Inhibitors; Ritonavir; Time Factors; Treatment Outcome | 2017 |
Use of Adult Sensory Panel to Study Individual Differences in the Palatability of a Pediatric HIV Treatment Drug.
Topics: Adult; Child; Drug Combinations; Female; Genotype; HIV Infections; Humans; Lopinavir; Middle Aged; Protease Inhibitors; Reproducibility of Results; Ritonavir; Taste; Young Adult | 2017 |
Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV.
Topics: Adult; Alkynes; Angiopoietin-1; Angiopoietin-2; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Drug Combinations; Endoglin; Female; HIV Infections; Humans; Infant, Newborn; Infant, Small for Gestational Age; Lopinavir; Neovascularization, Physiologic; Placenta Growth Factor; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Premature Birth; Ritonavir; Stillbirth; Uganda; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Female; Genotype; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand | 2017 |
Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
Topics: Amino Acid Motifs; Drug Resistance, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Envelope Protein gp41; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kenya; Lopinavir; Male; Mutation; Treatment Failure | 2017 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug Interactions; Ethambutol; Female; HIV; HIV Infections; Humans; Isoniazid; Lopinavir; Male; Models, Statistical; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Protease inhibitors and preterm delivery: another piece in the puzzle.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Ireland; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Risk Assessment; Ritonavir; United Kingdom | 2018 |
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Darunavir; Eswatini; Female; HIV Infections; HIV-1; Humans; Kenya; Lesotho; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zambia | 2018 |
Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lopinavir; Los Angeles; Male; Medication Adherence; Middle Aged; Pilot Projects; Post-Exposure Prophylaxis; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Young Adult | 2018 |
Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes.
Topics: Antiretroviral Therapy, Highly Active; Body Mass Index; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Malnutrition; Plasma; Treatment Outcome | 2018 |
Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Calibration; Chromatography, High Pressure Liquid; Colostrum; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Milk, Human; Pregnancy; Pregnancy Complications, Infectious; Reference Standards; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Young Adult; Zidovudine | 2018 |
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
Topics: Animals; Anti-HIV Agents; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; HIV Infections; Injections, Subcutaneous; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Lymph Nodes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Tubules; Lopinavir; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Tenofovir; Vietnam | 2018 |
Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.
Topics: Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Combinations; Endoplasmic Reticulum Stress; Fibroblast Growth Factors; Hep G2 Cells; HIV Infections; HIV Integrase Inhibitors; Humans; Klotho Proteins; Liver; Lopinavir; Maraviroc; Membrane Proteins; Muscle, Skeletal; Obesity; Oxidative Stress; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Thapsigargin; Tunicamycin | 2018 |
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Disease Transmission, Infectious; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Zidovudine | 2018 |
HIV-1 status is independently associated with decreased erectile function among middle-aged MSM in the era of combination antiretroviral therapy.
Topics: Anti-Retroviral Agents; Cross-Sectional Studies; Erectile Dysfunction; HIV Infections; Homosexuality, Male; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Surveys and Questionnaires | 2018 |
Biomarkers of Aging in HIV-Infected Children on Suppressive Antiretroviral Therapy.
Topics: Aging; Biomarkers; Case-Control Studies; Child; Child, Preschool; Cohort Studies; DNA Methylation; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Multiplex Polymerase Chain Reaction; Ritonavir; South Africa; Telomere | 2018 |
Plasma metabolic changes in Chinese HIV-infected patients receiving lopinavir/ritonavir based treatment: Implications for HIV precision therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Plasma; Precision Medicine; Ritonavir; ROC Curve; Young Adult | 2018 |
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Endothelial Cells; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Lymphocyte Activation; Male; Prospective Studies; Pulse Wave Analysis; Random Allocation; Ritonavir | 2018 |
Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women.
Topics: Adult; Amniotic Fluid; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthetics, Local; Bupivacaine; Case-Control Studies; Cesarean Section; Drug Combinations; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Maternal-Fetal Exchange; Permeability; Placenta; Pregnancy; Pregnancy Complications, Infectious; Ritonavir | 2018 |
Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cyclopropanes; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Mali; Mothers; Safety; Tissue Distribution; Young Adult | 2018 |
Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Benzoxazines; Biological Transport; Cohort Studies; Cyclopropanes; Dried Blood Spot Testing; Drug Monitoring; Female; Health Resources; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Rural Population; Switzerland; Tanzania | 2018 |
HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Topics: Adult; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; Health Resources; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Medication Adherence; Ritonavir; South Africa; Viral Load | 2018 |
Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.
Topics: Anti-HIV Agents; Blood Chemical Analysis; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Lopinavir; Male; Metabolome; Metabolomics; Prospective Studies; Randomized Controlled Trials as Topic; Ritonavir | 2018 |
HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Kenya; Lopinavir; Male; Middle Aged; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; Sequence Analysis, DNA; Treatment Failure; Viral Load; Viremia | 2018 |
Absence of effect of the antiretrovirals Duovir and Viraday on mitochondrial bioenergetics.
Topics: Adenosine Triphosphate; Animals; Anti-Retroviral Agents; Drug Combinations; Energy Metabolism; Hepatocytes; HIV Infections; Ion Channels; Lopinavir; Mice; Mitochondria; Mitochondria, Liver; Mitochondrial Proteins; Oxidative Stress; Reactive Oxygen Species; Ritonavir | 2018 |
A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy.
Topics: Adult; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Multivariate Analysis; Mutation | 2019 |
Assessing the adoption of lopinavir/ritonavir oral pellets for HIV-positive children in Zimbabwe.
Topics: Anti-HIV Agents; Caregivers; Child, Preschool; Drug Combinations; Drug Implants; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Ritonavir; Viral Load; Zimbabwe | 2018 |
Antiretroviral Drug Concentrations in Breastmilk, Maternal HIV Viral Load, and HIV Transmission to the Infant: Results From the BAN Study.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Pregnancy; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zidovudine | 2019 |
Dolutegravir for second-line antiretroviral therapy.
Topics: Adult; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lopinavir; Oxazines; Piperazines; Pyridones; Ritonavir; RNA-Directed DNA Polymerase | 2019 |
Gag-protease coevolution shapes the outcome of lopinavir-inclusive treatment regimens in chronically infected HIV-1 subtype C patients.
Topics: Bayes Theorem; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phylogeny | 2019 |
Optimising HIV antiretrovirals for mothers and infants.
Topics: Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Mothers; Ritonavir | 2019 |
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Ritonavir; Uganda; Viral Load | 2019 |
Symptomatic HIV CNS viral escape among patients on effective cART.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Central Nervous System Viral Diseases; Encephalitis; Female; HIV Infections; Humans; India; Lamivudine; Lopinavir; Male; Plasma; Retrospective Studies; Viral Load | 2019 |
Pursuing use of optimal formulations for paediatric HIV epidemic control - a look at the use of LPV/r oral pellets and oral granules.
Topics: Administration, Oral; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Combinations; Drug Compounding; Epidemics; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Male; Pediatrics; Ritonavir | 2019 |
A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Namibia; Pharmacovigilance; Young Adult | 2019 |
Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
Topics: Alanine Transaminase; Anti-HIV Agents; Antibiotics, Antitubercular; Child; Child, Preschool; Drug Combinations; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Male; Plasma; Prospective Studies; Rifampin; Ritonavir; Treatment Outcome; Tuberculosis | 2019 |
Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Cohort Studies; Drug Combinations; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Malawi; Male; Post-Exposure Prophylaxis; Postpartum Period; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Ritonavir; Uganda; Zidovudine | 2019 |
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Topics: Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Biomarkers; Coinfection; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Lopinavir; Male; Retrospective Studies; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis | 2019 |
Does less equal more yet?
Topics: Darunavir; HIV Infections; Humans; Lopinavir; Ritonavir; RNA | 2019 |
Complications of long-term antiretroviral therapy in HIV-infected children.
Topics: Anti-HIV Agents; Body Composition; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Nevirapine | 2013 |
Orbital floor triamcinolone causing Cushing's syndrome in a patient treated with Kaletra for HIV 1.
Topics: Adult; Cushing Syndrome; Diagnosis, Differential; Drug Combinations; Drug Interactions; Female; Follow-Up Studies; Glucocorticoids; HIV Infections; HIV-1; Humans; Injections; Lopinavir; Orbit; Ritonavir; Tomography, Optical Coherence; Triamcinolone | 2013 |
The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.
Topics: Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Models, Biological; Models, Economic; Nigeria; Pyrrolidinones; Quality-Adjusted Life Years; Raltegravir Potassium; Ritonavir; South Africa | 2013 |
Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; HIV Infections; Humans; Italy; Lopinavir; Oligopeptides; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Ritonavir | 2013 |
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Plasma; Ritonavir; Time Factors; Triazoles | 2013 |
Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Female; Gene Frequency; Genotype; Heterozygote; HIV Infections; HIV Protease Inhibitors; HIV-1; Homozygote; Humans; Infant; Lopinavir; Male; Polymorphism, Single Nucleotide; Pregnane X Receptor; Receptors, Steroid; Young Adult | 2013 |
Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Darunavir; Drug Combinations; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Models, Economic; Prognosis; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
[Usefulness of plasma lopinavir levels during pregnancy].
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious | 2013 |
Talk of HIV cure goes viral.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Nevirapine; Primary Prevention; Ritonavir; Secondary Prevention; Time Factors; Zidovudine | 2013 |
Contribution of follicular dendritic cells to persistent HIV viremia.
Topics: Dendritic Cells, Follicular; Drug Combinations; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lopinavir; Models, Biological; Ritonavir; Stavudine; Viral Load; Viremia; Virus Release | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation, Missense; Ritonavir; Suppression, Genetic; Treatment Outcome; Viral Load | 2013 |
Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
Topics: Adult; Aged; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Patient Compliance; Proportional Hazards Models; Prospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
After first-line ART: towards an evidence-based SECOND-LINE.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Lopinavir; Male; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir | 2013 |
Mortality and long-term virologic outcomes in children and infants treated with lopinavir/ritonavir.
Topics: Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Lopinavir; Male; Retrospective Studies; Risk Factors; Ritonavir; Survival Analysis; Viral Load | 2013 |
The effect of antiretrovirals on Plasmodium falciparum liver stages.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Liver; Lopinavir; Malaria, Falciparum; Nevirapine; Plasmodium falciparum; Reverse Transcriptase Inhibitors; Saquinavir | 2013 |
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2013 |
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
Topics: Adult; Anti-HIV Agents; Cognition Disorders; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Ritonavir; RNA, Viral; Viral Load | 2013 |
[Ophthalmological alterations at the initial diagnosis of HIV infection].
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine | 2014 |
Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.
Topics: Adolescent; Adult; Aged; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Lopinavir; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Dopamine D3; Ritonavir; Treatment Outcome; Young Adult | 2013 |
Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV.
Topics: Adolescent; Child; Child, Preschool; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infectious Disease Transmission, Vertical; Lopinavir; Male; Young Adult | 2014 |
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Substance-Related Disorders; Time Factors; Viral Load | 2014 |
Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
Topics: Analysis of Variance; Animals; Antiretroviral Therapy, Highly Active; Blotting, Western; Calcineurin; Calcium-Binding Proteins; Cholesterol, LDL; Connexin 43; DNA Primers; Drug Combinations; Gene Expression Regulation, Enzymologic; HIV Infections; HIV Protease Inhibitors; Liver; Lopinavir; Male; Myocardium; NFATC Transcription Factors; Oxidative Stress; Proteasome Endopeptidase Complex; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Ritonavir; Triglycerides | 2013 |
[Sick sinus syndrome possibly due to lopinavir-ritonavir: report of two cases].
Topics: Aged; Anti-Retroviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Sick Sinus Syndrome | 2013 |
Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Hospitals; Humans; Infant; Lopinavir; Male; Prospective Studies; Serum; South Africa | 2014 |
Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.
Topics: Adipokines; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Child; Child, Preschool; Dyslipidemias; Female; HIV Infections; Humans; Insulin Resistance; Lipids; Lopinavir; Male; Pregnancy; Ritonavir; Thailand | 2014 |
Simplifying antiretroviral therapy to lopinavir/ritonavir monotherapy did not improve quality of life and therapy adherence in pretreated HIV-infected children.
Topics: Adolescent; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Humans; Lopinavir; Male; Medication Adherence; Quality of Life; Ritonavir; Thailand | 2014 |
Effects of combined zidovudine/lopinavir/ritonavir therapy during rat pregnancy: morphological aspects.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Dose-Response Relationship, Drug; Female; Fetus; HIV Infections; HIV Protease Inhibitors; Kidney; Liver; Lopinavir; Pancreas; Pregnancy; Pregnancy Complications, Infectious; Rats; Rats, Wistar; Ritonavir; Zidovudine | 2013 |
[HIV prophylaxis kits. A concept for emergency treatment in the context of postexposure prophylaxis].
Topics: Administration, Oral; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Early Medical Intervention; Emergency Treatment; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Germany; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lopinavir; Needlestick Injuries; Organophosphorus Compounds; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Ritonavir | 2014 |
Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
Topics: Anti-Retroviral Agents; Child, Preschool; Cohort Studies; Coinfection; Cost-Benefit Analysis; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Infant; Lopinavir; Malaria; Male; Quality-Adjusted Life Years; Ritonavir; Uganda | 2014 |
Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.
Topics: Adult; Algorithms; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Models, Statistical; Orosomucoid; Population; Ritonavir; Viral Load | 2014 |
Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
Topics: Adult; CD4 Lymphocyte Count; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Quality-Adjusted Life Years; Ritonavir; Sulfonamides; United States; Viral Load | 2014 |
Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
Topics: Adolescent; Analysis of Variance; Body Weight; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Ritonavir; Tablets | 2014 |
Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lipids; Liver Function Tests; Lopinavir; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridines; RNA, Viral; Viral Load | 2014 |
Generic antiretroviral drugs in developing countries: friends or foes?
Topics: Anti-Retroviral Agents; Congo; Developing Countries; Drugs, Generic; HIV Infections; Humans; Lopinavir; Ritonavir; Treatment Outcome | 2014 |
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Eswatini; Female; HIV Infections; Humans; Lopinavir; Middle Aged; Nevirapine; Pregnancy; Pregnancy, Unplanned; Ritonavir; Young Adult | 2014 |
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2014 |
Comparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypes.
Topics: Analysis of Variance; Base Sequence; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Israel; Lopinavir; Molecular Sequence Data; Retrospective Studies; Ritonavir; Sequence Analysis, DNA; Species Specificity | 2014 |
Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients.
Topics: Adolescent; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Computer Simulation; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lopinavir; Male; Models, Biological; Practice Guidelines as Topic; Retrospective Studies; Ritonavir; Viral Load | 2014 |
Achilles tendinopathy following Kaletra (lopinavir/ritonavir) use.
Topics: Achilles Tendon; Adult; CD4 Lymphocyte Count; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Magnetic Resonance Imaging; Male; Ritonavir; Tendinopathy; Treatment Outcome | 2014 |
Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Epstein-Barr Virus Infections; HIV Infections; Humans; Infant; Kenya; Lopinavir; Nevirapine; Risk Factors; Ritonavir | 2014 |
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; C-Reactive Protein; CD4 Lymphocyte Count; Chemokine CXCL10; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Immune System; Inflammation; Interferon-gamma; Interleukin-6; Lipopolysaccharide Receptors; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2014 |
The effect of lopinavir/ritonavir on the antimalarial activity of artemether or artemether/lumefantrine in a mouse model of Plasmodium berghei.
Topics: Animals; Anti-Retroviral Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Coinfection; Disease Models, Animal; Drug Combinations; Drug Interactions; Ethanolamines; Fluorenes; HIV Infections; Lopinavir; Malaria; Mice; Plasmodium berghei; Ritonavir | 2015 |
Do lopinavir and ritonavir require a dose adjustment during pregnancy?
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir | 2014 |
Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Evolution, Molecular; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Phylogeny; pol Gene Products, Human Immunodeficiency Virus; Retrospective Studies; Ritonavir; RNA, Viral; Viral Load; Viremia | 2015 |
Initial therapy for HIV: can less be more?
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
Drug susceptibility and resistance mutations after first-line failure in resource limited settings.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; India; Lopinavir; Malawi; Male; Middle Aged; Mutation Rate; Nitriles; Pilot Projects; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Tanzania; Thailand; Treatment Failure; Young Adult | 2014 |
Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens.
Topics: Adult; Algorithms; Antiviral Agents; Cells; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Monocytes; Peptide Hydrolases; Ritonavir | 2014 |
Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.
Topics: Adolescent; Anti-HIV Agents; Drug Combinations; Drug Hypersensitivity Syndrome; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Lopinavir; Pleural Effusion; Postpartum Period; Pyrrolidinones; Radiography; Raltegravir Potassium; Respiratory Distress Syndrome; Ritonavir; Zidovudine | 2014 |
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Middle Aged; Plasma; Ritonavir; Semen; Triazoles | 2014 |
Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.
Topics: Adult; Antibiotics, Antitubercular; Coinfection; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Retrospective Studies; Rifampin; Ritonavir; South Africa; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2014 |
Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
Topics: Adult; Antiretroviral Therapy, Highly Active; Canada; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Darunavir; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Ritonavir | 2014 |
Modified pullulan nanoparticles for oral delivery of lopinavir: formulation and pharmacokinetic evaluation.
Topics: Acetylation; Administration, Oral; Animals; Drug Carriers; Glucans; HIV Infections; HIV Protease Inhibitors; Lopinavir; Male; Nanoparticles; Rats; Rats, Wistar; Tissue Distribution | 2014 |
CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.
Topics: Adult; Aged; Cytochrome P-450 CYP3A; Female; Genetic Variation; HIV Infections; HIV Protease Inhibitors; Humans; Liver-Specific Organic Anion Transporter 1; Lopinavir; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Single Nucleotide | 2014 |
Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
Topics: Adult; Alleles; Anti-HIV Agents; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Female; Gene Frequency; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome; Viral Load | 2014 |
Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Post-Exposure Prophylaxis; Retrospective Studies; Ritonavir; Zidovudine | 2014 |
Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography-tandem mass spectrometry and ultrafiltration methods.
Topics: Chromatography, High Pressure Liquid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Ultrafiltration | 2014 |
Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.
Topics: Anti-HIV Agents; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease; Humans; Lopinavir; Microbial Sensitivity Tests; Phenotype; Ritonavir; Treatment Failure | 2014 |
Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression.
Topics: Adult; Encephalitis, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Ritonavir | 2014 |
A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cognition Disorders; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Lopinavir; Male; Middle Aged; Prospective Studies; Sulfonamides | 2014 |
HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
Topics: Female; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Microbial Sensitivity Tests; Ritonavir; Sequence Analysis, DNA; Treatment Failure | 2015 |
Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
Topics: Child; Child, Preschool; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Induction Chemotherapy; Lopinavir; Male; Nevirapine; Retrospective Studies; Treatment Outcome; Viral Load | 2014 |
Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Emtricitabine; Female; France; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Treatment Failure; Viral Load | 2014 |
Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Topics: Administration, Oral; Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Dideoxynucleosides; Drug Combinations; Drug Dosage Calculations; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Models, Statistical; Ritonavir; Silybin; Silymarin; Viral Load; Zidovudine | 2015 |
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Bone Density; HIV Infections; HIV-1; Humans; Lopinavir; Multivariate Analysis; Oligopeptides; Pyridines; Ritonavir | 2015 |
Persistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patient.
Topics: Anti-HIV Agents; Base Sequence; Defective Viruses; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immune Evasion; Integrases; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Molecular Sequence Data; Proviruses; Sequence Analysis, DNA; Sequence Deletion; Viral Load; Zidovudine | 2015 |
Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.
Topics: Adolescent; Analysis of Variance; Anti-HIV Agents; Atazanavir Sulfate; Child; Cholesterol; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Retrospective Studies; Sulfonamides | 2014 |
CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.
Topics: Adult; Cytochrome P-450 CYP3A; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Polymorphism, Single Nucleotide; Pregnancy; Pregnancy Complications, Infectious | 2015 |
Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Monitoring; HIV Infections; Humans; Lopinavir; Nevirapine; Oligopeptides; Plasma; Pyridines; Retrospective Studies | 2014 |
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Carriers; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Indinavir; Lipids; Lopinavir; Lymph Nodes; Macaca; Nanoparticles; Organophosphonates; Ritonavir; Tenofovir; Viral Load; Virus Latency | 2015 |
Barriers to simplified HIV treatment in low-resource settings.
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy.
Topics: Anti-Bacterial Agents; Clarithromycin; Death, Sudden, Cardiac; Dideoxynucleosides; Drug Combinations; Drug Interactions; Electrocardiography; Fatal Outcome; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Piperazines; Purines; Ritonavir; Sexual Behavior; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2015 |
Human immunodeficiency virus post-exposure prophylaxis: primum non nocere.
Topics: Adult; Antiviral Agents; Bipolar Disorder; Cytochrome P-450 CYP3A Inhibitors; Dihydroergotamine; Drug Synergism; Drug Therapy, Combination; Ergotism; Female; HIV Infections; Humans; Hypotension, Orthostatic; Lamivudine; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Vasoconstrictor Agents; Zidovudine | 2015 |
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Sulfonamides; Survival Analysis; Treatment Outcome; Viral Load | 2015 |
[In Process Citation].
Topics: Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Ritonavir | 2014 |
[Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Meta-Analysis as Topic; Multicenter Studies as Topic; Patient Acceptance of Health Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk; Ritonavir; Therapeutic Equivalency; Viral Load | 2014 |
[Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
Topics: Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chronic Disease; Comorbidity; Drug Combinations; Drug Costs; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Meta-Analysis as Topic; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
[Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Meta-Analysis as Topic; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk; Ritonavir; Therapeutic Equivalency; Viral Load | 2014 |
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Cooperative Behavior; Developed Countries; Europe; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Treatment Outcome; United States; Viral Load; Young Adult | 2015 |
A pharmacokinetic model of lopinavir in combination with ritonavir in human.
Topics: Administration, Oral; Area Under Curve; Drug Therapy, Combination; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Ritonavir | 2014 |
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-Retroviral Agents; Asia; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Survival Analysis; Treatment Failure; Viral Load; Young Adult | 2015 |
Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Humans; Infant; Lopinavir; Male; Mutation, Missense; Ritonavir; South Africa; Treatment Failure; Viral Load | 2015 |
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cyclopropanes; HIV Infections; Humans; Lopinavir; Malnutrition; Models, Theoretical; Nevirapine; Poverty; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome; Uganda; Viral Load; Young Adult | 2015 |
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Analysis; Health Care Costs; HIV Infections; Humans; Infant; Infant, Newborn; Life Expectancy; Lopinavir; Male; Nevirapine; Ritonavir; South Africa | 2015 |
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reactive Protein; Carotid Intima-Media Thickness; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Ethiopia; Female; Heart Rate; HIV Infections; HIV-1; Humans; Lipodystrophy; Lopinavir; Male; Middle Aged; Nevirapine; Pulse Wave Analysis; Ritonavir; Triglycerides | 2015 |
Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject.
Topics: Adult; Anti-HIV Agents; Bone Density; Female; Femur; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Longitudinal Studies; Lopinavir; Male; Middle Aged; Ritonavir; Time Factors; Viral Load | 2015 |
Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; Chromatography, Liquid; Cohort Studies; Cyclopropanes; Drug Monitoring; Female; Hair; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Tandem Mass Spectrometry; Treatment Outcome; Uganda; Viral Load | 2015 |
Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; Hospitals, Teaching; Humans; Lopinavir; Male; Middle Aged; Nigeria; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Fluorometric assay for phenotypic differentiation of drug-resistant HIV mutants.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Resistance, Viral; Fluorometry; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Ritonavir; Saquinavir | 2015 |
[Comparative and evolutionary profile of people infected with HIV on antiretroviral therapy in Kinshasa, Democratic Republic of Congo].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Democratic Republic of the Congo; Disease Progression; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Zidovudine | 2014 |
Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Lopinavir; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immune Reconstitution Inflammatory Syndrome; Infant; Infant, Newborn; Lopinavir; Male; Prospective Studies; Ritonavir; South Africa; Tuberculosis; Tuberculosis, Lymph Node; Tuberculosis, Pulmonary | 2016 |
[Pharmacokinetic profiles of lopinavir (LPV) in Chinese HIV-infected patients].
Topics: China; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2015 |
Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lopinavir; Papillomaviridae; Papillomavirus Infections; Uterine Cervical Neoplasms | 2015 |
Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa.
Topics: Antiretroviral Therapy, Highly Active; Coinfection; Drug Resistance, Viral; Gene Frequency; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Host-Pathogen Interactions; Humans; Infant; Logistic Models; Lopinavir; Malnutrition; Mutation; Retrospective Studies; Risk Factors; Ritonavir; Time Factors; Tuberculosis | 2015 |
Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Topics: Adolescent; Adult; Atazanavir Sulfate; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Lopinavir; Middle Aged; Pregnancy; Pregnancy Outcome; Premature Birth; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.
Topics: Adolescent; Anti-HIV Agents; Asian People; Child; Chromatography, Liquid; Drug Monitoring; Female; Hair; HIV Infections; Humans; Longitudinal Studies; Lopinavir; Male; Medication Adherence; Plasma; Prospective Studies; Tandem Mass Spectrometry; Treatment Outcome | 2015 |
Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Sulfonamides; Viral Load | 2015 |
Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Bayes Theorem; Benzoxazines; Canada; Coinfection; Cyclopropanes; Dideoxynucleosides; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepatitis C; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Risk Factors; Tenofovir | 2016 |
Acute Myocarditis and Myopathy as Presenting Manifestations of Human Immunodeficiency Virus Infection.
Topics: Anti-HIV Agents; Arrhythmias, Cardiac; Autopsy; Coronary Angiography; Creatine Kinase; Deoxycytidine; Drug Combinations; Electrocardiography; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Fatal Outcome; HIV Infections; Humans; Lopinavir; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Muscular Diseases; Myocarditis; Myocardium; Organophosphorus Compounds; Pulmonary Edema; Ritonavir | 2015 |
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognitive Dysfunction; Coinfection; Cyclopropanes; Drug Therapy, Combination; Executive Function; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Memory; Middle Aged; Neuropsychological Tests; Ritonavir; Verbal Learning | 2016 |
[Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].
Topics: Adult; Aged; Darunavir; Drug Combinations; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Retrospective Studies; Ritonavir | 2015 |
Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; China; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Rural Population; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Antiretroviral Therapy for Nevirapine-Exposed Children With HIV Infection.
Topics: Anti-Retroviral Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Male; Nevirapine | 2015 |
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Quebec; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2015 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.
Topics: Adult; Age Factors; Alkynes; Anti-Retroviral Agents; Benzoxazines; Bone Density; Cross-Sectional Studies; Cyclopropanes; Female; Femur; HIV Infections; Humans; Lopinavir; Lumbar Vertebrae; Male; Radiography; Reverse Transcriptase Inhibitors; South Africa | 2015 |
Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Prospective Studies; Ritonavir; Treatment Failure | 2016 |
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Topics: Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Point-of-Care Systems; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2015 |
Lopinavir Resistance Classification with Imbalanced Data Using Probabilistic Neural Networks.
Topics: Algorithms; Antiviral Agents; Drug Resistance, Viral; HIV Infections; Humans; Logistic Models; Lopinavir; Neural Networks, Computer; Predictive Value of Tests; Software Design | 2016 |
Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.
Topics: 20-alpha-Hydroxysteroid Dehydrogenase; Animals; Anti-HIV Agents; Cells, Cultured; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Mice; Mice, Inbred C57BL; Placenta; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prolactin; Ritonavir; Trophoblasts; Zidovudine | 2016 |
Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
Topics: Amphetamine-Related Disorders; Atazanavir Sulfate; Catalytic Domain; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Inactivation, Metabolic; Lopinavir; Methamphetamine; Microsomes, Liver; Molecular Docking Simulation; Nelfinavir; Protein Binding; Pyridines; Pyrones; Sulfonamides | 2016 |
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Combinations; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Lopinavir; Male; Nevirapine; Ritonavir; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult | 2016 |
Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Ireland; Lopinavir; Population Surveillance; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; United Kingdom | 2016 |
Elevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice.
Topics: Adiponectin; Animals; Blood-Brain Barrier; Brain; Brain Injuries; Cognition; HIV Infections; HIV Protease Inhibitors; Homeostasis; Lopinavir; Male; Mice; Mice, Inbred C57BL; Ritonavir; Up-Regulation | 2016 |
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2016 |
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction.
Topics: Acetylcysteine; Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; NF-E2-Related Factor 2; Promoter Regions, Genetic; Reactive Oxygen Species; Ritonavir; Rotenone | 2016 |
Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results.
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Maleimides; Peptides; Ritonavir | 2017 |
Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester.
Topics: Adolescent; Adult; Algorithms; Computer Simulation; Drug Combinations; Drug Dosage Calculations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Ritonavir; Young Adult | 2016 |
Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.
Topics: Adult; Anti-HIV Agents; Black People; Cross-Sectional Studies; Cytochrome P-450 CYP3A; Ethnicity; Female; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Lopinavir; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Young Adult | 2016 |
Editorial Commentary: Neurocognitive Performance in Ritonavir-boosted Protease Inhibitor Monotherapy.
Topics: HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Ritonavir | 2016 |
Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Long Term Adverse Effects; Lopinavir; Male; Retrospective Studies; Ritonavir; RNA, Viral; Spain; Sulfonamides; Viral Load; Young Adult | 2016 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atherosclerosis; Benzoxazines; Biomarkers; Carotid Intima-Media Thickness; Child; Cyclopropanes; Ethiopia; Female; HIV Infections; Humans; Lipids; Lopinavir; Male; Middle Aged; Pulse Wave Analysis; Ritonavir; Young Adult | 2016 |
Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study - PEDA Study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Developing Countries; Drugs, Generic; HIV Infections; Humans; Lopinavir; Ritonavir; Thailand; Vietnam | 2016 |
Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Diagnosis, Differential; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Medication Adherence; Middle Aged; Plasma; South Africa; Treatment Failure; Young Adult | 2016 |
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Curve; Biological Availability; Coinfection; Female; HIV Infections; HIV-1; Humans; Isoniazid; Lopinavir; Male; Models, Statistical; Mycobacterium tuberculosis; Outpatients; Prospective Studies; Pyrazinamide; Rifampin; Ritonavir; South Africa; Tuberculosis, Pulmonary | 2016 |
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Topics: Acute Kidney Injury; Adult; Albuminuria; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Cross-Sectional Studies; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Proteinuria; Ritonavir | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
Topics: Child, Preschool; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Nevirapine; Treatment Outcome; Viral Load; Viremia | 2016 |
Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
Topics: Adolescent; Adult; Aged; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Developing Countries; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Incidence; Lipids; Lopinavir; Male; Middle Aged; Multicenter Studies as Topic; Risk Factors; Ritonavir; Viral Load; Young Adult | 2017 |
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Caco-2 Cells; Cell Membrane Permeability; Child; Drug Delivery Systems; High-Throughput Screening Assays; HIV Infections; Humans; Lopinavir; Male; Nanomedicine; Nanoparticles; Rats; Rats, Sprague-Dawley; Ritonavir; Small Molecule Libraries; Translational Research, Biomedical | 2016 |
[Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Topics: Adult; Cobicistat; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Prospective Studies; Ritonavir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2016 |
miR-34a is a common link in both HIV- and antiretroviral therapy-induced vascular aging.
Topics: Aging; Animals; Anti-Retroviral Agents; Arteriosclerosis Obliterans; Cellular Senescence; Drug Combinations; Gene Expression Regulation; HIV Infections; Humans; Lopinavir; Male; Mice; Mice, Knockout; Mice, Transgenic; MicroRNAs; Myocytes, Smooth Muscle; Ritonavir; tat Gene Products, Human Immunodeficiency Virus | 2016 |
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
Topics: Anti-HIV Agents; Bayes Theorem; Breast Feeding; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Mothers; Ritonavir | 2017 |
Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Topics: Atazanavir Sulfate; Darunavir; DNA Replication; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Virus Replication; Zambia | 2016 |
Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.
Topics: Anti-HIV Agents; Brazil; Drug Costs; Government Programs; HIV Infections; Humans; Longitudinal Studies; Lopinavir; Patents as Topic; Ritonavir | 2016 |
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Nevirapine; Phylogeny; Ritonavir; Zidovudine | 2016 |
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Uganda; Young Adult | 2016 |
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antitubercular Agents; Diarylquinolines; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Ritonavir; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Topics: Adult; Atazanavir Sulfate; Cohort Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Treatment Outcome; United Kingdom | 2017 |
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; RNA, Viral; Viral Load; Viremia; Young Adult | 2017 |
First-line antiretroviral drug discontinuations in children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; South Africa; Stavudine; Withholding Treatment; Zidovudine | 2017 |
[Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir].
Topics: Anti-HIV Agents; Anticoagulants; Aortic Valve Stenosis; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Middle Aged; Mitral Valve Insufficiency; Oxazines; Piperazines; Pyridones; Ritonavir; Warfarin | 2017 |
Kaletra lower-strength pediatric tablet approved in Europe.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Tablets | 2008 |
Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications.
Topics: Diarrhea; Drug-Related Side Effects and Adverse Reactions; Herb-Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones | 2008 |
Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy.
Topics: Adult; Cerebrospinal Fluid; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Meningoencephalitis; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
FDA notifications. FDA approves half-strength Kaletra.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2008 |
Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
Topics: Adenine; Creatinine; Drug Interactions; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Tubules; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; Sensitivity and Specificity; Tenofovir | 2008 |
Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Prednisolone; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
Topics: Chemistry, Pharmaceutical; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Lipids; Lopinavir; Pyrimidinones; Ritonavir; Tablets | 2008 |
Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Histamine H2 Antagonists; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medical Audit; Multivariate Analysis; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2008 |
Noninferiority and lopinavir/ritonavir monotherapy trials.
Topics: Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2008 |
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
Topics: Adolescent; Adult; Aged; Cohort Studies; Drug Resistance, Viral; Female; Genes, Viral; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; Young Adult | 2008 |
FDA notifications. Lopinavir/ritonavir label updated.
Topics: Adolescent; Child; Drug Labeling; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2008 |
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Viral Load; Young Adult | 2008 |
Initial treatment of HIV-1 infection.
Topics: Alkynes; Benzoxazines; Cause of Death; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.
Topics: Adult; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Initial treatment of HIV-1 infection.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Failure | 2008 |
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Failure, Chronic; Lopinavir; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidinones; Renal Dialysis; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Women and non-whites new to HAART respond similarly to men and whites.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Ethnicity; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Randomized Controlled Trials as Topic; Retrospective Studies; Sex Factors | 2008 |
Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation, Missense; Polymorphism, Genetic; Pyrimidinones; Treatment Outcome; Viral Load | 2008 |
Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Lopinavir; Male; Multivariate Analysis; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2008 |
Biomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infection.
Topics: Anti-HIV Agents; Biomarkers; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Likelihood Functions; Lopinavir; Pyrimidinones | 2009 |
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Blood; Chromatography, High Pressure Liquid; Cohort Studies; Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Plasma; Pyridines; Pyrimidinones; RNA, Viral; Semen; Statistics as Topic; Viral Load | 2008 |
Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.
Topics: Administration, Oral; Anti-HIV Agents; HIV Infections; Humans; Lopinavir; Pyrimidinones; Quality of Life; Ritonavir | 2008 |
HIV postexposure prophylaxis after sexual assault: why is it so hard to accomplish?
Topics: Adolescent; Animals; Anti-HIV Agents; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Macaca mulatta; Pyrimidinones; Sex Offenses; Zidovudine | 2008 |
Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.
Topics: Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides; Virus Replication | 2008 |
Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.
Topics: Adult; Cushing Syndrome; Drug Interactions; HIV Infections; HIV-1; Humans; Iatrogenic Disease; Lopinavir; Male; Pyrimidinones; Ritonavir; Triamcinolone | 2008 |
[A case of acquired encephalopathy in a child. A cause that we thought had disappeared].
Topics: AIDS Dementia Complex; Anti-HIV Agents; Anti-Infective Agents; Drug Therapy, Combination; Female; Fluconazole; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Polymerase Chain Reaction; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 2008 |
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
Topics: Anti-HIV Agents; Area Under Curve; Biological Availability; Cohort Studies; Drug Combinations; Half-Life; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Zalcitabine | 2009 |
[Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Sulfonamides; Viral Load | 2008 |
HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.
Topics: Animals; Anopheles; Female; HIV Infections; HIV Protease Inhibitors; Lopinavir; Malaria; Mice; Plasmodium; Plasmodium berghei; Plasmodium yoelii; Pyrimidinones; Ritonavir | 2009 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
[From research to clinical practice: use of lopinavir/ritonavir in monotherapy].
Topics: Adult; Biomedical Research; CD4 Lymphocyte Count; Clinical Medicine; Drug Evaluation; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2008 |
Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start?
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Protease inhibitor levels in hair strongly predict virologic response to treatment.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Monitoring; Epidemiologic Methods; Female; Hair; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Pyrimidinones; Ritonavir; Specimen Handling; Treatment Outcome; Viral Load | 2009 |
Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Drug Administration Schedule; Female; Half-Life; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Tablets | 2008 |
ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Genotype; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Pyrimidinones; Ritonavir; Saliva; Semen | 2009 |
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States | 2009 |
More Kaletra monotherapy results.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Viral Load | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Comparison of Markov model and discrete-event simulation techniques for HIV.
Topics: Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Economics, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Markov Chains; Models, Econometric; Models, Statistical; Pyrimidinones; Ritonavir | 2009 |
Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.
Topics: Adolescent; Child; Child, Preschool; Female; HIV Infections; HIV Protease Inhibitors; Humans; Linear Models; Lopinavir; Male; Models, Biological; Monte Carlo Method; Probability; Prospective Studies; Pyrimidinones | 2009 |
Civil society strategy for the compulsory licensing of lopinavir/ritonavir: the Brazilian case.
Topics: Brazil; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2008 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Treatment Outcome | 2009 |
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; Viral Load | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Lopinavir; Metabolic Clearance Rate; Monte Carlo Method; Plasma; Pregnancy; Pyrimidinones; Tissue Distribution | 2009 |
Does HIV-1 subtype D have a higher risk of vertical transmission than other HIV subtypes?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Risk Factors; Survival Rate; Viral Load; Young Adult | 2009 |
Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Gambia; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Pyrimidinones; Ritonavir; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Topics: Adult; CD4 Lymphocyte Count; Female; Hemoglobins; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral | 2009 |
Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
Topics: Adolescent; Child; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Ritonavir; Saquinavir; Thailand; Treatment Outcome | 2009 |
Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen.
Topics: Adult; Cohort Studies; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Obstetric Labor, Premature; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyrimidinones; Ritonavir | 2009 |
Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
Topics: CD4 Lymphocyte Count; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2009 |
Prezista fares better than Kaletra in first line therapy.
Topics: Adult; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Sulfonamides; Viral Load | 2009 |
Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube.
Topics: Administration, Oral; Adult; Anti-Retroviral Agents; Duodenal Neoplasms; Gastric Bypass; HIV Infections; Humans; Intestinal Absorption; Jejunum; Lopinavir; Lymphoma; Male; Pyrimidinones | 2009 |
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Lopinavir/r is superior to nevirapine in women who previously received single-dose nevirapine.
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors | 2009 |
[Lopinavir/ritonavir monotherapy in the treatment of HIV infection. Introduction].
Topics: Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2008 |
Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Phylogeny; Pyrimidinones; Selection, Genetic; Sequence Analysis, Protein | 2010 |
Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.
Topics: Adult; Capsules; Cholesterol; Cholesterol, HDL; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Ritonavir; Tablets; Triglycerides | 2009 |
Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; DNA Mutational Analysis; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; HIV; HIV Infections; HIV Protease; Humans; Longitudinal Studies; Lopinavir; Molecular Sequence Data; Mutation, Missense; Phylogeny; Pyrimidinones; Ritonavir; Sequence Analysis, DNA; Sequence Homology; Treatment Failure; Virus Replication | 2009 |
Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Rifabutin; Ritonavir; Serum; Tuberculosis; Young Adult | 2009 |
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Jaundice; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Torsades de Pointes; Viral Load | 2009 |
Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.
Topics: Adult; Anti-HIV Agents; Arrhythmias, Cardiac; Electrocardiography; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2009 |
[Regimen simplification: lopinavir/ritonavir with or without efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load; Viremia | 2009 |
Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biological Availability; Chemistry, Pharmaceutical; Dogs; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Solubility; Tablets; Therapeutic Equivalency | 2010 |
HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
Topics: Animals; Apoptosis; Carbamates; Cell Line; Cell Membrane Permeability; Endoplasmic Reticulum; Furans; HIV Infections; HIV Protease Inhibitors; Intestinal Mucosa; Lopinavir; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pyrimidinones; Ritonavir; Stress, Physiological; Sulfonamides; Transcription Factor CHOP | 2010 |
Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.
Topics: Animals; Anti-HIV Agents; Biological Availability; Chemistry, Pharmaceutical; Data Interpretation, Statistical; Dogs; Drug Combinations; Drug Evaluation, Preclinical; Food-Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Models, Biological; Pyrimidinones; Ritonavir; Tablets; Therapeutic Equivalency | 2010 |
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
Topics: Adult; Atazanavir Sulfate; DNA Mutational Analysis; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Young Adult | 2009 |
Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.
Topics: Abdominal Pain; Adult; Antineoplastic Agents, Phytogenic; Burkitt Lymphoma; Constipation; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Intestinal Pseudo-Obstruction; Lopinavir; Male; Pyrimidinones; Ritonavir; Vincristine | 2009 |
Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
Topics: Anti-HIV Agents; Edema; HIV Infections; Humans; Leg; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Uganda | 2009 |
[Medication change due to side effects or possible long-term complications. Side effect management with vision].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Lopinavir; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic | 2009 |
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; South Africa; Survival Analysis; Treatment Outcome; Viral Load; Zidovudine | 2010 |
Serial knife stabbings with HIV exposure--implications for post-exposure prophylaxis.
Topics: Anti-HIV Agents; Crime Victims; Disease Transmission, Infectious; Drug Combinations; Hepatitis B; Hepatitis C; HIV Infections; Humans; Lamivudine; Lopinavir; Post-Exposure Prophylaxis; Pyrimidinones; Viral Load; Wounds, Stab; Zidovudine | 2010 |
Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.
Topics: Adult; Alleles; Black People; Female; Gene Frequency; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Lopinavir; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pilot Projects; Polymorphism, Genetic; Pyrimidinones; White People | 2009 |
Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets.
Topics: Adolescent; Child; Drug Monitoring; HIV Infections; Humans; Lopinavir; Pyrimidinones; Serum; Tablets | 2010 |
Factors influencing lopinavir and atazanavir plasma concentration.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Weight; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrimidinones; Rifabutin; United Kingdom | 2010 |
A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.
Topics: Adolescent; Adult; Aged; Body Weight; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Models, Statistical; Population Surveillance; Pyrimidinones; Tablets | 2009 |
Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Proviruses; Pyrimidinones; Ritonavir; Viral Load; Young Adult | 2010 |
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birth Weight; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Oligopeptides; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Pyrimidinones | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
Topics: Adult; Antifungal Agents; Drug Combinations; Drug Interactions; Drug Monitoring; Histoplasmosis; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism.
Topics: Antiretroviral Therapy, Highly Active; Black People; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Female; Genotype; HIV Infections; Humans; Infant; Lopinavir; Pharmacogenetics; Polymorphism, Genetic; Pyrimidinones; Ritonavir; Treatment Failure | 2010 |
The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Treatment Outcome; Viral Load | 2009 |
Lopinavir protein binding in HIV-1-infected pregnant women.
Topics: Acute-Phase Proteins; Adolescent; Adult; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Protein Binding; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Carriers; Drug Combinations; Drug Compounding; HIV Infections; Humans; Lactic Acid; Lopinavir; Macrophages; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrimidinones; Ritonavir | 2009 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Patient Compliance; Pyrimidinones; Randomized Controlled Trials as Topic; RNA, Viral; Stavudine; Tenofovir; Treatment Outcome; Young Adult | 2010 |
The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Gene Frequency; Genotype; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Lopinavir; Male; Organic Anion Transporters; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrimidinones; Ritonavir; Tandem Mass Spectrometry | 2010 |
Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2010 |
Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lipids; Lopinavir; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrimidinones; Retrospective Studies; Ritonavir; Saquinavir | 2010 |
The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.
Topics: Drug Resistance, Viral; Evolution, Molecular; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Molecular Sequence Data; Mutation; pol Gene Products, Human Immunodeficiency Virus; Pyrimidinones; Sequence Analysis, DNA | 2010 |
The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
Topics: Adolescent; Adult; Aged; Alkynes; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proguanil; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Child; Child, Preschool; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Leptin; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir | 2010 |
Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases.
Topics: Anti-HIV Agents; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Molecular Dynamics Simulation; Pyrimidinones; Thermodynamics | 2010 |
Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy.
Topics: HIV Infections; HIV-1; Humans; Lopinavir; Meningitis, Viral; Pyrimidinones; Ritonavir | 2010 |
Syndrome of inappropriate antidiuretic hormone associated with lopinavir therapy.
Topics: Adolescent; Anti-HIV Agents; HIV Infections; Humans; Inappropriate ADH Syndrome; Lopinavir; Male; Pyrimidinones | 2010 |
Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended!
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Delayed-Action Preparations; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Lopinavir; Male; Middle Aged; Pyrimidinones; Tacrolimus | 2010 |
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; South Africa; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2010 |
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Plasma; Pyrimidinones; Young Adult | 2010 |
Once-daily dosing of lopinavir/ritonavir (Kaletra) receives FDA approval.
Topics: Anti-HIV Agents; Drug Approval; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2010 |
FDA notifications. FDA approves new dosing for Kaletra.
Topics: Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2010 |
Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.
Topics: Adolescent; Child; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Lopinavir; Pyrimidinones; Ritonavir; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
FDA notifications. Kaletra revisions to packaging approved.
Topics: Drug Interactions; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2010 |
Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.
Topics: Blood Specimen Collection; Case-Control Studies; Child; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Body Weight; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethnicity; Female; Gestational Age; HIV Infections; Humans; Lopinavir; Postpartum Period; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Pyrimidinones; Racial Groups; Zidovudine | 2010 |
Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.
Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; Buprenorphine; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Metabolic Clearance Rate; Middle Aged; Naloxone; Pyrimidinones; Ritonavir | 2010 |
Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Post-Exposure Prophylaxis; Practice Guidelines as Topic; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2010 |
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Topics: Alkynes; Argentina; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Israel; Lopinavir; Male; Nevirapine; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Benzoxazines; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Cyclopropanes; Dideoxynucleosides; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Middle Aged; Plasma; Pyrimidinones | 2010 |
Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy.
Topics: HIV Infections; HIV-1; Humans; Lopinavir; Meningitis, Viral; Pyrimidinones; Ritonavir | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Female; HIV Infections; Humans; Lipids; Lipoproteins; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Risk Assessment; Ritonavir | 2011 |
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
Topics: Adult; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Viral Load | 2011 |
Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin.
Topics: Acetylcysteine; Adult; Antioxidants; Case-Control Studies; Cell Proliferation; Cells, Cultured; Cellular Senescence; Coronary Vessels; Cyclin-Dependent Kinase Inhibitor p21; Drug Therapy, Combination; Endothelial Cells; Farnesyltranstransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lamin Type A; Lopinavir; Metalloporphyrins; Methionine; Middle Aged; Nuclear Proteins; Oxidative Stress; Paris; Pravastatin; Protein Precursors; Pyrimidinones; Ritonavir; Time Factors; Tumor Suppressor Protein p53 | 2010 |
Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice.
Topics: Animals; Cognition; Drug Administration Schedule; Drug Combinations; HIV; HIV Infections; HIV Protease Inhibitors; Lopinavir; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Motor Activity; Pyrimidinones; Ritonavir; Weight Loss | 2010 |
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Survival Analysis; Treatment Failure; Treatment Outcome; Viral Load | 2010 |
Diagnosing and responding to violations in the positivity assumption.
Topics: Anti-HIV Agents; Bias; Biomedical Research; Cohort Studies; Computer Simulation; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Drug Resistance, Viral; HIV Infections; Humans; Lopinavir; Models, Statistical; Mutation; Treatment Outcome | 2012 |
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Digoxin; Down-Regulation; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Middle Aged; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Genetic diversity of HIV type 1 in Montenegro.
Topics: Adult; Antiretroviral Therapy, Highly Active; Base Sequence; Drug Resistance, Viral; Female; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Montenegro; Nelfinavir; Phylogeny; Population Surveillance | 2011 |
Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; Thailand | 2011 |
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Body Fat Distribution; Body Mass Index; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Young Adult | 2011 |
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Darunavir; Drug Resistance, Viral; Female; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Lopinavir; Male; Markov Chains; Multicenter Studies as Topic; Pyrimidinones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Sulfonamides; Sweden; United Kingdom; Viral Load | 2010 |
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Guideline Adherence; HIV Infections; Humans; Lopinavir; Netherlands; Nevirapine; Pregnancy; Pyrimidinones; Randomized Controlled Trials as Topic | 2011 |
Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Ritonavir; Serum; Transaminases; Zidovudine | 2011 |
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cost-Benefit Analysis; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Sweden | 2011 |
Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial.
Topics: Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2011 |
Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cross-Sectional Studies; Drug Resistance, Viral; Female; Hair; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Plasma; Pyrimidinones; RNA, Viral; South Africa; Treatment Failure; Viral Load | 2011 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Clinical Trials, Phase II as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pyrimidinones; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; RNA, Viral; South Africa; Young Adult | 2011 |
Patent watch: Indian patent office rejects HIV drug formulation patent.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; HIV Infections; Humans; India; Lopinavir; Patents as Topic; Pyrimidinones | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Life Expectancy; Lopinavir; Male; Nevirapine; Pregnancy; Pyrimidinones; Ritonavir; South Africa; Treatment Outcome | 2011 |
[Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
Topics: Adolescent; Anti-HIV Agents; Child Behavior Disorders; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Kidney Calculi; Lopinavir; Male; Mutation, Missense; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2011 |
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
Topics: Amino Acid Substitution; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Mutation, Missense; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; RNA, Viral; Sequence Analysis, DNA; South Africa; Viral Load | 2011 |
[LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma].
Topics: Chromatography, Liquid; HIV Infections; Humans; Lopinavir; Ritonavir; Sensitivity and Specificity; Tandem Mass Spectrometry | 2010 |
Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Monitoring; Female; HIV Infections; Humans; Lopinavir; Plasma; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Retrospective Studies; Treatment Outcome; United Kingdom; Young Adult | 2011 |
Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.
Topics: Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Virus Shedding | 2011 |
Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.
Topics: Bradycardia; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Post-Exposure Prophylaxis; Pyrimidinones; Ritonavir | 2011 |
Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Insertional; Sequence Analysis, DNA; Virus Replication | 2011 |
Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Mutation; Paris; Pyrimidinones; Ritonavir; Treatment Failure | 2011 |
[Simplification to lopinavir/ritonavir monotherapy in HIV-infected children].
Topics: Adolescent; Child; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir | 2011 |
Trial in youngest group points to HIV treatment overhaul.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Reverse Transcriptase Inhibitors | 2011 |
Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, Third; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load | 2011 |
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child, Preschool; Drug Interactions; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infant; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; South Africa; Treatment Outcome; Tuberculosis | 2011 |
Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lopinavir; Male; Middle Aged; Pyrimidines; Pyrimidinones; Renal Insufficiency; Rhabdomyolysis; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus; Fasting; HIV Infections; HIV Protease Inhibitors; Humans; Insulin Resistance; Logistic Models; Lopinavir; Male; Middle Aged; Odds Ratio; Reverse Transcriptase Inhibitors; Ritonavir; Sex Hormone-Binding Globulin; Stavudine; Testosterone | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
Efficacy of lopinavir-ritonavir reduced dose in HIV-infected patients.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Viral Load | 2011 |
Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Insufficiency; Case-Control Studies; Cross-Sectional Studies; Dehydroepiandrosterone Sulfate; Female; France; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lopinavir; Male; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Retrospective Studies; Ritonavir; Zidovudine | 2011 |
An application of collaborative targeted maximum likelihood estimation in causal inference and genomics.
Topics: Causality; Drug Resistance, Viral; Female; Genomics; HIV Infections; Humans; Likelihood Functions; Lopinavir; Male; Models, Statistical; Probability; Propensity Score | 2010 |
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Coinfection; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Hospitals, Public; Humans; Infant; Lopinavir; Male; Mycobacterium tuberculosis; Recurrence; Ritonavir; South Africa; Survival Analysis; Tuberculosis, Pulmonary; Viral Load | 2011 |
CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Topics: Adolescent; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Cohort Studies; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Liver-Specific Organic Anion Transporter 1; Lopinavir; Male; Organic Anion Transporters; Polymorphism, Genetic; Prospective Studies; Ritonavir | 2011 |
Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
Topics: Adult; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Retrospective Studies; Ritonavir; RNA, Viral | 2011 |
Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Esophageal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Syndrome; Tenofovir; Ulcer | 2011 |
The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Databases, Factual; Drug Combinations; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Netherlands; Ritonavir | 2011 |
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome | 2011 |
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Developing Countries; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Health Planning; Health Services; HIV Infections; Humans; Lamivudine; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2011 |
Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Monitoring; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Models, Biological; Reproducibility of Results; Ritonavir | 2011 |
Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
Topics: gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Polymorphism, Genetic; Ritonavir; Treatment Outcome | 2011 |
Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.
Topics: Cohort Studies; Data Interpretation, Statistical; Drug Resistance, Viral; Genotype; Health Personnel; HIV; HIV Infections; Humans; Internet; Linear Models; Lopinavir; Mutation | 2011 |
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Biological Availability; Cohort Studies; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Rifampin; Ritonavir | 2012 |
Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cost-Benefit Analysis; Decision Support Techniques; Drug Combinations; Drug Costs; Health Care Costs; HIV Infections; Humans; Kenya; Lopinavir; Markov Chains; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Ritonavir; Uganda | 2011 |
Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Cell Line; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatic Stellate Cells; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Ireland; Lopinavir; Male; Monocytes; Recombinant Proteins; Ribavirin; RNA, Viral; Saquinavir; Tissue Inhibitor of Metalloproteinase-2; United Kingdom; Viral Load | 2011 |
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Plasma; Ritonavir; Time Factors; Treatment Outcome; Viral Load | 2012 |
Recent HIV-1 infection: to treat or not to treat, that is the question.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir; Viral Load | 2012 |
Association of nephrotic syndrome with immune reconstitution inflammatory syndrome.
Topics: Anti-Retroviral Agents; Brain Diseases; Drug Combinations; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Infant; Lopinavir; Nephrotic Syndrome; Pneumonia, Pneumocystis; Ritonavir | 2012 |
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Ritonavir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Treatment Failure; United Kingdom; Young Adult | 2012 |
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
Topics: Antitubercular Agents; Antiviral Agents; Child, Preschool; Coinfection; Drug Administration Schedule; Drug Dosage Calculations; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Models, Statistical; Mycobacterium tuberculosis; Rifampin; Ritonavir; Tuberculosis, Pulmonary | 2012 |
Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Cross-Over Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Prospective Studies; Ritonavir; Thailand | 2012 |
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hip Fractures; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Osteoporotic Fractures; Retrospective Studies; Risk; Risk Factors; Ritonavir; Spinal Fractures; Tenofovir; Time Factors; Treatment Outcome; Wrist Injuries; Young Adult | 2012 |
Incurred sample reanalysis comparison of dried blood spots and plasma samples on the measurement of lopinavir in clinical samples.
Topics: Anti-HIV Agents; Dried Blood Spot Testing; HIV Infections; Humans; Lopinavir; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Topics: Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Virus Cultivation | 2012 |
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes.
Topics: Animals; Calcium; Calcium Signaling; Cell Death; Central Nervous System Depressants; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Ethanol; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Homeostasis; Humans; Liver Diseases, Alcoholic; Lopinavir; Male; Mice; Mice, Inbred C57BL; Primary Cell Culture; Regulatory Factor X Transcription Factors; Ritonavir; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2012 |
The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Rifampin; Ritonavir; Tuberculosis | 2012 |
Trough lopinavir concentrations in preterm HIV-infected infants.
Topics: Anti-HIV Agents; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Plasma | 2012 |
Transplacental passage of nevirapine, nelfinavir and lopinavir.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Pregnancy | 2012 |
Nevirapine-based therapy after suppression: can we switch?
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nevirapine; Ritonavir | 2012 |
Perinatal lopinavir + ritonavir: adrenal insufficiency.
Topics: Adrenal Insufficiency; Adult; Anti-HIV Agents; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir | 2012 |
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Cohort Studies; Female; HIV; HIV Infections; HIV Protease; Humans; Lopinavir; Male; Mutation, Missense; Retrospective Studies; Ritonavir; Treatment Failure; United States | 2012 |
Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.
Topics: Anti-HIV Agents; Calibration; Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Limit of Detection; Lopinavir; Reference Standards; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Zidovudine | 2012 |
Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
Topics: Adult; Aged; Anti-HIV Agents; Computer Simulation; Female; Genotype; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Lopinavir; Male; Middle Aged; Models, Statistical; Organic Anion Transporters; Polymorphism, Single Nucleotide; Young Adult | 2012 |
Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Coronary Artery Disease; Female; HIV Infections; Humans; Lopinavir; Male; Myocardial Infarction; Pharmacovigilance; Risk Factors; Ritonavir | 2012 |
Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection.
Topics: Adolescent; Adult; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Male; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2012 |
Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.
Topics: Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Disease Reservoirs; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Ritonavir; Treatment Outcome; Viral Load; Virus Latency; Virus Replication | 2012 |
Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection.
Topics: Calibration; Chromatography, High Pressure Liquid; Diazepam; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Reference Standards; Reproducibility of Results; Ritonavir; Spectrophotometry, Ultraviolet | 2012 |
HIV: a growing concern in the elderly population.
Topics: Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antihypertensive Agents; Azithromycin; CD4 Lymphocyte Count; Depressive Disorder; Diltiazem; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Hypertension; Lopinavir; Male; Patient Compliance; Pharmacists; Renal Insufficiency; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 2012 |
Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Bleomycin; Dacarbazine; Doxorubicin; Female; Hematologic Diseases; HIV Infections; HIV Protease Inhibitors; Hodgkin Disease; Humans; Incidence; Kaplan-Meier Estimate; Lopinavir; Lung Diseases; Male; Mechlorethamine; Middle Aged; Nervous System Diseases; Prednisone; Procarbazine; Prognosis; Retrospective Studies; Ritonavir; Vinblastine; Vincristine | 2012 |
Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Plasma; Rifabutin; Ritonavir; Tuberculosis | 2012 |
Severe dyslipidaemia after the addition of raltegravir to a lopinavir/ritonavir-containing regimen.
Topics: Cholesterol, HDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Treatment Outcome; Triglycerides | 2012 |
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; France; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Microbial Sensitivity Tests; Middle Aged; Ritonavir; Treatment Failure; Viral Load | 2012 |
Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Ritonavir; Thailand; Treatment Outcome; Viral Load | 2013 |
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Topics: Adult; Anti-HIV Agents; Blood Proteins; Delivery, Obstetric; Female; HIV Infections; Humans; Lopinavir; Maternal-Fetal Exchange; Middle Aged; Orosomucoid; Postpartum Period; Pregnancy; Prospective Studies; Protein Binding; Serum Albumin; Young Adult | 2013 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
Topics: DNA, Viral; Drug Resistance, Viral; Female; gag Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Molecular Sequence Data; Mutation; pol Gene Products, Human Immunodeficiency Virus; Protease Inhibitors; Viral Load | 2013 |
Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Child; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Retrospective Studies; Rifampin; Ritonavir; South Africa; Time Factors; Tuberculosis; Young Adult | 2012 |
Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.
Topics: Databases, Factual; Drug Combinations; Drug Industry; Economic Competition; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Patents as Topic; Ritonavir | 2012 |
Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland.
Topics: Anti-HIV Agents; Chi-Square Distribution; Child; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; Ireland; Lopinavir; Male; Ritonavir; United Kingdom; Viral Load | 2013 |
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors | 2013 |
Long-term lopinavir/ritonavir monotherapy in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Child; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Ritonavir; Time Factors; Treatment Outcome; Viral Load | 2013 |
ART regimen protects children from malaria.
Topics: Child; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria, Falciparum; Reverse Transcriptase Inhibitors; Ritonavir | 2012 |
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.
Topics: Adolescent; Adult; Blood Proteins; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prospective Studies; Protein Binding; Ritonavir; Young Adult | 2013 |
Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Medication Adherence; Odds Ratio; Ritonavir; Viral Load | 2013 |
Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cell Line; Cell Survival; Cyclopropanes; Drug Therapy, Combination; HeLa Cells; HIV Infections; HIV-1; Humans; Lactic Acid; Lopinavir; Microscopy, Confocal; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Subcellular Fractions; U937 Cells | 2013 |
Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia, Southeastern; Blood Glucose; CD4-Positive T-Lymphocytes; Child; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Lipoproteins; Lopinavir; Male; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2013 |
Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus.
Topics: Age Factors; Anthropometry; Anti-Retroviral Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Ritonavir; South Africa; Stavudine; Time Factors; Treatment Outcome | 2013 |
Ongoing HIV replication in cerebrospinal fluid under successful monotherapy.
Topics: Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Viral Load; Virus Replication | 2013 |
[When nucleoside analogs cannot be tolerated. HIV therapy with booster].
Topics: Anti-HIV Agents; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Saquinavir; Treatment Outcome; Viral Load | 2002 |
Anti-HIV agents. Lopinavir--results after one year.
Topics: CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Viral Load | 2001 |
Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome | 2002 |
Kaletra OK'd by FDA.
Topics: Drug Approval; Drug Combinations; Drug Costs; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Lopinavir; Pyrimidinones; Ritonavir; United States; United States Food and Drug Administration | 2000 |
Kaletra (ABT-378/r) application for accelerated approval.
Topics: Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2000 |
Limited penetration of lopinavir into seminal plasma of HIV-1-infected men.
Topics: HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Semen | 2002 |
Kaletra (ABT-378/r) approved.
Topics: Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2000 |
Antiretroviral news from ICAAC 2000.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance; HIV Infections; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Ritonavir; Tenofovir | 2000 |
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
Topics: CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Outcome; Viral Load | 2002 |
Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma.
Topics: HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pleural Effusion; Pyrimidinones; Sarcoma, Kaposi | 2002 |
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Retrospective Studies; RNA, Viral; Sulfonamides; Viremia | 2002 |
Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Spinal Cord Diseases | 2002 |
Lopinavir/ritonavir absorption in a gastrectomized patient.
Topics: Adult; Drug Combinations; Female; Gastrectomy; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2003 |
Fresh data on new anti-HIV drugs presented in Durban.
Topics: Anti-HIV Agents; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Peptide Fragments; Pyrimidinones; South Africa | 2000 |
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Multivariate Analysis; Pyrimidinones; Retrospective Studies; Ritonavir; Treatment Outcome | 2003 |
Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Arteriosclerosis; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lipids; Lipoproteins, LDL; Lopinavir; Pyrimidinones; Ritonavir | 2003 |
Phase II clinical trials of Kaletra.
Topics: Clinical Trials, Phase II as Topic; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2003 |
Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Outcome | 2003 |
[Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2002 |
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
Topics: Algorithms; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Phenotype; Pyrimidinones; Sulfonamides | 2003 |
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.
Topics: Adult; Anti-HIV Agents; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones | 2003 |
Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
Topics: Adult; Antiretroviral Therapy, Highly Active; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Biomarkers; Cholesterol, HDL; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipoproteins, LDL; Lipoproteins, VLDL; Lopinavir; Male; Phospholipids; Pyrimidinones; Ritonavir; Statistics as Topic; Time Factors; Treatment Outcome; Triglycerides; Viral Load | 2003 |
'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.
Topics: Anti-HIV Agents; Dermatitis, Irritant; Diagnosis, Differential; Drug Eruptions; HIV Infections; Humans; Lipodystrophy; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones | 2003 |
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.
Topics: Adult; Anti-Bacterial Agents; Atorvastatin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Pyrroles; Rhabdomyolysis; Ritonavir | 2003 |
Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.
Topics: Adult; Arteriosclerosis; Biomarkers; Black People; C-Reactive Protein; Calcium; Cholesterol; Coronary Artery Disease; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir | 2003 |
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Drug Monitoring; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Salvage Therapy; Saquinavir | 2003 |
Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient.
Topics: Antiretroviral Therapy, Highly Active; Bronchoalveolar Lavage Fluid; Epithelial Cells; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Lung; Male; Pyrimidinones | 2003 |
Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir.
Topics: Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Methadone; Middle Aged; Narcotics; Pyrimidinones; Ritonavir | 2003 |
The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Methadone; Narcotics; Opioid-Related Disorders; Pyrimidinones; Ritonavir; Substance Withdrawal Syndrome | 2003 |
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine | 2003 |
[Lopinavir/r in new packaging].
Topics: Anti-HIV Agents; Capsules; Delayed-Action Preparations; Drug Administration Schedule; Drug Packaging; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones | 2003 |
Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks.
Topics: Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Neural Networks, Computer; Phenotype; Predictive Value of Tests; Pyrimidinones | 2003 |
Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.
Topics: Adult; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Diseases; Liver Transplantation; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Tacrolimus | 2003 |
Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir.
Topics: Adolescent; Adult; Drug Combinations; Female; Hemophilia A; Hemorrhage; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir | 2003 |
Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.
Topics: Adult; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Ritonavir; Triglycerides | 2003 |
Treating advanced HIV infection.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2003 |
More data released on 908.
Topics: Clinical Trials, Phase III as Topic; Drugs, Investigational; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Pyrimidinones; Ritonavir; Viral Load | 2003 |
Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Femur Head Necrosis; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir | 2003 |
Kaletra goes it alone.
Topics: CD4 Lymphocyte Count; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Viral Load | 2003 |
No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oxazines; Polymorphism, Genetic; Pyrimidinones; Retrospective Studies | 2003 |
Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
Topics: Carbamates; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyridines; Pyrimidinones; Pyrones; RNA, Viral; Sulfonamides | 2004 |
[Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Time Factors; Viral Load | 2003 |
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load | 2003 |
Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
Topics: Binding Sites; Crystallization; Crystallography, X-Ray; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Models, Molecular; Molecular Sequence Data; Pyrimidinones | 2004 |
Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Topics: Adult; Alopecia; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Nelfinavir; Pyrimidinones; Ritonavir; Stavudine | 2003 |
FDA notifications. UCB Pharma and FDA issue advisory letter.
Topics: Anticonvulsants; Drug Industry; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Levetiracetam; Lopinavir; Piracetam; Pyrimidinones; United States; United States Food and Drug Administration | 2004 |
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
Topics: Adolescent; Adult; Drug Evaluation; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir | 2004 |
Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Viremia | 2004 |
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Cholesterol, HDL; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Diseases; Pyrimidinones; Risk Factors; Ritonavir; Triglycerides | 2004 |
French investigators warn of LPV/TDF/ddI interaction.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
The longer the better? Four years of durable, initially boosted protease treatment.
Topics: Antiretroviral Therapy, Highly Active; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Pyrimidinones; Ritonavir; Stavudine; Time Factors; Treatment Failure | 2004 |
Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.
Topics: Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Leukocytes, Mononuclear; Lopinavir; Male; Phenotype; Pyrimidinones; Ritonavir; Salvage Therapy; T-Lymphocyte Subsets; Viral Load; Virus Replication | 2004 |
Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases.
Topics: Adult; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lithiasis; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2004 |
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Capsules; Cohort Studies; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Saquinavir; Viral Load | 2004 |
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides | 2004 |
Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Drug Therapy, Combination; Histoplasmosis; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2004 |
Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient.
Topics: Adult; Drug Combinations; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Failure | 2004 |
Changes in Kaletra labelling.
Topics: Drug Combinations; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2004 |
Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
Topics: Adult; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mutation; Predictive Value of Tests; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Viral Load | 2004 |
[Lopinavir: also effective using once daily dose in therapy-naive HIV patients].
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; Humans; Lopinavir; Pyrimidinones; Viral Load | 2004 |
IQ predicts treatment response.
Topics: Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Predictive Value of Tests; Pyrimidinones; Ritonavir | 2004 |
[New treatment options for HIV-infected patients].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2004 |
Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.
Topics: Adult; Anti-Retroviral Agents; Antidiarrheals; Antiretroviral Therapy, Highly Active; Cohort Studies; Diarrhea; Georgia; HIV Infections; Humans; Incidence; Lopinavir; Middle Aged; Nelfinavir; Pyrimidinones; Retrospective Studies; Ritonavir; United States; United States Department of Veterans Affairs | 2004 |
Lipid abnormalities in HIV-Infected patients and lopinavir plasma concentrations.
Topics: Anti-HIV Agents; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperlipidemias; Lipids; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir | 2004 |
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretro
Topics: Amino Acid Substitution; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Furans; Genes, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multivariate Analysis; Mutation; Phenotype; Pyrimidinones; Regression Analysis; Sulfonamides | 2004 |
Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Hepatitis C; HIV Infections; Humans; Incidence; Liver; Lopinavir; Male; Pyrimidinones | 2004 |
Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Middle Aged; Pyrimidinones; Ritonavir; Thrombocytopenia | 2004 |
Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; HIV Infections; Humans; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; RNA, Viral | 2004 |
Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
Topics: Adult; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Intracellular Fluid; Lopinavir; Male; Middle Aged; Multivariate Analysis; Mutation; Pyrimidinones; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2004 |
Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.
Topics: Adult; Aged; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; gamma-Glutamyltransferase; Hepatitis B; HIV Infections; Humans; Liver; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Risk Factors; Ritonavir; Statistics, Nonparametric | 2004 |
[Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].
Topics: Adult; Atazanavir Sulfate; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2004 |
[From HAART to "smart": maximizing the advantages of lopinavir/ritonavir].
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Topic; Delayed-Action Preparations; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Long-Term Care; Lopinavir; Pyrimidinones; Ritonavir; Viral Load | 2004 |
[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
Topics: Atazanavir Sulfate; Blood Glucose; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2004 |
[5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Long-Term Care; Lopinavir; Organophosphonates; Oxazines; Pyrimidinones; Ritonavir; Tenofovir; Viral Load | 2004 |
Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.
Topics: Child; Child, Preschool; Drug Interactions; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir | 2004 |
Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
Topics: Adult; Area Under Curve; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2004 |
Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
Topics: Adult; Canada; Cohort Studies; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Multivariate Analysis; Mutation; Phenotype; Predictive Value of Tests; Pyrimidinones; Ritonavir; Salvage Therapy | 2004 |
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Area Under Curve; Benzoxazines; Cognition Disorders; Cyclopropanes; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Lopinavir; Male; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Valproic Acid | 2004 |
The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Lopinavir; Male; Pyrimidinones; Ritonavir | 2004 |
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Chronic Disease; Drug Therapy, Combination; Female; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Liver; Lopinavir; Male; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Saquinavir; Treatment Outcome | 2004 |
First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2004 |
Kaletra monotherapy controversy: AmfAR publishes overview.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones | 2004 |
Acquired macroglossia due to lopinavir/ritonavir treatment.
Topics: Aged; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Macroglossia; Pyrimidinones; Ritonavir | 2005 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.
Topics: Adult; Antibodies; Chromatography, High Pressure Liquid; Enzyme-Linked Immunosorbent Assay; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Lopinavir; Male; Pyrimidinones; Sensitivity and Specificity | 2004 |
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.
Topics: Adult; Aged; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2005 |
Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy".
Topics: Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Viral Load | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; Creatinine; Fanconi Syndrome; Female; HIV Infections; Humans; Hypophosphatemia; Lopinavir; Male; Organophosphonates; Phosphates; Prospective Studies; Pyrimidinones; Reproducibility of Results; Tenofovir; Urea | 2005 |
Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.
Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Depression; Dideoxynucleosides; Ethnicity; HIV; HIV Infections; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Pyrimidinones; Risk Factors; RNA, Viral; Treatment Refusal | 2005 |
Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pilot Projects; Pyrimidinones; Ritonavir | 2005 |
Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
Topics: Adult; Cholesterol; Cholesterol, HDL; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Ritonavir; Time Factors | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Hepatitis coinfection and LPV/RTV.
Topics: Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir | 2004 |
Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Failure | 2005 |
Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral | 2005 |
[Meningeal cryptococcosis as a sign of immune reconstitution syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Fluconazole; Flucytosine; HIV Infections; Humans; Immunologic Memory; Lamivudine; Lopinavir; Male; Meningitis, Cryptococcal; Pyrimidinones; Recurrence; Ritonavir; Syndrome; T-Lymphocyte Subsets; Zidovudine | 2005 |
Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2005 |
Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Administration Schedule; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrimidinones; Risk Factors; Ritonavir | 2005 |
Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mass Spectrometry; Middle Aged; Prospective Studies; Pyrimidinones | 2005 |
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.
Topics: Dose-Response Relationship, Drug; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir | 2005 |
FDA approves once-daily Kaletra.
Topics: Administration, Oral; AIDS Serodiagnosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Early Diagnosis; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Prognosis; Pyrimidinones; Survival Rate; Treatment Outcome; United States | 2005 |
An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Italy; Lopinavir; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrimidinones; Ritonavir; Safety | 2005 |
Once-daily Kaletra approved.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Prospective Studies; Pyrimidinones; Risk Assessment; Treatment Outcome; United States; United States Food and Drug Administration; Viral Load | 2005 |
Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Italy; Liver Diseases; Lopinavir; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrimidinones; Ritonavir | 2005 |
Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Anti-HIV Agents; Bilirubin; Biomarkers; Cholestasis; Female; gamma-Glutamyltransferase; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Retrospective Studies | 2005 |
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Capsules; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Models, Chemical; Pyrimidinones; Retrospective Studies; Ritonavir | 2005 |
Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lopinavir; Male; Mutation; Prognosis; Prospective Studies; Pyrimidinones; Ritonavir; Salvage Therapy; Viral Load | 2005 |
Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir.
Topics: Acute Disease; Adult; Anti-HIV Agents; Drug Eruptions; Exanthema; HIV Infections; Humans; Lopinavir; Male; Occupational Exposure; Pyrimidinones; Ritonavir; Skin Diseases, Vesiculobullous | 2005 |
Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2005 |
Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Camptothecin; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Irinotecan; Lopinavir; Male; Pyrimidinones; Ritonavir; Sarcoma, Kaposi | 2005 |
Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2005 |
Meeting notes from the 3rd IAS Conference. Old drugs, new data.
Topics: Alkynes; Anti-HIV Agents; Atenolol; Benzoxazines; Brazil; Congresses as Topic; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Oxazines; Pyrimidinones; Ritonavir | 2005 |
High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Male; Middle Aged; Mutation; Phenotype; Pyrimidinones; Ritonavir; Treatment Failure | 2006 |
Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Middle Aged; Patient Compliance; Pilot Projects; Pyrimidinones; Ritonavir; Treatment Outcome | 2006 |
Antiretroviral treatment in the Northern Cape.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Ritonavir; South Africa; Stavudine; Viral Load | 2005 |
Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Interactions; Hepatitis C; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Valproic Acid | 2006 |
[First-line monotherapy with boostered protease inhibitor. Effectively reduce viral load with only one drug?].
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Early Diagnosis; HIV; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Lopinavir; Pyrimidinones; Treatment Outcome; Viral Load | 2005 |
[HIV therapy in childhood. Also once daily lopinavir/r is effective].
Topics: Age Factors; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Pyrimidinones; Treatment Outcome; Viral Load | 2005 |
[Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; RNA, Viral; Viral Load | 2005 |
[Efavirenz--comprehensive status of studies].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; Humans; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2005 |
[New data on atazanavir/r]].
Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome; Viral Load | 2005 |
[HIV infection presenting with bilateral optic neuropathy].
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Visual; Facial Nerve Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ischemia; Lamivudine; Lopinavir; Male; Meningitis, Viral; Methylprednisolone; Middle Aged; Optic Disk; Optic Nerve Diseases; Polyradiculopathy; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Visual Fields; Zidovudine | 2006 |
Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.
Topics: Adult; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2006 |
Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients.
Topics: Adult; Chi-Square Distribution; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Ritonavir; Time Factors; Treatment Outcome; Viral Load | 2006 |
Hyponatraemia associated with lopinavir--ritonavir?
Topics: Adult; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Hyponatremia; Lopinavir; Male; Pyrimidinones; Ritonavir | 2007 |
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.
Topics: Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyrimidinones; Retrospective Studies; Treatment Outcome; Virus Replication | 2006 |
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides | 2006 |
Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir | 2006 |
Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
Topics: Biological Availability; Brazil; Cross-Sectional Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Regression Analysis; Ritonavir; Semen; Time Factors; Urogenital System; Viral Load | 2006 |
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides; Viral Load | 2006 |
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.
Topics: Anti-HIV Agents; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Viral Load | 2006 |
Focus on hepatitis. Low rate of liver problems seen with LPV/r.
Topics: Chemical and Drug Induced Liver Injury; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Liver; Lopinavir; Pyrimidinones; Ritonavir | 2005 |
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Combinations; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Failure; Treatment Outcome; Viral Load | 2006 |
Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient.
Topics: Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypothyroidism; Lopinavir; Middle Aged; Pyrimidinones; Ritonavir; Thyroxine | 2006 |
Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Female; HIV Infections; Humans; Lopinavir; Models, Biological; Nevirapine; Pyrimidinones; Ritonavir; South Africa | 2006 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Lopinavir; Organophosphonates; Pregnancy; Pregnancy Complications; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
FDA notifications. HIV-1 adult treatment guidelines are updated.
Topics: Adult; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; United States; United States Food and Drug Administration | 2006 |
Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Mass Spectrometry; Maximum Tolerated Dose; Metabolic Clearance Rate; Pyrimidinones; Ritonavir; Viral Load | 2006 |
Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
Topics: Crystallography, X-Ray; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazolidines; Lopinavir; Magnetic Resonance Spectroscopy; Mutation; Pyrimidinones; Structure-Activity Relationship | 2006 |
Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Genotype; HIV; HIV Infections; Humans; Lopinavir; Male; Oxazines; Oxidoreductases, N-Demethylating; Pyrimidinones | 2006 |
Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Creatinine; Female; HIV Infections; HIV-1; Humans; Kidney Tubules; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Tenofovir; Thinness | 2006 |
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
Topics: Amniotic Fluid; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Placenta; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyrimidinones; Viral Load | 2006 |
The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.
Topics: Adolescent; Adult; Animals; Benzoates; CCR5 Receptor Antagonists; Diketopiperazines; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Mice; Middle Aged; Piperazines; Pyrimidinones; Rats; Ritonavir; Spiro Compounds | 2006 |
Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Nelfinavir; Patient Compliance; Pyrimidinones; Ritonavir; Saquinavir; Viral Load | 2006 |
Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypertriglyceridemia; Italy; Lopinavir; Male; Middle Aged; Nucleosides; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Viral Load | 2006 |
Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Patient Selection; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genetic Variation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Orosomucoid; Oxazines; Phenotype; Pyrimidinones; Ritonavir; Switzerland | 2006 |
A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.
Topics: Adolescent; Adult; Aged; Body Weight; Databases, Factual; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Regression Analysis; Retrospective Studies; Tissue Distribution | 2006 |
Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multivariate Analysis; Predictive Value of Tests; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome | 2006 |
Abbott expands low cost Kaletra.
Topics: Developing Countries; Drug Industry; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Private Sector; Pyrimidinones; Ritonavir | 2006 |
The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone.
Topics: Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Longitudinal Studies; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure; Viral Load; Viremia | 2006 |
Measuring below the bar: what is it telling us?
Topics: Anti-Retroviral Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; RNA, Viral | 2006 |
Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function.
Topics: Adult; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Exanthema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Myelopoiesis; Pyrimidinones | 2006 |
Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir | 2006 |
Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Ritonavir; Time Factors | 2006 |
Nifedipine-lopinavir/ritonavir severe interaction: a case report.
Topics: Acute Kidney Injury; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Hypertension; Lopinavir; Male; Middle Aged; Nifedipine; Pyrimidinones; Ritonavir | 2007 |
XVI International AIDS Conference: Part 2.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides | 2006 |
[Histoplasmosis leading to diagnosis of HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Biopsy; Female; Histoplasma; Histoplasmosis; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Lopinavir; Pyrimidinones; Skin; Treatment Outcome | 2006 |
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors | 2007 |
Report from the XVI International AIDS Conference. Lopinavir/ritonavir monotherapy.
Topics: HIV Infections; Humans; Lopinavir; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2006 |
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
Topics: Area Under Curve; Chromatography, High Pressure Liquid; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Liver Function Tests; Lopinavir; Pyrimidinones; Ritonavir | 2007 |
The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Topics: Adult; Aged; Algorithms; Cohort Studies; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Ritonavir; Sensitivity and Specificity; Viral Load | 2007 |
Better lipid profile for Invirase.
Topics: Cholesterol; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Multicenter Studies as Topic; Pyrimidinones; Randomized Controlled Trials as Topic; Saquinavir; Triglycerides | 2006 |
Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Viral Load | 2004 |
[Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Topics: Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Tolerance; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pilot Projects; Pyrimidinones; Ritonavir; Treatment Failure | 2007 |
LPV monotherapy: 72-week data.
Topics: CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Viral Load | 2006 |
[Kaletra, a new anti HIV agent].
Topics: Anti-HIV Agents; Contraindications; HIV Infections; Humans; Lopinavir; Pyrimidinones | 2006 |
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4-CD8 Ratio; Clinical Trials, Phase II as Topic; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Stavudine | 2007 |
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
Topics: Atazanavir Sulfate; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Quality Control; Reference Standards; Reproducibility of Results; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Time Factors | 2007 |
Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyrimidinones; Ritonavir; Viral Load; Zidovudine | 2007 |
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones | 2007 |
Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Peptide Fragments; Pyrimidinones; Ritonavir; Tenofovir; Viral Load; Viremia | 2007 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Ritonavir; Severity of Illness Index | 2007 |
Antimalarial activity of sera from subjects taking HIV protease inhibitors.
Topics: Animals; Antimalarials; Antiretroviral Therapy, Highly Active; Chloroquine; Drug Synergism; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria, Falciparum; Plasmodium falciparum; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome | 2007 |
Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Romania | 2007 |
Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.
Topics: Analgesics, Opioid; Anti-Retroviral Agents; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Methadone; Middle Aged; Pyrimidinones; Ritonavir; Torsades de Pointes | 2007 |
Steady-state lopinavir levels in third trimester of pregnancy.
Topics: Adolescent; Adult; Drug Combinations; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load | 2007 |
HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
Topics: Adult; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Patient Compliance; Pyrimidinones; Retrospective Studies; Ritonavir; Time Factors; Treatment Outcome; Viral Load; White People | 2007 |
Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.
Topics: Adult; Antacids; Area Under Curve; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir | 2007 |
Response to "Nifedipine-lopinavir/ritonavir severe interaction: a case report".
Topics: Anti-HIV Agents; Antihypertensive Agents; Drug Interactions; HIV Infections; Humans; Lopinavir; Nifedipine; Pyrimidinones; Ritonavir | 2007 |
Pivotal moments in HIV treatment: the 14th CROI.
Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Congresses as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Maraviroc; Multicenter Studies as Topic; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles; United States | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2007 |
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Databases, Factual; Endpoint Determination; Female; Genotype; HIV Infections; Humans; Lipids; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Outcome | 2007 |
Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coronary Disease; Costs and Cost Analysis; Data Collection; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Markov Chains; Models, Statistical; Pyrimidinones; Quality of Life; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; United States; Viral Load | 2007 |
Kaletra single agent HAART after intolerance of NRTI- and NNRTI-containing regimens following kidney transplantation.
Topics: Adult; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Transplantation; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Clinical ritonavir and lopinavir hypersensitivity confirmed by a specific in vitro cellular allergen stimulation test.
Topics: Adult; Anti-HIV Agents; Drug Hypersensitivity; HIV Infections; Humans; Immunoassay; Lopinavir; Male; Protease Inhibitors; Pyrimidinones; Ritonavir | 2007 |
FDA notifications. FDA grants approval for generic didanosine for oral solution.
Topics: Administration, Oral; Didanosine; Dideoxynucleosides; Drugs, Generic; HIV Infections; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Stavudine; United States; United States Food and Drug Administration | 2007 |
Hair loss induced by lopinavir-ritonavir.
Topics: Adult; Alkynes; Alopecia; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Probability; Pyrimidinones; Ritonavir | 2007 |
Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2007 |
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Report from the XVI International HIV Drug Resistance Workshop.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Lopinavir; Maraviroc; Nitriles; Piperazines; Pyridazines; Pyrimidines; Pyrimidinones; Triazoles | 2007 |
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphates; Prevalence; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2007 |
Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study.
Topics: Adult; Aged; Cross-Sectional Studies; Endothelium, Vascular; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nitroglycerin; Pilot Projects; Proteinuria; Pyrimidinones; Regional Blood Flow; Ritonavir; Vasodilation | 2007 |
Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Anti-HIV Agents; Blood Chemical Analysis; Body Composition; Female; HIV Infections; Humans; Lipids; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
Topics: Alanine Transaminase; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Lopinavir; Peptide Fragments; Pyridines; Pyrimidinones; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.
Topics: Alopecia; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2007 |
Peripheral Neuropathy Induced by Lopinavir-Saquinavir-Ritonavir Combination Therapy in an HIV-Infected Patient.
Topics: Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Peripheral Nervous System Diseases; Ritonavir; Saquinavir | 2007 |
Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
Topics: Adult; Anti-HIV Agents; Cholesterol; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; Triglycerides | 2008 |
Patient preferences among third agent HIV medications: a US and German perspective.
Topics: Anti-Retroviral Agents; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; Female; Germany; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Patient Satisfaction; Pyrimidinones; Ritonavir; Treatment Outcome; United States | 2007 |
Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Topics: Amino Acid Substitution; Databases, Protein; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Models, Molecular; Mutation; Nelfinavir; Pyrimidinones; Ritonavir; Spain; Treatment Failure | 2007 |
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Substance-Related Disorders; United States | 2007 |
Aluvia tablet approved in 19 African countries.
Topics: Africa; Anti-HIV Agents; Drug Approval; Drug Industry; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Tablets | 2007 |
Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir | 2007 |
Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Interactions; HIV Infections; Humans; Lopinavir; Male; Panuveitis; Pyrimidinones; Rifabutin; Ritonavir; Tuberculosis, Pulmonary | 2007 |
Darunavir phase 3 study data released.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Middle Aged; Pilot Projects; Pyrimidines; Pyrimidinones; Ritonavir; Rosuvastatin Calcium; Sulfonamides | 2007 |
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom | 2007 |
Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir; Time Factors; Treatment Outcome | 2008 |
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Pyridines; Pyrimidinones; Pyrones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2007 |
Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Case-Control Studies; Dideoxynucleosides; Femur Neck; HIV Infections; Humans; Lamivudine; Lopinavir; Lumbar Vertebrae; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; Zidovudine | 2008 |
Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
Topics: Antiretroviral Therapy, Highly Active; Codon; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Point Mutation; Pyrimidinones; Spain | 2008 |
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
Topics: Antibiotics, Antitubercular; Child, Preschool; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; Tuberculosis | 2008 |
A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Topics: Animals; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Lipodystrophy; Lopinavir; Membrane Proteins; Metabolic Syndrome; Metalloendopeptidases; Mice; Mice, Knockout; Nuclear Proteins; Protein Precursors; Protein Processing, Post-Translational; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Thymidine; Treatment Outcome | 2007 |
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Saquinavir; Treatment Outcome; Viral Load | 2007 |
Pharmacokinetic parameters of lopinavir determined by moment analysis in Japanese HIV type 1-infected patients.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Japan; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors | 2008 |
CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Polymorphism, Genetic; Pyrimidinones; Ritonavir | 2008 |
Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Patient Compliance; Pyrimidinones; Ritonavir; Viral Load | 2008 |
Anti-HIV agents. Monotherapy studies--points to consider.
Topics: Canada; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Mutation; Pyrimidinones; Ritonavir | 2008 |
Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Viral Load; Viremia | 2008 |
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pilot Projects; Prospective Studies; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Longitudinal Studies; Lopinavir; Male; Nelfinavir; Pregnancy; Pyrimidinones; Ritonavir; Switzerland; Treatment Outcome; Viral Load; Withholding Treatment | 2008 |
Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ontario; Pyrimidinones; Rape; Risk Factors; Zidovudine | 2008 |
FDA notifications. Abbott sends out provider letter about Kaletra for kids.
Topics: Child; Drug Industry; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; United States; United States Food and Drug Administration | 2007 |
Ugandan children receive lower-strength Aluvia.
Topics: Child; Child, Preschool; Developing Countries; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Uganda; World Health Organization | 2008 |
[Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].
Topics: Acquired Immunodeficiency Syndrome; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2007 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
Initial treatment for HIV infection--an embarrassment of riches.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
ABT-378 lowers viral load.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Viral Load | 1999 |
ABT-378/r helpful in failing patients.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Treatment Failure; Viral Load | 2000 |
[New generation protease inhibitor. Tolerance and potency, a tight association].
Topics: Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Treatment Outcome | 2000 |
From the Food and Drug Administration.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buprenorphine; Child; Drug and Narcotic Control; Drug Combinations; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Leukemia, Promyelocytic, Acute; Lopinavir; Opioid-Related Disorders; Oxides; Pyrimidinones; Receptors, Opioid; Ritonavir; United States; United States Food and Drug Administration | 2000 |
FDA approves new protease inhibitor for HIV infection.
Topics: Adult; Child; Clinical Trials as Topic; Drug Approval; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; United States; United States Food and Drug Administration | 2000 |
Lopinavir/ritonavir: a protease inhibitor combination.
Topics: Adolescent; Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Pyrimidinones; Ritonavir | 2001 |
Lopinavir.
Topics: Adult; Child; Child, Preschool; Drug Combinations; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Molecular Structure; Pyrimidinones; Ritonavir | 2000 |
ATIS site news.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones | 2000 |
HIV drug-resistance cutoffs available.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Treatment Outcome | 2000 |
ICAAC eyes PIs, NNRTIs, and STIs.
Topics: Animals; Anti-HIV Agents; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Mutation; Ontario; Pyrimidinones; Reverse Transcriptase Inhibitors; Viral Load | 2000 |
ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antiprotozoal Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Leishmaniasis; Lopinavir; Male; Pyrimidinones; Renal Dialysis; Renal Insufficiency; Ritonavir | 2001 |
Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.
Topics: Adult; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Sulfonamides | 2001 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Imidazoles; Kidney Diseases; Lopinavir; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |
Retrovirus conference report: three new agents to the rescue.
Topics: Anti-HIV Agents; Carbamates; Congresses as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Peptide Fragments; Pyrimidinones; Salvage Therapy; Sulfonamides; Viral Load; Virus Replication | 1999 |
ABT-378 early access program begins.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Patient Selection; Pyrimidinones | 1999 |
Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
ABT-387/r early access program expanded further.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones | 1999 |
Drug works in treatment-naive, experienced patients.
Topics: Clinical Trials, Phase III as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir | 1999 |
Expanded access program for ABT-378 under way.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Patient Selection; Pyrimidinones | 1999 |
New anti-HIV drugs in development.
Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Capsules; Carbamates; Chemistry, Pharmaceutical; Didanosine; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Menorrhagia; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 1999 |
Expanded access.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Investigational; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organophosphonates; Organophosphorus Compounds; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir | 1999 |
Inflammatory oedema of the legs: a new side-effect of lopinavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Edema; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Leg; Lopinavir; Male; Middle Aged; Pyrimidinones | 2001 |
[No resistance even after 1 year. New drug combination against HIV].
Topics: Drug Combinations; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2001 |
[An option even for patients with multiple pretreatment].
Topics: Clinical Trials as Topic; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load | 2001 |
[Overcoming weaknesses in therapy. Protease inhibitors with high IQ].
Topics: Biological Availability; Drug Administration Schedule; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2001 |
Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy.
Topics: Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutagenesis; Pyrimidinones; Retrospective Studies; Salvage Therapy; Time Factors | 2001 |
Antiretroviral approved for use in infants.
Topics: Drug Approval; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Pyrimidinones; Ritonavir; United States; United States Food and Drug Administration | 2001 |
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
Topics: Drug Resistance; Genome, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones | 2001 |
Kaletra versus nelfinavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nelfinavir; Pyrimidinones; Ritonavir; Viral Load | 2001 |
Resistant to everything.
Topics: Aged; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lopinavir; Male; Patient Compliance; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Viral Load | 2001 |
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 2001 |
Lopinavir/ritonavir. (Kaletra).
Topics: Drug Combinations; Drug Interactions; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir | 2000 |
Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?
Topics: Carbamates; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Pyrimidinones; Ritonavir; Sulfonamides | 2002 |
Kaletra: applying advances in pharmacokinetics to treating HIV.
Topics: Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones | 2001 |
Newest protease inhibitor Kaletra has a unique profile.
Topics: Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors | 2001 |
Drug resistance test shows encouraging results.
Topics: Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2002 |
Inflammatory oedema associated with lopinavir-including HAART regimens in advanced HIV-1 infection: report of 3 cases.
Topics: Adult; Antiretroviral Therapy, Highly Active; Edema; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones | 2002 |
Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
Topics: Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides | 2002 |
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Delavirdine; Drug Synergism; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
[After 3 years no resistance development. Protease inhibitor with staying power].
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir | 2002 |
In vitro antiviral interaction of lopinavir with other protease inhibitors.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Lopinavir; Microbial Sensitivity Tests; Pyrimidinones | 2002 |
Increasing choices for HIV therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2002 |